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Metallothioneins (MTs) are a group of low molecular weight, cysteine-rich, 
heavy metal-binding proteins that consist of four isoforms. MT-I and MT-II isoforms 
are inducible; MT-I and -II are mainly found in astrocytes while MT-III is expressed 
exclusively in neurons but new studies also showed MT-III expression in astrocytes. 
MT-IV is found in non-neural tissues. MTs may serve as endogenous neuroprotective 
agents by acting as antioxidants and by buffering elevated intracellular zinc level. 
Moreover, MTs may function as a thiol donor and free radical scavenger, thus 
providing a line of protection against oxidative damage. 
Oxidative stress had been shown to play a key role in the development of 
Parkinson's Disease (PD). Astrocytes may be important mediators in this process. 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its toxic metabolite 1-
methyl-4-phenyl-pyridinium (MPP+) are commonly used to model PD. MPTP is 
converted to MPP+ in astrocytes and MPP+ is taken up by dopaminergic neurons, thus 
resulting in dopamine (DA) depletion in the striatum and cell loss in the substantia 
nigra (SN) pars compacta. 
The aim of the study is to investigate whether antioxidants can attenuate 
astrocytic reactive oxygen species (ROS) production after MPP+ treatment. This 
study particularly focuses on MTs' role in this process. To achieve this goal, an in 
vitro and an in vivo study were used. 
For the in vitro study, astrocytes were cultured from the cortex, striatum and 
ventral mesencephalon of neonatal C57BL/6 mice. The ability of MTs to ameliorate 
MPP^-induced ROS production was examined. When cells were examined at 4, 8，24 
and 48 h after lOjiM MPP+ treatment, a significant increase in ROS production in the 
order of mesencephalic > striatal > cortical astrocytes was observed, with maximal 
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increase at 48 h post-treatment. 24 h pretreatment with 50|iM zinc sulfate (ZnS04) 
showed that it is effective in inducing MTs mRNA contents, especially in 
mesencephalic astrocytes. When cells were pretreated with ZnS04 for 24 h prior to 
MPP+ treatment, results showed that ZnS04 could effectively reduce MPP+-induced 
ROS production by 54.7%, 42.2% and 28.6% respectively. Cell viability and 
mitochondrial function were assessed using lactate dehydrogenase (LDH) and 3,(4,5-
dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) assays respectively. 
Similar to the results observed for ROS production, ZnSCU treatment could reduce 
LDH production by 61.4%, 53.8% and 64.1% and MTT reduction by 74.1，75.1 and 
51.1% in mesencephalic, striatal and cortical astrocytes respectively. These results 
suggest that ZnSCU could partially protect cells against ROS production and attenuate 
cell viability. 
In order to establish the maximal conditions whereby ROS production can be 
reduced after MPP+ treatment, cells were also treated with 20mM N-acetyl-cysteine 
(NAc), a glutathione inducer, and 200|iM deferoxamine (DeQ, an iron chelator, alone 
or in combination with ZnSO^ Both NAc and Def alone can effectively reduce the 
MPP+-induced ROS production, however, the protective effects of NAc and Def were 
not as effective as ZnS04. NAc alone reduced ROS effectively by 34.7, 30.1 and 
21.4% and Def alone by 35.2, 33.6 and 21% in mesencephalic, striatal and cortical 
astrocytes respectively. When cells pretreated with 24 h ZnSCU + NAc + Def, there 
was maximal reduction in MPP^-induced ROS production by 82.6%, 80.6% and 
71.9%, while LDH production was reduced by 82.7%, 76.4% and 36.6% in 
mesencephalic, striatal and cortical astrocytes respectively. The present results 
showed that ZnSCU > GSH > Def and that the combined treatment of ZnSCU + NAc + 
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Def is most effective in reducing ROS formation and increasing cell viability after 
MPP+ treatment. 
For the in vivo study, MT-I, -II knockout (MT-null) mice were used to 
examine whether the lack of MTs in the brain may exacerbate MPTP-induced injury. 
MT-null mice, Svl29 their inbred control, as well as C57BL/6 mice were examined 
after 1 dose of 40mg/kg (s.c.) MPTP treatment to ascertain whether there was any 
strains difference in response. At 3 days after MPTP treatment, some of the animals 
were anaesthetized, perfused and brains paraffin embedded. Serial sections were cut 
and stained with tyrosine hydroxylase (TH) and TH positively-stained cells were 
counted in order to examine the amount of cell loss in the SN. Other animals were 
sacrificed by decapitation and striata removed for dopamine transporter (DAT) 
specific binding assay and the measurement of DA and metabolites by HPLC. 
Results showed that MT-null mice showed a significantly more severe loss 
(48%) of SN neurons when compared to Svl29 (32%) and C57BL/6 (36%) mice. 
Although a strain difference also exists for DAT binding with MT-null mice 
exhibiting significantly greater binding than Svl29 and C57BL/6 mice, the percentage 
of DAT, DA, DOPAC and HVA loss after MPTP treatment did not differ 
significantly between the 3 types of mice. This suggested that a decrease in thiol-
related defenses against free radicals associated to MPTP action may exacerbate the 
injury process in the SN and not at the DA terminals. 
In conclusion, MTs seemed to play an important role in the protection against 
MPP+-induced oxidative stress, especially in combination with NAc and Def. This 
treatment is the most effective in the order of mesencephalic > striatal > cortical 
astrocytes although these cells also showed the same order of susceptibility to MPP+-
induced oxidative stress. The in vivo study further confirms the protective role MTs 
vii 
have on MPTP-induced injury. This may further shed light on the role of MTs in the 
pathogenesis of PD. If the ROS production can be effectively reduced by MTs there 
will be less oxidative damage to the dopaminergic neurons, therefore, the 
degenerative process of PD may be slowed down. Further studies on the expression 
and regulation of MT genes are likely to culminate in novel strategies for 
manipulating intracellular MT levels, providing insight to their protective role in PD. 
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CHAPTER ONE: INTRODUCTION 
1.1 Parkinson's Disease 
1.1.1 Epidemiology 
Parkinson's Disease (PD) was first discovered by James Parkinson in 1817. He 
first described the symptoms of the disease as: "Involuntary tremulous motion, with 
lessened muscular power, in parts not in action and even when supported; with a 
propensity to bend the trunk forwards, and to pass from a walking to a running pace: the 
senses and intellects being uninjured" (Pearce, 1989). 
There are various epidemiological studies showing that PD affects all ethnic 
groups and the prevalence ratio of PD differs amongst different populations in the world. 
Previous reports showed that within Europe and North America, the prevalence rate for 
PD ranged from 65/100,000 to 187/100,000 respectively (Li et al., 1985; Schoenberg 
1987). These were much higher rates when compared to that reported for China where 
the prevalence ratio ranged from 44/100,000 to 57/100,000 (Li et al.，1985; Schoenberg 
1987). When the prevalence rates were examined across different ethnic groups, it was 
shown that White and Black Americans had a much higher incidence (257/100,000) 
when compared to Asians and African Blacks (14/100,000) (Tanner, 1989). The highest 
rate was observed in the Caucasian population with a prevalence of over 1:1000 (Marttila 
and Rinne, 1987). Most patients develop PD between 50 and 79. One of the studies 
showed a male predominance with the prevalence rate of 147 and 103 per 100,000 for 
white males and females respectively. Among non-whites, the rates were 51/100,000 and 
12.3/100,000 respectively (Kessler, 1978). It was shown in China that the male-female 
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PD ratio was 3.7:1 (Li et al.，1985). 
1.1.2 Neuropathology 
In PD, the neurotransmitter system that is affected most is the nigrostriatal 
dopaminergic pathway. This pathway consists of the dopaminergic neurons situated in 
the pars compacta of the substantia nigra (SN) with their terminals located in the 
striatum. 
PD is characterized by a marked degeneration of the highly pigmented 
neuromelanin-rich neurons in the SN with most nerve cell loss observed in the lateral and 
ventral cell groups of this region (Gibb and Lees, 1991). PD is also associated with a 
massive reduction of striatal DA content (Kish et al., 1988; Rapisardi et al., 1990). A 
minimal loss of 70 - 80% of dopaminergic function is required for the clinical symptoms 
of PD to manifest, thus revealing the ability of the central nervous system (CNS) to 
compensate for such massive losses (Bemheimer et al., 1973). 
A compensatory mechanism is achieved by the increase in DA output from 
existing neurons to maintain normal extracellular DA concentration (Robinson and 
Whishaw, 1988) and by the reduction of DA reuptake sites responsible for the removal of 
DA from the synaptic cleft (Donnan et al.，1991). Finally, postsynaptic receptors also 
increase in expression to account for DA supersensitivity (Lee et al, 1978). It was shown 
that there was an increase in DA D2 receptors (Peroutka et al., 1985) (Falardeau et al., 
1988; Lange, 1990) but not DA D1 receptors in PD brains (Graham et al., 1990). 
The loss of nigrostriatal function in PD results in a decrement of striatal output, 
thus disinhibiting the subthalamic neurons on the medial pallidal output. Excessive 
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inhibition of external globus pallidus results in disinhibition of the subthalamic nucleus, 
which, in turn, provides excessive drive to the internal globus pallidus and SN, finally 
causing an excess inhibition to the thalamus (Hardie, 1989). 
Apart from the loss of pigmented neurons in the SN, a proliferation of astrocytes 
in this region was also observed (Tanaka and Fukuda, 1997). Moreover, the presence of 
round, concentric intraneuronal inclusions known as Lewy bodies can also be observed in 
some of the remaining neurons in the SN of PD postmortem brains (Jellinger, 1989). A 
collection of protein filaments including ubiquitin and alpha-synuclein was also 
observed. Lewy bodies, ubiquitin and alpha-synuclein are not unique to the 
neuropathology of PD, they are known to be linked to a number of other motor neuron 
disease like Alzheimer's disease (Fomo 1992; Schapira, 1999). 
1.1.3 Clinical Symptoms 
The major clinical symptoms of PD include bradykinesia, muscle rigidity, resting 
tremor, and postural instability (Williams, 1986; Langston J.W., 1992; Nutt J.G. et al., 
1992). 
Bradykinesia, or slowness of movement, is manifested in the patient's difficulty 
in initiating, arresting and slowness in execution of movement. The sequential actions 
may also be interrupted by an intermittent immobility or "freezing", thus impairing the 
smooth execution of daily tasks. This is most apparent when the patient undresses or 
searches his/her own pocket or purse. Bradykinesia is present in 77% to 98% of patients 
with PD (Martin et al., 1973; Hughes et al., 1993; Louis et al., 1997). Bradykinesia is not 
unique to PD, it can occur as a result of normal ageing, depression, Alzheimer disease as 
3 
well as movement disorders such as progressive supranuclear palsy (PSP) and multiple 
system atrophy (MSA). An extreme form of bradykinesia is akinesia, referring to the 
complete absence of movement. This may last for several seconds to hours and is most 
evident when the patient starts to gait (Gelb et al.，1999). 
A waxing resistance in passive movement characterizes rigidity in PD. It can be 
most easily detected at the patient's wrist and elbow joint. The joint cannot be moved 
smoothly, resulting in a cogwheel phenomenon during joint movement. Individuals with 
PD also have difficulty starting voluntary movements. Even changing one's facial 
expression requires intense concentration, and the individual acquires a blank, static 
expression. The frequency with which rigidity occurs in PD has been reported with 
values ranging from 89% to 99% (Hoehn and Yahr 1967; Hughes et al., 1993; Louis et 
al., 1997). 
Tremor is a recognizable initial symptom of PD and it represents a tug of war 
between antagonistic muscle groups that produces a background shaking of the limbs. 
The classical sign of tremor is 3-6 Hz distal resting tremor, which begins usually in one 
or both hands, starts from one side of the body and affects the extremities first. Patients 
with PD may have a resting tremor, an action tremor, or both, and the character of the 
tremor may change during the course of illness (Salisachs and Findley, 1984; Rajput, 
1995). The thumb and forefinger of advanced patients may show a rapid repetitive 
movement described as “pill rolling". Also, tremor can be stimulated by stress and 
fatigue. The portion of patients with PD who have tremor ranges from 79% to 90% in 
clinical analysis (Hoehn and Yahr, 1967; Martin et al., 1973; Selby, 1984), and from 76% 
to 100% in 3 series of patients with autopsy proven PD. 
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Postural instability can be defined into two types: static and kinetic. Static 
instability may be manifested as scoliosis, a stooped posture and dystonic hand or foot 
with flexed metacarpophalangeal joints, extented proximal interphalangeal joints and 
flexed distal interphalangeal joints. Kinetic instability indicates the loss of balance 
during the execution of daily tasks, and is characterized by difficulty in attempting to rise 
from the chair or adapting to an unexpected disturbance of postural equilibrium. 
Moreover, a shortening of muscles along the front of the neck tends to bend the head and 
spine forward, and cause a faulty balance (Jankovic et al.，1992). 
Ward and Gibb found that only 69% to 75% of patients with the postmortem 
diagnosis of PD had at least 2 of 3 cardinal parkinsonian features (tremor, rigidity, and 
bradykinesia). In fact, 13% to 19% of patients who demonstrated all 3 cardinal features 
had pathologic diagnoses other than PD (Ward and Gibb, 1990). 
As these PD symptoms worsen, chronic fatigue, mental confusion, and speech 
impairment may develop, and eventually the patient may die of bronchopneumonia. 
Apart from the motor deficit, other systems are also affected. The autonomic dysfunction 
can account for the diaphoresis and constipation observed in the patients. Depression, 
dementia and bradyphrenia may accompany PD. Accordingly, PD presents a complex 
syndrome with rich and variable expressions in different patients which then cause delay ‘ 
treatment and diagnostic difficulty (Stacy and Jankovic, 1992). 
Apart from the motor features, there are also a number of non-motor clinical 
features. Dementia is a cognitive impairment which develops in a subset of patients with 
PD and it was estimated that dementia occurs in 25% to 40% of patients with PD (Brown 
and Marsden, 1984; Cummings, 1988). PD patients frequently demonstrate impaired 
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cardiovascular response to postural changes on laboratory testing, but they are usually 
asymptomatic (Tanner, 1992). Furthermore, patients can develop abnormal 
thermoregulation, gastrointestinal or urinary abnormalities of both the saccadic and 
pursuit oculomotor systems (Corin et al., 1972; Vidailhet et al., 1994; Martignoni et al.， 
1995). 
1.1.4 Treatment 
The treatment of PD with levodopa (L-dopa) in the mid-1960s led to relief of 
Parkinson's symptoms in many patients. L-dopa acts as a DA precursor and stimulates 
the production of DA in surviving neurons in the SN. At present, (L-dopa) is still the 
most commonly used treatment for PD. However, the patients eventually experienced 
side effects after chronic L-dopa therapy, including "end of dose" deterioration, 
dyskinesia, and “on-off’ effects (Langston and Ballard, 1984). L-dopa is always 
combined with a dopa decarboxylase inhibitor to reduce peripheral side effects and 
enhance absorption (Hardie, 1989). The response diminished over time in most patients 
but 7% to 35% of patients remained at least partially responsive to L-dopa until the time 
of death (Rajput et al., 1991; Colosimo et al., 1995). Moreover, in vitro and in vivo 
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studies showed that L-dopa was toxic to dopaminergic and other neurons (Stanley, 1996; ‘ 
Mena et al., 1997; Fahn, 1998). Because of the toxic effects of high doses of L-dopa, a 
significant low level of L-dopa should be maintained, and thus the use of a selective and 
long-lasting monoamine oxidase (MAO) inhibitor like selegeline to retard this process 
had been recommended (Knoll 1983; The Parkinson study group, 1989; Lieberman, 
1992a). 
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Selegiline was shown to reduce free radicals (Cohen and Spina, 1989a), enhance 
the activity of free radical scavenging enzymes, superoxide dismutase (SOD), catalase 
(Carrillo et al., 1991; Clow et al.，1991) and astrocytic activation after lesions in rat brain 
(Biagini et al., 1993). Furthermore, it has been reported that selegiline increased the fiber 
network between neurons, the survival of fetal nigral neurons (Roy and Bedard，1993), 
protect primary brain astrocytes from 1 -methyl-4-phenyl-pyridinium (MPP^)-induced 
toxicity (Koutsilieri et al” 1996) and decrease 1 -benzyl-1,2,3,4-tetrahydroisoquinoline, an 
endogenous parkinsonism-inducing compound, in both in vivo and in vitro studies 
(Kotake et al., 1998). 
Apart from the protective effects of selegiline alone, the combined effects of 
selegiline and L-dopa have also been examined. Birkmayer (1985) showed that patients 
receiving selegeline together with L-dopa survived longer and showed less disability than 
patients treated with L-dopa alone. Furthermore, it was shown that, when compared to 
the L-dopa group, the addition of selegeline to L-dopa therapy resulted in a significant 
reduction in the functional disability score (Elizan et al., 1991). There was also evidence 
that the early use of selegiline slowed down the progression of parkinsonian disability 
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and, therefore, delayed the need to start L-dopa by 9-12 months (Myllyla et al., 1992; 
Parkinson's Study Group, 1993; Olanow et al., 1995; Koller, 1996). Recently, it was ‘ 
reported that selegiline treatment selectively improved the directional control of arm 
movement in a dose-related manner (Giladi et al., 1999). 
However, there were also limitations in using selegiline in patients. Selegiline at 
doses greater than 10 mg per day was a nonselective MAO inhibitor with a potential to 
induce a fatal hypertensive reaction known as the "cheese effect" (Olanow and Tatton, 
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1999). So the safety of selegiline remained controversial since there was a study 
indicating that selegiline in combination with L-dopa was associated with selective 
orthostatic hypotension in PD (Churchyard et al., 1999). 
Other drugs that affect the action of CNS neurotransmitters including DA agonists 
such as pergoline or bromocriptine have proven useful in relieving tremors, and delaying 
the need for L-dopa (Lieberman et al., 1984; Lieberman 1992b;), therefore, they provided 
symptomatic benefits in PD (Dohi et al., 1993). Other DA agonists, pramipexole and 
cabergoline also showed similar protective effects in PD (Montastruc et al., 1993; Jenner, 
1995; Goetz and Diederich, 1996). Actually, the development of motor complications 
with L-dopa limited its general usefulness and direct-acting DA agonists, bromocriptine 
and pergoline have been available for some years, but some evidence suggested that those 
agonists that are developed more recently have better efficacy and are associated with 
fewer side effects (Fischer, 1995). 
In the last few years, a new antioxidant, apomorphine, has been used as a 
replacement for L-dopa in the therapy for PD in the last stage (Gancher and Mayer, 
1995). Apomorphine was shown to be a powerful DA agonist and the only one with a 
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clinical effect similar to that of L-dopa. It was best used as a rescue strategy to induce a 
rapid "on" effect during the difficult “off，situation. It is a very emetic drug and ‘ 
therefore could not be used until the advent of the peripheral DA receptor antagonist, 
domperidone. Co-treatment of patients with domperidone permits utilization of 
apomorphine (Melamed et al., 1999). Apomorphine was also shown to be an antioxidant 
in scavenging iron-stimulated reactive oxygen species (ROS) production in rat brain 
mitochondria (Gassen et al., 1996) and in preventing hydrogen peroxide (H202)-induced 
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degeneration of PC 12 cells (Gassen et al., 1998). Vitamin E was reported as an 
antioxidant by Golbe et al., in 1988 showing that all food items with high vitamin E 
content were more commonly consumed by non-PD people (Golbe et al., 1988) and the 
antioxidant property of vitamin E was further reported by Tanner et al. However, more 
recent studies on vitamin E have not shown an association between vitamin E intake and 
protection against PD (Logroscino et al., 1996; Morens et al” 1996; Seidler et al., 1996; 
Johnson et al., 1999). 
The newly developed catechol-O-methyltransferase inhibitors, tolcapone and 
entecapone increased the availability of L-dopa to the brain, and their action was 
complementary to that of the dopa decarboxylase inhibitors (Kaakkola et al., 1994; Kurth 
et al., 1997). Antimuscarinic drugs and amantadine remained viable alternatives to DA 
related drugs, although their use was often limited by side effects and tolerance 
(Schapira, 1999). 
The medical management of PD has its limitations, and new surgical techniques 
with low morbidity have emerged as a viable alternative for carefully selected patients. 
In patients who are very severely affected, pallidotomy or thalamotomy may be 
performed (Obeso et al., 1997). Pallidotomy has been shown in some cases to reserve the 
excessive inhibitory output from the pallidum and thus reduce contralateral dyskinesias ‘ 
and improve bradykinesia and rigidity (Ceballos-Baumann et al, 1994; Kishore et al., 
1997; Koller et al., 1999). Recent studies concluded that pallidotomy was an effective 
and safe procedure in the treatment of medically intractable L-dopa-induced dyskinesia 
since the mean unified PD rating scale (UPDRS) of the disability and pain decreased 
from 1.95 to 0.74 and from 1.02 to 0.17 respectively after pallidotomy (Jankovic et al.， 
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1999). Gross and colleagues demonstrated that the lesions' locations will determine the 
clinical outcome following microelectrode-guided pallidotomy (Gross et al , 1999a，b). 
This was further supported by Lombardi et al., who demonstrated that the cognitive 
effects of pallidotomy can be dissociated from the motor effects, and, thus supporting the 
segregation of functionally distinct circuits in the human (Lombardi et al” 2000). 
Thalamotomy is associated with a less than 0.3% mortality rate (Selby, 1987) and 
has been preferably used in unilateral cases to reduce contralateral tremor, stiffness and 
dyskinesia (Scott et al., 1970; Laitinen et al., 1992). Improvement in tremor and rigidity 
of the limbs contralateral to the side of the lesion occurred in more than 90% of patients 
(Jankovic et al., 1995; Koller et al., 1999). However, bilateral thalamotomy were not 
recommended because complications from this surgery were more common, with more 
than 25% of patients experiencing speech impairment (Selby, 1987). Nevertheless, it has 
been suggested that with the advances in stereotaxic techniques, bilateral operations 
could be performed with reduced morbidity (Koller et al., 1999). 
Deep brain stimulation (DBS) to the globus pallidus or subthalamic nucleus may 
substantially improve contralateral symptoms, resulting in both decreased neuronal 
I 
/ 
activity and suppression of tremor (Pollak et al., 1997). Benabid and colleagues showed , 
that 78 out of 80 patients were said to have benefited (Pollak et al., 1996). Moreover, ‘ 
morbidity and mortality of DBS was low, adverse reactions related to surgery and 
complications related to the device occurred very rarely (Koller et al , 1999). More 
advantages of DBS over ablative surgery included reversibility (no destructive lesion) 
and adaptability (changing of stimulus parameters to increase efficacy or decrease 
adverse reactions). On the other hand, the disadvantages included the added cost of the 
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device, battery replacement, equipment failure and the risk of infection (Koller et al., 
1999). 
Fetal nigral implants improve the symptoms of PD considerably, and postmortem 
examination of brains of transplanted patients (who had died later of unrelated causes) 
demonstrated outgrowth and new synaptic formation from the transplanted tissue (Jenner 
and Olanow 1996). Implantation of stem cells is a potentially powerful means to 
reconstitute damaged nervous tissue. In the mammalian CNS, stem cells undergo 
differentiation in response to appropriate growth factors (Weiss et al., 1996; Azizi et al., 
1998). However, this surgical treatment has been subjected to ethical concerns over the 
use of human fetal tissues. Despite its benefits, the application of surgery in treating PD 
is limited: procedures carry some risk of injury and death, long term effects are unknown, 
and benefits are only unilateral unless surgery is undertaken on both sides of the brain 
(Schapira, 1999). 
1.2 Proposed Mechanisms of Neurodegeneration in Parkinson's Disease 
1.2.1 Oxidative Stress 
Free radicals are defined as any species which contains one or more unpaired 
electrons (Fridovich, 1993). Thus, free radicals tend to undergo reactions to get rid of or 
gain one more electron to attain stability, so they are highly reactive and will initiate 
disruptive peroxidative reactions. During normal cellular respiration, oxygen is reduced 
to water and such reduction causes the formation of free radicals (Giulivi et al., 1995). 
Free radicals will cause oxidative stress and consequent cell death by radical chain 
reactions, and, thus result in peroxidation of cellular and mitochondrial proteins and 
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lipids. Lipid peroxidation is a chain reaction due to the interaction of hydroxy 1 radicals 
with polysaturated fatty acid side chains of the lipid membrane and it may lead to a 
reduction of the receptor density. Besides, it also alters the viscosity of the plasma 
membrane, thus affecting the receptor coupling mechanism and finally cause DNA strand 
break and hence cell death (Halliwell and Gutteridge, 1986; Halliwell 1992b). 
Oxidative stress in the dopaminergic system is characterized by a shift in the 
redox reaction towards the oxidation of DA during cellular metabolism, thus causing an 
accumulation of ROS like superoxide (O2.)，H2O2 and hydroxyl free radicals (OH ). (Fig. 
1) Moreover, the autoxidation of DA will lead to the production of semiquinones, which 
are themselves toxic and may also lead to the generation of ROS (Olanow, 1990). Thus, 
oxidative stress has received the most attention in the etiology of PD because of the 
potential of the oxidative metabolism of DA to yield ROS (Halliwell and Gutteridge, 
1985; Olanow, 1990，1993). 
Normally, there are various protective enzymes within the cells to scavenge free 
radicals and prevent oxidative damage to the tissue. When the balance is shifted, either 
with over production of free radicals or with the loss of antioxidant enzymes, tissue will 
undergo lipid peroxidation and oxidative stress (Halliwell, 1992a). 
The free radical scavenging enzymes include SOD, which scavenges O2 , as well 
as glutathione peroxidase (GSH-Px) and catalase which scavenge H2O2 (Fig. 1). Growing 
attention has also focused on metallothioneins (MTs) as antioxidants, due to their ability 
to scavenge the potent OH (Lazo et al., 1995; Desagher et al., 1996; Pitt et al., 1997). 
Postmortem studies of PD brains demonstrated an increased activity of SOD 
(Marttila et al., 1988; Saggu et al.，1989; Hirsch, 1992) and iron (Dexter et al., 1989a; 
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Fig 1: Mechanisms of reactive oxygen species generation and scavenge by 
antioxidants in CNS. 
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Riederer et al., 1989) in the SN. A decreased in reduced glutathione (GSH) content 
(Perry and Yong, 1986; Di Monte et al , 1992a; Sofic et al., 1992), as well as a reduced 
activity of GSH-Px and catalase (Ambani et al , 1975; Kish et al., 1985) were also 
observed. The decreased GSH content in the SN of PD postmortem brains provided the 
initial clues to the possible pathogenic role of ROS in the etiology of PD (Evans, 1993). 
Further evidences of oxidative damage in postmortem brains of PD patients were 
also shown. This included the increased levels of malondialdehyde, a lipid peroxidation 
product, and hydroperoxide in the SN but not in the cerebellum of PD patients (Dexter et 
al., 1989b，1994). Increased staining for 4-hydroxynonenal, another product of lipid 
peroxidation that has the capacity to alter proteins and promote cell toxicity, has also 
been detected in SN neurons (Yoritaka et al., 1996). In addition, increased levels of 
protein carbonyls and 8-hydroxy-2-deoxyguanosine, reflecting oxidative damage to 
proteins and DNA respectively, have been found in the SN as well as in numerous other 
brain regions of PD brains (Fleming et al., 1994; Alam et al., 1997a,b; Obeso et al., 
1997). Overall, these findings suggested that there is widespread oxidative damage in PD 
postmortem brains. However, it still remains to be determined whether the oxidative 
damage that occurs in PD is a primary event or it is a secondary occurrence due to an 
alternate etiology like drug or toxin exposure or that it is simply a postmortem event. 
1.2.2 Mitochondrial Dysfunction 
Mitochondria are the location where a number of vitally important cellular 
functions take place, this include lipid metabolism, the citric acid cycle, the respiratory 
chain and oxidative phosphorylation. There are several enzyme systems of the metabolic 
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pathway inside the mitochondria and they are situated in the mitochondrial inner 
membrane and comprise four protein complexes, assigned as complex I, II, III and IV. 
Previous studies showed that impaired mitochondrial function is a feature of PD 
(Schapira and Cooper, 1992; Schapira 1994). A selective 30-40% decrease in complex I 
activity of mitochondrial respiratory chain has been found in the SN of PD patients 
(Schapira et al” 1990b) while unaffected in other brain regions (Mizuno et al, 1990; 
Janetzky et al., 1994; Cooper et al., 1995). 
Inhibition of complex I has been shown to increase the generation of O2 
(Hasegawa et al., 1990; Ramsay and Singer, 1992) and thus enhance oxidative stress 
(Giulivi et al.，1995). Accordingly, mitochondrial complex I defect could lead to cell 
damage through free radical formation. Furthermore, due to the interference of oxidative 
phosphorylation, ATP production is affected and as a result, the normal cellular function 
is disturbed and cells will eventually die resulting from low energy supply. This can be 
flirther confirmed by a study in mouse brain synaptosomes where it was found that 
complex I inhibition by 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or MPP+ 
can lead to a depletion of cellular ATP (Scotcher et al.，1990). Overall, a mitochondrial 
complex I defect could contribute to cell degeneration in PD through decreased ATP 
synthesis. 
In a recent study, a complex I defect was found in cybrids carrying mitochondrial 
DNA derived from platelets of PD patients (Swerdlow et al., 1996). This showed that the 
presence of a defect in the mitochondrial genome could be transferred through multiple 
passages suggesting that the defect could be due to an inherited mutation or to a toxic 
insult. 
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A complex I defect might also contribute to the development of apoptosis. 
Increasing evidence showed that a reduction in the mitochondrial membrane potential as 
a result of an impaired proton pump can lead to the opening of a mitochondrial 
permeability transition pore and the release of small mitochondrial proteins that signal the 
onset of apoptosis. As complex I is the major site of proton pumps, it is possible that a 
complex I defect in PD may contribute to neuronal vulnerability and thus lead to 
apoptosis of dopaminergic neurons (Olanow and Tatton, 1999). 
1.2.3 Genetic Factors 
Earlier twin studies did not find a significant difference in concordance rate 
between monozygotic and dizygotic twins for PD (Ward et al., 1983; Bharucha et al., 
1986; Vieregge et al., 1992). These results suggested that the etiology of PD does not 
favour a genetic cause. In 1990，Johnson (1990) re-analyzed the twin studies and ruled 
out that PD is an autosomal dominant mode of inheritance with low penetrance. Later 
report suggesting that the lack of concordance in twins studies could be explained if prion 
analogues, the modification of transmissible agent hypothesis, were involved in PD 
(Sommer and Rocca, 1996). 
Approximately 5-10% of PD patients has a familial form of parkinsonism with an 
autosomal-dominant pattern of inheritance and a large pedigree has been identified where 
members in different generations suffer from PD. Furthermore, family members in this 
cohort were shown to have a higher incidence of PD than their age-matched controls 
(Wood, 1998). Tanner et al. (1999) found that there was no difference in concordance 
between monozygotic and dizygotic twins of PD patients aged 50 years or older but a 
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significantly increased incidence was observed in monozygotic twins who suffered from 
PD at less than 50 years of age. Such reports indicated that genetic factors are important 
in young-onset patients but are not likely to play a major role in patients with sporadic 
PD. Numerous studies also indicated that familial aggregation of PD does occur and 
demonstrate a positive history of up to 20-30% in all apparently sporadic cases (Hubble 
et al., 1993a; Lazzarini et al., 1994; Seidler et al, 1996). 
In a very large family with early onset autosomal dominant PD (Golbe et al” 
1990), the disease has been mapped to chromosome 4q21-q23 (Polymeropoulos et al., 
1996). Further analysis in this Italian and in three Greek families with autosomal 
dominant PD revealed this mutation gene was coded for a brain protein called alpha-
synuclein (Polymeropoulos et al., 1997). 
In these affected families, 85% of patients who expressed the mutant gene had 
clinical features of PD (Kruger et al, 1998). These findings provide strong evidence that 
a single mutation in the human alpha-synuclein gene is sufficient to account for the PD 
phenotype. However, most cases of PD do not have affected family members (Marder et 
al., 1996) and the alpha-synuclein mutation appeared to be rare in patients with younger 
onset of PD (Chan et al, 1998a). An absence of mutations in the coding region of alpha-
synuclein gene in pathologically proven sporadic PD brains was also observed (Chan et 
al., 1998b). A most recent study by Tanner et al. (1999) reported that no genetic 
component was evident when PD began after age 50 years. Thus whether genetic factors 
are important in sporadic cases of PD remains to be determined. 
Apart from the alpha-synuclein gene, there are also a number of candidate genes 
have been screened and found not to be associated with an increased risk of PD. These 
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include tyrosine hydroxylase (TH), GSH-Px, catalase, SOD-1 and -2, and the DA D2, 
D3，and D4 receptors (Gasser et al., 1994). Swerdlow et al. (1996) suggested that the 
nigral complex I defect in PD is caused by genetic abnormalities in mitochondrial DNA. 
However, no disease-specific mitochondrial DNA mutation was identified so far, and the 
role played by gene mutation in the pathogenesis of idiopathic PD requires additional 
confirmation. 
1.2.4 Environmental Factors 
Epidemiologic studies indicated that a number of factors may increase the risk of 
developing PD (Tanner and Langston, 1990). These included exposure to well water, 
pesticides, herbicides, industrial chemicals, wood pulp mills, farming and living in a rural 
environment. A number of exogenous toxins have been associated with the development 
of PD, these include trace metals, cyanide, lacquer thinner organic solvents, carbon 
monoxide and carbon disulfide (Olanow and Tatton, 1999). Previous studies found that 
there were an increased association of PD with iron, manganese (Zayed et al., 1990; 
Gorell et al., 1997), copper ( Rybicki et al , 1993; Gorell et al., 1997), aluminium (Zayed 
et al., 1990) and lead (Gorell et al, 1997). 
In 1984, Rajput et al. made the first observation of a correlation between early age 
exposure to rural environment and the development of idiopathic PD. Those living in 
rural areas are at a high risk and the consumption of well water in early life predisposes 
individuals to idiopathic PD (Rajput et al, 1984). These findings were subsequently 
confirmed in 1985 (Tanner, 1985) and 1987 (Rajput et al., 1987). Later on, the 
relationship between PD and rural living were further proved in Hong Kong (Ho et al., 
17 
1989), China (Tanner et al., 1989), Alberta (Svenson et al., 1993)，Italy (De Michele et 
al” 1996) and Taiwan (Liou et al” 1997). There was also one study that detected low 
nigral neuronal cell counts from postmortem brains of rural provincial residents 
(Thiessen et al” 1990). Recently, living in a rural environment was shown to be a risk 
factor for PD in African-Americans (Marder et al., 1998). 
Many factors associated with a rural environment have been studied, the most 
frequent being herbicides-pesticides and well-water use (Veldman et al., 1998). There 
are reports suggesting an association between PD and herbicides-pesticides (Hubble et 
al” 1993b; Seidler et al , 1996; Liou et al” 1997). Taiwanese fanners who used both 
paraquat and other herbicides-pesticides had a 4.74 fold increased risk for PD, whereas 
farmers using herbicides-pesticides other than paraquat had a 2.17 fold increased risk 
(Liou et al., 1997). The incidence of PD patients who are well water users has been 
found to be about five times greater in each of the kibbutzim than in the remainder of the 
Neger, suggesting that well-water from the common aquifer could be involved 
(Herishanu et al., 1989). In an univariate analysis on African-Americans, a positive 
relationship between PD and drinking well water was also shown (Marder et al., 1998). 
However, others could not find any association between well water use and PD (Tanner 
and Langston; 1990; Stem et al., 1991; Liou et al., 1997). In young onset parkinsonism, a 
greater exposure to rural living and well water consumption is found, indicating a dose-
response relationship between environmental risk factors and age of PD onset (Rajput et 
al.，1986; Koller et al., 1990). In addition, it was shown that PD patients that drank 
unfiltered tap water were almost twice as likely to be at risk than their control subjects 
(Marder et al., 1998). 
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PD is most prevalent in industrialized countries, a fact consistent with a 
hypothesis involving industrial toxins (Tanner, 1989). In China, the prevalence of PD is 
much lower than in the far more industrialized USA (Li et al” 1985). A number of 
metals has been discussed as possible risk factors for PD. Metals, particular copper, iron, 
manganese and zinc, may be involved in PD through the formation of free radicals 
(Montgomery, 1995), thus enhancing oxidative stress, which could play a role in nigral 
cell loss in PD. Moreover, numerous studies indicated that there were increased levels of 
both iron and copper in the SN of PD brains (Fahn and Cohen, 1992; Olanow, 1992; 
Mann et al., 1994). Gorell et al found a significant association of PD with manganese and 
copper but not zinc with more than 20 years of occupational contact. Moreover, more 
than 20 years exposure to combinations of lead-copper, lead-iron and iron-copper also 
demonstrated a greater association with PD than did any of these metals alone (Gorell et 
al., 1997，1999a). 
Other than the influence of metals, the association of dietary factors with PD has 
also been investigated (Golbe et al., 1988). Some authors suggested a neuroprotective 
effect of the antioxidant vitamin E (Golbe et al , 1988; de Rijk et al” 1997) while vitamin 
C，which may also act as an antioxidant, did not show any protection (Femandez-Calle et 
al.，1993). Apart from neuroprotective effects, dietary factors may also improve the 
symptoms of PD: for example, broad beans increase levodopa plasma level and improve 
motor performance in PD (Rabey et al, 1993), and it also prolongs the "on" periods in 
patients have “on-off，fluctuations (Apaydin et al., 2000). Recently, a reduced risk of PD 
in southeastern Sweden was found for the consumption of coffee, wine and liquor and for 
smoked ham or meat, white bread and tomatoes (Fall et al., 1999). Increased risk of PD 
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was also shown to be associated with foods containing animal fats (Anderson et al., 1999) 
as well as the high intake of total fat, saturated fats, cholesterol, lutein and iron (Johnson 
et al., 1999). 
Furthermore, smoking has been suggested to play a protective role in the 
development of PD (Butterfield et al” 1993; Martyn and Osmond, 1995; Morens et al” 
1995; Gorell et al., 1999b). This may be due to the presence ofMAO-B inhibitors in the 
cigarette smoke (Baron, 1986). One study demonstrated a 40% reduction of MAO-B in 
the brains of smokers (Liu et al., 1996). Furthermore, nicotine has been shown to 
stimulate DA release (Janson et al., 1992) and carbon monoxide from cigarette smoke to 
reduce free radicals formation, this may therefore lessen the damage to cells in the SN 
(Kirch et al., 1988). Although a recent study reported that smoking was negatively 
associated with PD, suggesting a protective role for PD (Smargiassi et al., 1998), other 
studies however did not show this protective effect (Sasco and Paffenbarger, Jr. 1990; 
Semchuk et al., 1993). Therefore, the development of PD associated with smoking habits 
remains open to question (Veldman et al., 1998). 
1.2.5 Ageing 
Ageing is a general phenomenon that affects all individuals. It represents various 
morphological and biochemical changes that occur from maturity to senescence, 
rendering humans more vulnerable to disease and toxicity and eventually leading to 
death. In addition, specific chronic degeneration conditions also occur with increasing of 
age. It was proposed that the imbalance in favour of oxidants is a cause of ageing itself 
(Harman, 1981). Harman states: The ageing process may be simply the sum of random 
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changes produced by free radical reactions' (Harman, 1992). 
Most of the incidence of PD begins in later life with an average onset age of 60, 
this rate of onset increases sharply with age, reaching a peak of about 1 in every 200 in 
those between 70-79 years (Roman et al., 1995). Therefore, ageing itself appears to be a 
key factor that contributes to the development of PD. In fact, it was observed that there is 
a loss of dopaminergic cells in the zona compacta of the SN (Thiessen et al, 1990) and 
that striatal dopamine declines progressively with age (Kish et al., 1992). This suggests 
that with the advancement of age, one is more predisposed to the depletion of DA and 
thus the increased risk of developing PD. 
Moreover, human studies have demonstrated that there was a decrease in the activity of 
mitochondrial respiratory complexes with age in various cell types (Muller-Hocker et al., 
1989; Cliver et al., 1992) but not in neurons. Also increases in oxidative damage markers 
have been shown in glial cells. The most common free radical-induced DNA adduct, 8-
hydroxy-2-deoxyguanosine, increased with age and was found to be increased 10-fold in 
mitochondrial DNA (mtDNA) compared to nuclear DNA (Richter 1988; Hayakawa et al, 
1991; Hayakawa et al., 1992). Lipid peroxidation, another marker of age-related 
oxidative stress, was also described to increase in the ageing brain (Sawada et al., 1992). 
Complexes I, II and IV have been reported to have reduced activity in aged rats (Curti et 
al.，1990). Generally, complex I appear to be the most affected, although complex IV 
activity also declines with time, whether this decrease is responsible for or is merely an 
epiphenomenon of ageing remains controversial. All these evidences suggested that the 
ageing effect may also be a contributing factor to PD. 
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1.3 l-methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP) as a Parkinson's 
Disease Model 
1.3.1 Discovery of MPTP 
Davis et al. (1979) reported the first case of parkinsonism occurring after the 
intravenous self-administration of l-methyl-4-phenyl-4-propionooxypiperidine (MPPP), 
a meperidine analogue which is an illicit narcotic analgesic, and is often referred to as 
synthetic heroin. The patients developed severe symptoms of parkinsonism and the 
postmortem brains showed prominent pathological changes in the nigrostriatal 
dopaminergic neurons similar to that of idiopathic PD. 
In 1983, a group of heroin addicts in the United States also developed 
parkinsonian symptoms after the injection of MPPP. Langston et al. (1983) reported four 
cases of marked parkinsonism after the use of synthetic heroin, containing a mixture of 
MPPP and MPTP. Later on, the generation of MPTP in the process of heroin synthesis 
turned out to result from the omission of a purification step (Langston et al., 1983; 
Wright et al., 1984; Ballard et al , 1985). 
MPTP was shown to cause the destruction of the nigrostriatal dopaminergic 
neurons mainly in the SN in human (Langston and Ballard, 1983)，monkey (Bums et al., 
1983; Langston et al., 1984; German et al, 1988; Fomo et al , 1993)，cat (Jenner and 
Marsden 1986; Schneider et al., 1986; Williams and Schneider 1989), rat (Heikkila et al., 
1985; Takada et al, 1987) and mouse (Heikkila et al., 1984; Ambrosio et al., 1987) and 
many other mammalian species to different extents (Gerlach and Riederer, 1996). It was 
also shown that MPTP caused the depletion of DA in the striatum (Kish et al., 1988). 
Moreover, primates treated with MPTP were shown to have similar 
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neuropathologies and symptoms to idiopathic PD, and in some cases, even induce 
permanent parkinsonism, with varying degrees of motor resemblance to PD. The 
degeneration of the nigrostriatal dopaminergic pathway was shown to be the most 
consistent involvement of MPTP treatment. Although the mechanism whereby this 
neurodegenerative process occurs is unknown, MPTP has been a successful and widely 
used model in the study of the neurodegenerative process of PD (Langston 1995; Fomo 
1996). 
1.3.2 The Mechanisms of MPTP-induced Neurotoxicity 
The metabolic activation of MPTP requires a two-step process in order to cause 
tissue damage. The first step involves conversion of MPTP to its intermediate 
metabolite, 1 -methyl-4-phenyl-1,2-dihydropyridine (MPDP+). In turn, MPDP+ is further 
oxidized to form its toxic metabolite MPP+ (Castagnoli et al., 1985; Greenfield, 1992) 
which induces its toxic effect (Bradbury et al, 1986; Wu et al., 1992). The first 
conversion of MPTP to MPDP+ is catalyzed by MAO-B (Chiba et al., 1984; Hallman and 
Jonsson, 1984) while the next slow oxidation of MPDP+ for the subsequent formation of 
MPP+ is proposed to be a non-enzymatic mechanism because the rate of conversion from 
MPDP+ to MPP+ is quite similar in the presence or absence of cells (Wu et al., 1992). 
Others have suggested that the conversion occurs spontaneously and may be catalyzed by 
neuromelanin, which is present at high concentrations in the nigrostriatal region 
(D'Amato et al., 1987a). 
Besides being a substrate for MAO-B, MPTP is a mechanism-based inhibitor of 
the enzyme (Singer et al., 1985; Tipton et al., 1986). MPDP+ is also a mechanism-based 
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inhibitor, as well as a substrate of both MAO-A and MAO-B. The rate of inactivation of 
MAO-B during the oxidation of MPDP+ to MPP+ is faster than that occurring during the 
oxidation of MPTP to MPDP+ (Krueger et al., 1990). Thus, the oxidation of MPTP is a 
self-limiting process in which the total amount of MPP+ formed will depend on the 
amount of MAO-B initially present (Tsai and Lee, 1994). 
In the brain, astrocytes appeared to be responsible for the MAO-B mediated 
conversion of MPTP to its metabolite MPP+ (Ransom et al” 1987; Brooks et al., 1989; 
Raps et al., 1989; Di Monte et al., 1991). Although serotonergic neurons also contain 
MAO-B (Levitt et al., 1982; Westlund et al., 1985), the contribution of these neuronal 
cells to MPP+ formation is unlikely to be significant because lesions of these neurons did 
not attenuate MPTP neurotoxicity (Melamed et al” 1986; Brooks et al., 1989). This 
further suggested that astrocytes, but not serotonergic neurons are the primary locus for 
MPTP metabolism in the CNS. 
Such evidence establishes the key role for astrocytes in the MPTP model for PD. 
MPDP+ and MPP+ that are formed in astrocytes can diffuse out of the astrocytic 
membrane to the extracellular compartment (Greenfield, 1992) and they can be actively 
taken up by the DA transporters at the DA neuronal membrane (Javitch et al., 1985; 
Schinelli et al., 1988). On the other hand, astrocytes showed heightened resistance to the 
MPTP and MPP+ (Fomo et al., 1992; Wu et al., 1992; Wong et al., 1999) because of the 
high level of antioxidants, SOD (Saint-Jacques et al., 1998), GSH and GSH-Px (Raps et 
al., 1989; Sagara et al., 1993). MPP+ is a potent inhibitor of mitochondrial oxidation of 
nicotinamide adenine dinucleotide-linked substrates which can accumulate within the 
mitochondria (Ramsay and Singer, 1986; Cleeter et al., 1992) and thus inhibit the 
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nicotinamide adenine dinucleotide phosphate (NADPH) ubiquinone (complex I) of the 
electron transport chain (Nicklas et al., 1985; Mizuno et al., 1987; Mizuno et al., 1987; 
Cleeter et al., 1992) resulting in the depletion of ATP (Di Monte et al., 1986). 
Inhibition of mitochondrial complex-I will lead to the cessation of oxidative 
phosphorylation (Nicklas et al, 1985). Since the CNS depends on aerobic synthesis for 
maintenance of cellular energy integrity, this blockage will lead to the rapid depletion of 
ATP and consequently the loss of membrane potential. This in turn will lead to 
nigrostriatal nerve cell death by mechanisms that may involve altered calcium 
homeostasis and, perhaps, free radical formation (Tipton and Singer, 1993). 
The inhibitory effects of MPP+ on mitochondria are not organ-specific. Therefore, 
the selective neurotoxic action observed may be the result of the specific ability of 
nigrostriatal dopaminergic nerve terminals to take up MPP+ and retain it at sufficiently 
high concentrations to cause neuronal cell death. The selectivity of the toxic effects may 
be enhanced further due to the binding of MPP+ by neuromelanin (D'Amato et al., 
1987b). 
Another important aspect of MPTP toxicity is the generation of the ROS because 
during the conversion from MPTP to MPP+，cytotoxic OH , O2 were formed and this can 
also cause neuronal death (Chiueh et al” 1992; Zang and Misra 1993). Hasegawa et al. 
(1990) provided evidence in favour of the free radical hypothesis by showing that the 
inhibition of complex I by MPP+ led to O2 generation. MPP+ has been shown to induce a 
massive efflux of DA in the rat striatum (Rollema et al., 1988). Increased intracellular 
levels of DA are associated with the production of H2O2, thus also may lead to 
neurotoxicity (Cohen and Spina, 1989). 
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MPP+ perfusion into the rat striatum can cause an increased generation of OH in 
the presence of iron ( F e � ) (Chiueh et al , 1993) and in ROS production in astrocytes 
(Wong et al., 1999). It was shown that blocking the Fenton reaction with iron chelators 
like phenanthroline and deferoxamine, could abolish the conversion of MPTP to MPP+ 
(Di Monte et al., 1995). Thus the presence of a high level of iron in the SN may render 
the area more vulnerable to the effects of MPTP (Poirier et al, 1985). Even though the 
formation of ROS may contribute to the underlying mechanism of MPTP neurotoxicity, 
however, it was not shown whether iron chelation attenuates ROS production. 
1.4 Antioxidants in the Central Nervous System 
Antioxidants can be defined as substances that are capable of inhibiting oxidation 
as well as prolonging the initiation phase or inhibiting the propagation phase of auto-
oxidation, but they cannot completely prevent oxidation. The intracellular antioxidant 
system provides a means for a cell to counteract directly the actions of various free 
radicals, thereby attempting to maintain essential cell functions. 
1.4.1 Superoxide Dismutase (SOD) 
O2. is generated in the mitochondria and endoplasmic reticulum by a one-electron 
reduction of oxygen, which can occur by several means. During the normal respiration of 
the cell, the inefficiency of the electron carrying components of the mitochondrial 
transport chain is thought to lead to a small but constant production of O2 (Fridovich, 
1978). 
O2 is metabolized by the metalloenzymes, SOD, (McCord and Fridovich, 1969) 
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which consists of two types: the first type is present in the cytosol known as copper-zinc-
SOD (CuZn-SOD); the other type is present in the mitochondria and called manganese-
SOD (Mn-SOD). SOD is the first step of the oxygen free radical detoxification chain, 
leading to the formation of H2O2 and molecular oxygen. 
The increase in CuZn-SOD activity was observed in the temporal cortex, red 
nucleus, thalamus and SN in PD brains(Marttila et al, 1988) while Saggu et al. (1989) 
found an increase only in mitochondrial Mn-SOD in the SN. In the SN pars compacta, 
CuZn-SOD gene is preferentially expressed in the neuromelanin-pigmented neurons and 
its mRNA were shown to increase in PD brains (Ceballos et al., 1990). Such increase in 
SOD level suggested that an adaptive increase to the excess formation of O2 through 
mitochondrial respiratory chain was formed (Jenner et al., 1992). 
Furthermore, the over-expression of CuZn-SOD gene in transgenic mice was 
shown to be protective against MPTP neurotoxicity (Przedborski et al., 1992). However, 
whether SOD acts as an inhibitor of the initiation or the propagation of the 
neurodegenerative process is still unclear. 
1.4.2 Glutathione (GSH) 
Hydrogen peroxide (H2O2), just like O2 , can be generated as part of the normal 
physiology of a cell. Auto-oxidation of DA- and MAO-dependent oxidative deamination 
both contribute to the formation of H2O2 (Halliwell 1992a; Chiueh et al., 1993). 
H2O2 is not a free radical as it does not contain an unpaired electron, but it is a 
frequent consequence of oxidative stress and may exert its action by altering the 
intracellular redox state of the cell. Besides, it crosses the cell membrane easily and thus 
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its effects can be at a distant site within the cell or extend to the neighbouring cells. In 
addition, H2O2 can act as an oxidizing agent and is also a precursor for the tissue-
damaging OH . So, the continuous production of H2O2 will lead to the formation of the 
highly toxic and reactive OH . This reaction is catalyzed by iron through the Fenton 
reaction or in combination with O2 by the Haber-Weiss reaction. 
Normally, catalase and selenium-dependent GSH-Px remove H2O2. Since GSH-
Px is much more abundant than catalase in the brain, it is probably a more important 
enzyme for the scavenging of H2O2 in the CNS (Marklund, 1982). Approximately 90% 
of total cellular GSH is localized in the cytosolic fraction, the rest being 
compartmentalized within the mitochondria (Reed, 1990). GSH was synthesized and 
degraded in most cell types by a series of well-characterized enzymatic reactions and it 
exists in both the reduced GSH and oxidized state (GSSG) which are interconvertible by 
the action of two enzymes GSH-Px and glutathione reductase (GSH-R). GSH content of 
neurons gradually decreases during development, whilst that of the glia remain relatively 
constant (Lowndes et al., 1994). Rap et al. (1989), in the histochemical evaluation of 
freshly prepared adult rodent and primate brain tissues, showed that GSH is located 
predominantly in non-neuronal elements such as glia. Neurons co-cultured with 
astrocytes have markedly elevated GSH concentration compared with neurons cultured 
alone (Sagara et al., 1993)，this further showed that GSH is mainly located in glial cells. 
Most cells keep the ratio of the reduced GSH to GSSG to greater than 300 
(Peuchen et al., 1997) and this ratio serves as a sensitive index of oxidative stress 
(Toborek and Hennig, 1994). Reduced GSH strongly modulates the redox state (ratio of 
oxidizing to reducing equivalents) of the cell, a role which is critical for cell survival 
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(Chance et al., 1979). H2O2 reacted with reduced GSH to form GSSG and water, this 
reaction was catalyzed by enzyme GSH-Px. Reduced GSH was regenerated by the 
action of GSH-R (Meister and Anderson, 1983) which require the reduction of NADPH 
as a hydrogen donor (Toborek and Hennig, 1994). Peuchen et al. (1997) concluded that 
due to the higher GSH content in astrocytes than neurons in the CNS, one of the roles of 
astrocytes is to counteract oxidative stress (Sengstock et al., 1994; Bolanos et al., 1995). 
This observation supported the tenet that astrocytes provide antioxidant support in the 
CNS via the GSH system. 
1.5 Metallothioneins (MTs) 
1.5.1 Characteristics of MTs 
MTs were first discovered in 1957 by Margoshes and Vallee. MTs were 
identified in the kidney as a protein which is responsible for the accumulation of 
cadmium, a non-essential post-transition metal ion that leads to cytotoxicity (Margoshes 
and Vallee 1957; Ebadi et al.，1998). MTs are 6-7 kDa low molecular weight intracellular 
proteins. They are cysteine-rich proteins with no aromatic amino acids or disulfide bonds. 
There are 61-68 amino acids residues, with 25-30% of them being cysteine. MTs have 
high affinity for both essential (zinc and copper) and non-essential (cadmium and 
mercury) metals (Wan et al., 1993). The genes encoding each MTs isoform are clustered 
on mouse chromosome 8 and human chromosome 16 and they share a similar intron / 
exon structure (Palmiter et al., 1993). 
The mammalian MTs family consists of four similar but distinct isoforms, 
designated as MT-I to MT-IV (Quaife et al., 1994). MT-I and MT-II isoforms are 
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expressed in various tissues and organs like the liver, kidney and CNS. In the CNS, 
expression of MT-I and MT-II is abundant in fibrous and protoplasmic astrocytes but are 
absent from microglia and oligodendrocytes. MT-I and MT-II are relatively low in 
neurons (Nishimura et al., 1992; Blaauwgeers et al., 1993). In vitro studies showed an 
approximately 10-fold higher MT-I level in astrocytes when compared with neuronal 
cultures (Hidalgo et al” 1994). In situ hybridization showed that MT-I mRNA expression 
was predominantly localized in glial cells of the Purkinje cell layer of the cerebellum and 
also on the ependymal cells of the lateral ventricles. MT-I and -II are also shown to be 
mainly localized in the ependymal choroid plexus epithelium (Young et al” 1991). 
Furthermore, MT-I and -II expression are increased in myelin-deficient jimpy mouse 
(Vela et al., 1997) and in several human adult neurodegeneration disorders such as 
Alzheimer's disease, Duguid and amyotrophic lateral sclerosis (Sillevis Smitt et al” 
1992) as well as in ageing (Suzuki et al., 1994) and ischemic brains (Neal et al., 1996). 
MT-III isoform, known also as a growth inhibitory factor, possesses an addition 
of 7 amino acids and has a total of 68 amino acids as compared to 61 amino acids for 
MT-I and MT-II isoforms. It is expressed only in the brain and to a very minute extent in 
the intestine and pancreas (Uchida et al” 1991; Palmiter et al., 1992). In situ 
hybridization showed that MT-III is predominately expressed in zinc-containing neurons 
of the hippocampus and is absent from glial elements (Masters et al., 1994). 
Recently,Carrasco et al. further showed that MT-III was also present in astrocytes 
(Carrasco et al, 1999). The function of MT-III differs from those of MT-I and -II, as 
suggested from in vitro (Uchida et al., 1991; Palmiter 1995) and in vivo studies (Quaife et 
al.，1998) where MT-III function as a growth inhibitory factor and MT-I and -II are 
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involved in antioxidant functions as well as zinc and copper metabolism (Sato and 
Bremner 1993; Aschner et al., 1997). The expression ofMT-IV is restricted to comified 
and stratified squamous epithelium of skin, tongue, and upper part of the alimentary tract 
(Kobayashi et al., 1993; Quaife et al., 1994). 
Heavy metals, glucocorticoid hormones, oxidative agents, cytokines, endotoxins, 
acute stress and irradiation all induce the expression of MT-I and MT-II (Klaassen, 1981; 
Hidalgo et al., 1990). Although liver is the most responsive organ to MTs’ induction, 
MTs are also induced in other organs including the brain. It was reported that 
intracerebral expression of MT-I and -II is clearly upregulated during pathological 
conditions such as trauma (Penkowa and Moos, 1995), immobilization stress (Hidalgo et 
al., 1990), kainic acid-induced seizure (Zheng et al., 1995) and administration of 6-
aminonicotamide (Penkowa et al., 1997). 
1.5.2 Functions of MTs 
Brain MTs are implicated in metal metabolism, cellular repair processes, growth, 
and differentiation. They are likely to serve as the source of zinc for the newly 
synthesized apoenzymes (Kelly et al., 1996; Aschner et al., 1997) as well as serve as 
regulator molecules in gene expression. Resistance to heavy metal toxicity is closely 
related to the cellular ability to synthesize MTs. Induction of MTs endow the astrocytes 
with a tolerance to heavy metal neurotoxicity (Aschner, 1996). It was shown that 
methylmercury (MeHg) will be metabolized to Hg2+ after long term exposure and Hg2+ 
then binds to MTs within the astrocytes (Vahter et al., 1995), neutralizing its cytotoxicity. 
In addition, MTs provide cellular cytoprotection from ROS by scavenging free 
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radicals. OH, the most potent ROS, can react with almost any molecules found in 
the living cell resulting in inactivation of enzymes, strand breaks and base modification 
of DNA (Floyd and Carney, 1992) as well as in causing lipid peroxidation. Up to now, 
there are still no specific scavengers for OH and there is growing attention on the ability 
of MTs to play this role. Recent data suggested that MTs itself may function as a thiol 
donor and free radical scavenger, thus providing a line of protection against oxidative 
damage (Lazo et al., 1995). Moreover, the rate constant of MTs for its reaction with OH 
is also quite high (Sato and Bremner, 1993). It has been shown that the scavenging 
activity of MTs was approximately 50 times greater then reduced GSH on a molar basis 
(Toshiki et al., 1997). 
As thiols are known targets for both peroxynitrite anion and peroxynitrous acid 
(Radi et al., 1991), it is plausible that MTs may intercept both these oxidizers to further 
produce OH . Schwarz et al. (1995) suggested that the antioxidant properties of MTs 
may be due to the formation of iron-thiol-nitrosyl complexes, secondary to the 
sequestration of the transition metals, iron. Others have suggested that the cysteine 
residues of MTs might serve as an expandable target for ROS (Lazo et al., 1995). 
Although the mechanisms associated with the antioxidant properties of MTs remain 
speculative, circumstantial evidence supports the hypothesis that increased levels of MTs 
could potentially provide the "neutralizing" effects to ROS in the CNS. Evidences 
include increased expression of MTs genes in the brain by bacterial endotoxin, as 
revealed by in situ hybridization (Itano et al” 1991). It was also shown that 
transcriptional induction of MT-I gene in the CNS is increased both by oxidative stress, 
kainic acid, and by 6-hydroxydopamine, which generates ROS and is known to be toxic 
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to dopaminergic neurons (Shiraga et al, 1993). MTs have also been shown to protect 
against the cytotoxic and DNA-damaging effects of nitric oxide (Schwarz et al., 1995). 
In addition, mice deficient in MT-I and II genes showed an enhanced sensitivity to 
oxidative stress (Lazo et al., 1995). Besides, transfection and over-expression of 
astrocytic MT-I increases their resistance to MeHg-induced cytotoxicity (Yao et al., 
1999). Furthermore, increase in MTs protect against MPTP-induced neurotoxicity in 
mice and this result suggested that MTs may play a significant role in protecting the brain 
against MPTP-induced neurotoxicity (Rios et al, 1995). 
A role of MT-I and II in the control of apoptosis has received much support in 
recent in vitro and in vivo studies. MT-I and -II knock-out (MT-null) mice had been 
shown to be more sensitive to cadmium-induced liver c-jun and p53 mRNA expression 
(Zheng et al., 1996). Enhanced apoptosis was shown in MT-null cells (Kondo et al., 
1997) and MT-null mice showed more sensitivity to cisplatin-induced hepatotoxicity (Liu 
et al, 1998). Recently, it was shown that MT-I and II are essential for normal wound 
repair in the CNS, and that their deficiency impairs neuronal survival. This study 
demonstrated that in the absence of MT-I and II, neuronal apoptosis was dramatically 
increased (Penkowa et al., 1999). These studies demonstrated that MT-I and -II play a 
significant role in causing apoptosis of brain cells, however, the actual mechanisms 




1.6.1 Characteristics of Astrocytes 
Astrocytes were regarded at first as a passive support element for neurons in the 
brain due to the presence of a large amount of filaments and the absence of action 
potentials (Peuchen et al., 1997). However, increasing evidence suggested that they 
fulfill an important physiological role in many aspects of CNS function and dysfunction. 
Astrocytes, named after their star-like shapes, are the most abundant cell type in the CNS. 
They are the major constituents of the glial cells in the CNS with a ratio of 10:1 to 
neurons and comprising up to 30% of brain volume. Taking into account their large 
numbers and intimate relationship with juxtaposed neurons, it is possible, if not probable, 
that astrocytes play an important role in the injury process of the CNS (Aschner, 1993). 
Astrocytes could be divided into protoplasmic and fibrous form based on their 
different morphology. Protoplasmic astrocytes are mainly located in the gray matter, 
they have spiny projections and have many long branched processes while the fibrous 
astrocytes are located in the white matter and have fewer and thinner branched processes 
(Guroff, 1980). However, the separation of these two types is much more difficult to 
assess in vitro, since the protoplasmic astrocytes can be converted into stellar forms by 
replacing serum in the medium with growth factors or with physiological saline. This 
conversion is also promoted by raising the intracellular c-AMP concentrations (Peuchen 
et al., 1997). 
Astrocytes are identified most easily by the presence of the subunit of glial-
specific intermediate filament, a ubiquitous marker, glial fibrillary acidic protein (GFAP) 
(Eng et al., 1971) using immunohistochemical and electron microscope method. 
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Vimentin, another intermediate filament protein in neonatal astrocyte has also been 
regarded as a marker of undifferentiated astrocytes (Galon et al., 1996)，this is usually 
lost when the brain reaches maturity (Pixley and de Vellis, 1984). Apart from GFAP and 
vimentin, the presence of the glial specific enzyme glutamine synthetase and S-100 
protein has also been used to identify astrocytes. (Ridet et al., 1996, 1997). 
1.6.2 Functions of Astrocytes 
For decades, astrocytes have previously been assigned to a passive support role 
for neurons (Barres, 1991). It is now established that in addition, astrocytes contribute to 
the formation of the blood-brain barrier so well as maintainance of the stability of the 
CNS microenvironment (Cancilla et al., 1993). The end feet of astrocytes are a major 
component of the blood-brain barrier and they can induce the formation of tight junctions 
between endothelial cells (Janzer and Raff, 1987). Continuous endothelial layers 
possesses structural and biochemical properties, which can restrict and regulate the 
passage of different substances between blood vessels and cerebral interstitial space. 
Astrocyte swelling is a common pathological finding and represents one of the 
earliest response to CNS injury (Norenberg, 1994). Astrocytes are not structurally 
independent cells but rather are organized into a syncytium that is connected by gap 
junctions (Kettenmann et al., 1983). These junctions are vital for intercellular 
communication and cellular homeostasis. Thus, one can conceptualize the potential for 
an enormous recruitment of astrocytes in responding to physiologic or pathologic stimuli 
(Norenberg, 1994). Astrocytes have a well-defined role in potassium homeostasis of the 
CNS (Kuffler et al” 1966). Potassium is a major ionic species contributing to the resting 
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membrane potential and excitability of neurons. Potassium released during neuronal 
activity is actively taken up by astrocytes, and then redistributed to distant areas 
(Vemadakis, 1988). 
Furthermore, astrocytes are not morphologically static as their shape can be 
influenced by interactions with neurons (Hatten, 1985), with neurotransmitters (Cornell-
Bell et al., 1990) or various physiologic states (Hatton, 1990). Besides, the CNS 
responds to neural injuries with an increase in the number and size of cells expressing 
GFAP, a phenomenon generally referred to as reactive astocytosis or astrogliosis. In vivo, 
this increase in GFAP-positive cells reflects predominantly phenotypic changes of 
resident astrocytes rather than migration or proliferation of such cells (Bignami et al., 
1972; Bignami and Dahl, 1974). Astrocytic response occurs rapidly and can be detected 
within one hour after focal mechanical trauma (Mucke et al., 1991). The prominence of 
astrogliosis in various diseases, the rapidity of the astrocytic response and the 
evolutionary conservation of reactive astrogliosis indicate that the reactive astrocytes 
fulfill important functions for the CNS. However, the exact role that reactive astrocytes 
may play in the injured CNS so far remained elusive. 
Apart from that, astrocytes are the main sites of energy metabolism in the CNS 
(Hamprecht and Dringen, 1995). Glucose is the main form of energy used by the brain, 
which can be taken up by facilitated diffusion. A continuous supply of glucose is 
essential to the normal function of the brain. Glycogen, a storage form of glucose, is 
mainly found in astrocytes (Cataldo and Broadwell 1986). The breakdown of glycogen 
can be induced by hormones such as noradrenaline, which leads to a rapid degradation of 
glycogen through the activation of glycogen phosphorylase (Coopersmith and Leon， 
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1995) and undergo glycogenolysis. Astrocytes have also been shown to metabolize fatty 
acids，as well as octanoic acids to ketone bodies, which are the dominant fuel of the brain 
when under starvation. Moreover, the cytosolic malic enzyme, which is used to convert 
Kreb's cycle intermediate malate to pyruvate, appears to be prominent in astrocytes. 
Pyruvate can be used locally or transported to others cells for energy production. So it 
can be concluded that astrocytes can form energy-rich compounds for the utilization of 
neighbouring cells (Dringen and Hamprecht, 1992). 
Astrocytes have also been shown to participate in immunological responses in the 
CNS (Prochiantz and Mallat, 1988) and they are thought to be the immune effector cells 
of the CNS and to protect the integrity of the CNS (Xiao and Link, 1998). Reactive 
astrocytes is the initiation of immune responses within the CNS (Hertz et al., 1990). 
When cultured astrocytes are activated, they are able to present antigens to major 
histocompatibility complex (MHC) class I and to MHC class II restricted T lymphocytes. 
They can also produce many different cytokines like interlukin-1, interlukin-6 and tumor 
necrosis factor-a (Fontana and Grob 1984; Fontana et al., 1986; Eddleston and Mucke 
1993), and participate in local immune regulation. So, astrocytes may facilitate and 
amplify immune mechanisms within the CNS (Xiao and Link, 1998). 
Another aspect of astrocytes is their detoxification ability. They are involved in 
the uptake, and thereby elimination of the excitotoxin glutamate from the extracellular 
space. Astrocytes have been demonstrated to possess glutamate receptors (Matute et al., 
1994) and the internalized glutamate is metabolized through the tricarboxylic acid cycle 
(Westergaard et al., 1995) to glutamine by glutamine synthetase, which is mainly 
localized in the astrocytes (Martinez-Hernandez et al., 1977). It has been shown that 
37 
neurons in astrocyte-poor cultures are more vulnerable to glutamate excitotoxicity 
(Rosenberg and Aizenman, 1989) and that astrocytic glutamate uptake may mitigate 
neuronal excitotoxicity (Sugiyama et al., 1989). In addition, astrocytes have been shown 
to clear the extracellular fluid of glutamate by means of a secondary active transport 
mechanism in the plasma membrane (Norenberg 1994; Wilson, 1997). 
Astrocytes contain a large amount of MAO-B and antioxidants such as GSH, 
CuZn and Mn-SOD, and catalase (Hirsch 1992; Thiffault et al” 1995). Therefore, they 
may play an important role in the defense against oxidative stress in the CNS. In the 
adult brain, GSH occurs at higher levels in astrocytes when compared to neurons 
(Lowndes et al., 1994). It also occurs three times greater in concentration in astrocytes 
than in oligodendrocytes (Thorbume and Juurlink, 1996). In cell culture studies, the 
cytosolic GSH concentration and GSH-Px activity are markedly higher in astrocytes than 
in neurons (Huang and Philbert, 1995) and the high level of GSH was shown to be 
responsible for the detoxification of H2O2 (Raps et al., 1989). Besides, recent reports 
indicated that the neurotoxic effect of H2O2 on neurons co-cultured with astrocytes were 
strongly attenuated compared with that observed on a pure population of neurons seeded 
at the same density (Desagher et al.，1996). Dringen et al. (1999) further showed that 
neuronal GSH synthesis was dependent upon the delivery of cysteine from astrocytes to 
neurons. Astrocytes also contain a high level of MTs which has high binding affinity 
with metals (Wan et al., 1993) and can also act as a free radical scavenger (Hussain et al., 
1996). Therefore, astrocytes have an important role to play in the defense against 
oxidative stress in the CNS. 
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1.6.3 Role of Astrocytes in Parkinson's Disease 
Glial scarring is a common phenomenon in PD and it was initially thought to be 
the result of rapid proliferation of astrocytes to fill up the space left by nerve cell loss 
(Hatten et al., 1986; Abbott 1991). Glial scars are usually localized in the areas most 
severely affected by neurodegeneration (Fomo et al., 1992). As a result, it was suggested 
that astrocytes might play a passive role, secondary to neuronal loss in PD. 
With the increased knowledge of both biochemical and physiological functions of 
astrocytes, evidence seems to suggest that astrocytes are actively involved in the process 
of neuroprotection and neurodegeneration. Astrocytes are more resistant to oxidative 
stress than oligodendrocytes or neurons. For example, astrocytes are much less affected 
than neurons induced by peroxynitrite, the depletion of GSH, mitochondria damage 
(Bolanos et al , 1995) and lack of NMDA receptors and the presense of specific 
glutamate transporter GLTl and GLAST. In addition, astrocytes are at least 25-fold less 
sensitive to free radical mediated cell death induced by glutamate when compared to 
oligodendrocytes and cortical neurons (Oka et al, 1993). The high resistance to 
oxidative stress of astrocytes is due to the low level of iron, the high concentrations of 
antioxidants like SOD (Saint-Jacques et al, 1998)，GSH and GSH-Px which is important 
for detoxification (Amemiya et al, 1989; Sagara et al., 1993). 
It was reported that there was a high density of GSH-Px positive astrocytes 
around the mesencephalic dopaminergic neurons in normal postmortem brains (Hirsch 
1992; Damier et al., 1993). These authors therefore suggested that this may render the 
DA neurons more resistant to the pathological process of PD. While in the postmortem 
PD brains, the density of GSH-Px positive astrocytes was lower. A 40% decrease in the 
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levels of reduced GSH in PD was observed in these brains (Dexter et al., 1994). These 
indicated that the amount of GSH-Px-containing astrocytes might be critical for the 
protective effect against oxidative stress in PD. 
MT-I and MT-II are free radical scavengers (Hussain et al., 1996) that are located 
in astrocytes but not in oligodendrocytes or neurons (Nakajima and Suzuki 1995; 
Aschner 1996). MTs inducers have been shown to protect against MPTP-induced 
neurotoxicity in mice (Rojas and Rios，1997). This may be due to the putative action of 
astrocytic MTs as OH scavengers. MTs ability to bind metals such as zinc and copper 
may also play an important role in protecting dopaminergic neurons from free radicals 
induced by MPTP (Rojas and Rios, 1997). 
An approximately 40% decrease in mitochondrial complex I activity occurs in PD 
(Schapira et al” 1990b). However, astrocytes are more resistant to MPTP-induced ATP 
depletion because astrocytes have an alternative pathway to produce energy (Di Monte et 
al” 1992b). Astrocytes can utilize the accumulated energy substrate, glycogen, in 
conditions of energy crisis (Cataldo and Broadwell, 1986). So, astrocytes can act as an 
energy source for neurons when there is a MPTP-induced ATP depletion. 
Astrocytes contain large amounts of MAO-B in the CNS (Levitt et al.，1982). 
MAO-B is responsible for the metabolism of DA and this is believed to be a major route 
for the degradation of this neurotransmitter in the CNS (Gaal and Hermecz, 1993). 
Astrocytes are the primary site for the bioactivation of MPTP where MPTP is converted 
to its toxic metabolite MPP+ (Yang et al., 1988; Di Monte et al , 1991) and thus generate 
ROS like O2 and OH which will finally cause neuronal death (Chiueh et al., 1992; Zang 
and Misra 1993). In fact, the rate of ROS production was largely determined by MAO-B 
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activity. Increase in glial MAO-B activity may lead to a higher rate of DA turnover and a 
consequent increase in ROS production. Thus it is important to establish the extent in 
which astrocytes may play in ROS production in MPTP-induced parkinsonism. 
1.7 Aim of Project 
Given that oxidative stress may play a key role in the development of PD, and that 
astrocytes may be an important mediator in this process, the aim of the study is to 
investigate whether antioxidants can attenuate astrocytic mediated ROS production after 
MPTP or MPP+ treatment. This study particularly focuses on MTs' role in this process. 
To achieve this goal, an in vitro and an in vivo study were carried out. 
Firstly，the in vitro study examined whether MTs can attenuate MPP^-induced 
ROS production in cultured astrocytes. Cultured astrocytes had been reported to generate 
ROS after MPP+ treatment (Wong et al , 1999). The ability of MTs to ameliorate this 
process was thus examined. Astrocytes were pretreated with 50jLiM zinc sulphate 
(ZnSCU) to induce MT-I and -II expression 24 h prior to MPP+ treatment. Cell viability 
and mitochondrial function were assessed using lactate dehydrogenase (LDH) and 3,(4,5-
dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) assays respectively. ROS 
production was measured using the non-fluorescent probe 2，,7，-
dihydrodichlorofluorescein diacetate (DCFH-DA) which crosses cell membrane and is 
hydrolyzed to another non-fluorescent species, 2'7'-dichlorofluorescein (DCFH). In the 
presence of ROS, DCFH will be oxidized to the highly fluorescent 2,7，-
dichlorofluorescein (DCF) and can be detected spectrofluorometrically. 
In order to establish the maximal conditions whereby ROS production can be 
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ameliorated after MPP+ treatment, cells were also treated with N-acetyl-cysteine (NAc)，a 
GSH inducer, as well as with deferoxamine (Def), an iron chelator, alone or in 
combination with ZnS04. 
Astrocytes were cultured from the frontal cortex, striatum and ventral 
mesencephalon of neonatal C57 BL/6 mice. Cells were treated with 10 |liM MPP+ and 
then examined at different time points during 48 hours (h) of treatment. Ventral 
mesencephalon is selected because it is the location of the dopaminergic cell bodies. 
Striatum is the location of the dopaminergic axon terminals and cortex is selected to serve 
as a non-dopaminergic control. Previous studies showed that astrocytes from different 
regions of the CNS responded differently to MPP+-induced ROS production (Wong et al., 
1999). Given the MPTP/MPP+ primarily affects cells and terminals in the mesencephalon 
and striatum respectively, it is important to determine whether astrocytes from these 
regions are more susceptible to oxidative damage. 
In order to further establish MTs protective effects in an in vivo condition, MT-
null mice were used. These mice were employed to further establish whether the lack of 
MT-I and -II would exacerbate MPTP-induced neurotoxicity. MT-null mice, Svl29 their 
inbred control, as well as C57 BL/6 mice were examined after 1 dose of 40mg/kg (s.c.) 
MPTP treatment. C57 BL/6 mice were used because strain difference in response to 
MPTP treatment had been reported (Tsai and Lee, 1994) and C57 BL/6 mice had been 
widely used as a mouse model for MPTP treatment. The neurotoxic effect of MPTP was 
first examined by counting the number of TH-positive cells in the SN. Terminal damage 
in the striatum was ascertained by measuring the striatal DA, dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) contents using high performance liquid 
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chromatography (HPLC). The specific binding of DA transporters (DAT) in the striatum 
was also examined. These results not only enable us to ascertain the best conditions 
whereby MPP^-induced oxidative stress can be ameliorated, but also shed light on the 
protective role of MTs in the pathogenesis of PD. 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 In Vitro Study 
2.1.1 Astrocyte cultures 
Newborn C57 BL/6 mice (provided by the animal house of the Chinese 
University of Hong Kong) were used. In order to study the regional differences, cortical, 
mesencephalic and striatal astrocytes were cultured from the neonatal brains. 
Mesencephalic and striatal astrocytes were used because the cell bodies and terminals of 
the dopaminergic neurons are located in these areas, respectively. Cortical astrocytes 
(with the removal of the pre-frontal cortex) were used as non-dopaminergic controls. 
Brain Isolation 
After decapitation, the head was rinsed with 70% alcohol and the brain was 
removed and immersed into Hank's Balanced Salt Solution (HBSS, supplemented with 
15mM HEPES and 0.35g sodium bicarbonate in IL, pH7.4，GIBCO BRL 21250-022, 
USA). The meninges were removed and the cortical, mesencephalic and striatal regions 
were dissected out under a dissecting microscope according to Robertson et al., (1989). 
After the isolation of the three regions, the brains were minced into pieces. 
Trypsinization 
The minced brain tissues were trypsinized with 0.125% trypsin solution dissolved 
in HBSS for 10 minutes (min) at 37�C, shaking occasionally. After trypsinization, the 
enzyme reaction was stopped with one fold of 10% fetal bovine serum (FBS) in 
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Dulbecco's modified Eagle's medium containing Ham's nutrient mixture F-12 
(DMEM/F12) (GIBCO BRL 12400-024, USA). The suspension was centrifuged at 
19,000 rpm for 3 min (Centraur 2，MSE, UK). The supernatant was removed and the 
pellet was resuspended in 10% FBS in DMEM/F12 and triturated with medium and then 
passed through an ISV2 gauge needle and syringe. The cells were subsequently filtered 
through a 70|im sterile nylon Nitex sieve (Spectrum Medical Industries Inc., Spectrum & 
Spectra/Mesh, 146490, USA) to further triturate the cells. 
Cell Counting 
Cell viability was determined by mixing 10|LI1 of astrocytes-containing medium 
with 10|Lil trypan blue (Sigma, USA) (Philip 1973) and transferring lOjLil of the mixture to 
the haemocytometer for cell counting under the microscope. The dead cells were stained 
blue while live cells were phase bright. Total number of live cells = no. of live cells x 2 
(dilution factor) x cell volume x ICA The percentage of viability = total no. of live 
cells/total no. of cells counted. 
Seeding 
The seeding density for 75cm^ flask (Becton Dickson & Company，Falcon, 3110， 
USA) was approximately 1 x 10^  per flask. Cells were incubated in a ST '^C and 5% 
CO2/950/0 air incubator. The culture medium (DMEM/F-12) was supplemented with 10% 
heat-inactivated FBS, 1% penicillin (lOOOunit/ml) and 1% streptomycin (lOOOjug/ml). 
The medium was changed every three days until the cells were confluent around 12-14 
days. When cells were confluent, they were shaken overnight at 260 rpm, 3TC (Lab-line 
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Orbit Environ-shaker, USA). This process removed most microglia and 
oligodendrocytes. The detached cells were washed twice with HBSS and trypsinized 
with 0.05% trypsin in HBSS + 0.02% ethylenedinitrilo-tetraacetic acid (EDTA). Cells 
were subsequently subcultured onto 35mm tissue culture dishes (Coming 25000, USA) at 
a seeding density of 1 x 10^ per dish. 
2.1.2 Treatment regimen 
All the drugs used in this study were dissolved in serum free DMEM/F12 medium 
(pH 7.4) and filtered with 0.22|Lim filter (Schleicher & Schuell, FP03013, Germany). For 
each time course and treatment, there was a corresponding control in which cells were 
incubated with serum-free medium only. Each time point was repeated at least four times. 
2.1.2.1 l-methyl-4-phenyl-pyridinium (MPP^ Treatment 
Astrocytes were treated with lOjiM MPP+ in serum free medium and incubated 
for 0, 4，8, 24 and 48 h. Astrocytes incubated with serum free medium only were used as 
the corresponding controls. Samples were collected at each designated time point for 
biochemical assays. 
2.1.2.2 Induction of Metallothioneins (MTs) and Glutathione (GSH) 
Prior to MPP+ treatment, cells were pretreated with 50|LIM ZnS04 (Sigma Z-4750, 
USA) or 20mM NAc (Sigma A-9165，USA) for 24 h to induce an increase in endogenous 
MTs and GSH respectively. 
Hidalgo et al. (1995) reported that 50jaM ZnS04 significantly increased MT-I 
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levels by up to 3.5 fold in neurons and 2.5 fold in astrocytes. Later studies reported that 
neuronal MTs were highly induced by lO i^M ZnS04 for 48 h while hepatic MTs were 
induced by 100|LIM ZnS04 for 24 h (Ebadi et al., 1996). 
For NAc, previous studies showed that 20 - 60mM NAc can increase the 
intracellular GSH level and prevent apoptotic cell death of neuronal PC 12 cells (Ferrari et 
al., 1995). Besides, the protective effects of NAc were also examined in other studies by 
using 20mM NAc (Pahan et al., 1998; Turtle et al, 1998). In order to establish the 
appropriate concentrations of ZnS04 and NAc for this study, concentration dependent 
studies were performed where the effects of 10 - lOOfiM ZnS04 or 10 - lOOmM NAc 
treatment were examined. The incubation period of ZnS04 or NAc was examined from 2 
-72 h. Results showed that 50|aM ZnSCU and 20mM NAc at 24 h incubation induced the 
highest amount of MTs and GSH respectively (data not shown). 
Evidence of MTs expression and GSH levels was examined by Northern blot 
analysis and GSH assay respectively. Astrocytes were also immunostained with MTs 
antibody to provide further evidence of an increased expression in MTs protein after 
ZnS04 treatment. 
2.1.2.2.1 Northern Blotting 
Whole cell RNA was isolated by TRI REAGENT® (Molecular Research Center, 
OH, USA) according to the manufacturer's protocol. 7fag of total RNA per lane were 
electrophoresed on a 1.2% (w/v) agarose gel under denaturing conditions. After 
migration, total RNA was transferred to a Hybond-N+ membrane (Amersham, UK) and 
cross-linked to the membrane with UV light. After prehybridization in buffer containing 
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0.25M Na2P04 and 7% SDS, the membrane was hybridized overnight at 65'C with 
labeled rat MT- I cDNA probe (gift from Professor M. Aschner) generated by means of 
random priming. The membrane was washed with O.lx SSC (sodium chloride + sodium 
citrate) and 0.5% SDS for 1 h at 65。C and the membrane was then exposed to X-ray fi lm 
(Eastman Kodak Co.) at -70°C with intensifying screen. Stripped membranes were 
rehybridized overnight with human glyceraldehyde-3 -phosphate dehydrogenase 
(GAPDH) cDNA probe under the same conditions and then band densities were 
measured. 
2.1.2.2.2 Immunocytochemical Staining for MTs 
Primary astrocytes, after shaking, were subcultured onto poly-L-lysine (Sigma P-
8920, USA) -coated 15mm glass slides with a seeding density of 1 x 10^ cells / well and 
grown for 5 days in DMEM/F12 medium with 10% FBS. After cells became confluent, 
they were pre-treated with 50|IM ZnSCU for 24 h prior to 10|LIM MPP+ treatment. Cells 
were fixed at 0, 4，8, 24, 48 h after MPP+ treatment. Control cells were incubated either 
with medium only or with 50|aM ZnSCU. 
Cells were washed three times in ice-cold PBS and fixed with 4% 
paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.2 for 1 h. After fixation, cells 
were washed in PBS for three times. Cells were then incubated with primary mouse anti-
metallothionein (1:200’ E-9 DAKO, Denmark) antibody, in PBS containing 0.1% Triton 
X-100, 0.1% BSA and O.OSNaNs (PBT), overnight at room temperature (RT). Cells 
without the incubation of primary antibody served as a negative control. The cells were 
washed three times in PBS and incubated with biotinylated goat anti-mouse secondary 
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antibody (1:500, Vector, USA) in PBT for 2 hours at RT. Cells were then washed in PBS 
and incubated with avidin-biotinlated peroxidase (1:1000, Zymed, USA) in PBT for 1 h 
and then washed in PBS. The cells were pre-incubated with ammonium nickel sulfate 
(Fluka 09885，Switerland)- diaminobenzidine (DAB) (Sigma D-5637, USA) solution for 
10 min and then glucose oxidase (Sigma G-2133, USA) solution was added. The reaction 
sites were then visualized by the glucose oxidase-DAB-nickel procedure (Shu et al., 
1988) and the signals were shown as a dark blue colour. 
Cells were dehydrated in an alcohol series, cleared with xylene and mounted with 
mountant (Permount SP15-500, Fisher Scientific, USA). Cells were then observed under 
a photomicroscope (Zeiss, Germany). MT-I, - I I immunocytochemical staining for each 
time course and each treatment group were done in triplicate. 
2.1.2.2.3 Glutathione (GSH) Assay 
GSH was measured using the method of Giffard et al. (1998) which was a 
modified technique described by Femandez-Checa and Kaplowitz (Femandez-Checa and 
Kaplowitz 1990). The astrocytic GSH level was determined by specific reaction of 
monochlorobimane (mBCl) with GSH. mBCl belongs to the bimanes which are a family 
of heterocyclic compounds that form fluorescent adducts with thiols. Monobromobimane 
(mBBr) has been used as a fluorescent thiol reagent but does not discriminate between 
GSH and other non-protein and protein sulfhydryls. mBCl, however, had been found to 
be less reactive with thiols than mBBr, forming a fluorescent adduct with GSH more 
specifically than mBBr and preferentially over other thiols in a reaction catalyzed by 
glutathione transferase. mBCl, itself non-fluorescent, forms a stable, fluorescent adduct, 
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GSH-bimane, with GSH in a reaction catalyzed by the GST. Once the fluorescent adduct 
is formed within the cell, it wi l l not be released from the cell. So the cellular GSH level 
can be assayed by measuring the fluorescent adduct spectrophotometrically. 
In order to perform this assay, astrocytes were subcultured onto poly-L-lysine-
coated 24-well plates ( N u n c l o n ™ ^ Nunc, USA) at a seeding density of 1 x 10^  cells per 
well. After different treatments, the culture media were removed and cells were gently 
washed once with 0.5ml PBS, pH 7.4 and all the solution removed. 0.5ml PBS and 5|il 
of 5mM mBCl stock were diluted in ethanol and added to each well to give a final well 
concentration of 50|aM mBCl. The cells were incubated at 3TC for 10 min and washed 
with 0.5ml PBS, then all solution was removed. Cells were then lysed with 0.2% Triton 
X-100 in PBS and scraped into microcentrifuge tubes. Cells were left to stand at 4°C for 
half an hour and then centrifuged at 13,600 g for 5 min. The supernatant was collected 
and 5|LI1 of supernatant was diluted in 2ml PBS. The supernatant was placed in a 
fluorimeter cuvette, mBCl fluorescence was read at 400nm excitation and 480nm 
emission using a spectrofluorometer (Molecular Devices, Spectra MAX Gemini 
Spectrophotometer, USA). Protein concentration was determined using the Lowry 
method (Lowry OH et al., 1951). The concentration of GSH was calculated from the 
standard curve and expressed as nmol/mg protein. 
GSH standard was purchased from Sigma (Sigma G-6529, USA) and prepared as 
a serial dilution from 0 to lOOnM, then incubated overnight with 2 units/ml of GST 
(Sigma G-6511, USA) at 37°C. 50|iM mBCl was added to the standard and incubated for 
10 min, and fluorescence measured. The GSH assay for each time course and each 
treatment was repeated four times. 
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2.1.2.3 Iron Chelation 
In order to examine the effects of iron chelation on ROS production, 200jiM 
deferoxamine (Def) (Sigma D-9533, USA), an iron chelator, was added at the same time 
as lOjiM MPP" treatment. The concentration of Def used in the present study was shown 
not to cause significant changes in astrocytic cell viability (Di Monte et al., 1995). After 
treatment, culture media was removed for LDH and ROS assays. 
2.1.2.4 Combined Pretreatment 
In order to study the efficacy of a combined treatment on MPP^-induced oxidative 
stress, cells were pretreated with 50|iM ZnS04 + 20mM NAc in serum free medium for 
24 h prior to MPP+ treatment. Apart from 50|aM ZnSCU + 20mM NAc pretreatment, 
cells pretreated with ZnSCU and NAc were also treated with 200|iM Def at the time of 
lOjiM MPP+ treatment. After treatment, culture media were removed for LDH and ROS 
assays. Results were compared to that of ZnS04 + NAc treatment only. 
2.1.3 Lactate Dehydrogenase (LDH) Assay 
The measurement of the LDH activity was according to the method of Amador et 
al. (1963). 
The principle of the LDH assay is based on the oxidation of lactate to pyruvate. 
LDH is used to catalyze the oxidation of lactate to pyruvate with simultaneous reduction 
of nicotinamide adenine dinucleotide (NAD) and is shown as follows: 
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LDH 
Lactate + NAD > Pyruvate + NADH + H+ 
The formation of the reduced nicotinamide adenine dinucleotide (NADH) results 
in an increase in absorbance at 340nm which is directly proportional to LDH activity in 
the sample. 
So in order to examine the cytotoxicity of MPP+ on astrocytes, secretion of LDH 
to the culture media was determined. LDH is released to the culture medium when the 
cells undergo increased activities of glycolysis due to the failure of mitochondrial ATP 
formation. Thus, measuring the LDH activity of the astrocytes after MPP+ treatment 
would reflect the metabolic state of the cells. 
After MPP+ treatment or the different pretreatment with MPP+ treatment, the 
culture media were collected at 0，4，8，24, 48 h. 15|il of culture medium from each 
sample were mixed with SOOfal pre-warmed (30。C) LD-L reagent (Sigma Diagnostics, 
LDH-L 50 kit; Sigma, USA). The reaction was left to stand for 30 second and the initial 
reading was recorded spectrophotometrically (Molecular Device, Spectra MAX 250， 
USA) at 340nm, 30°C. The reaction mixture was further incubated for 60 seconds and the 
final reading was recorded. The change of absorbance (AA) per minute (A/min) was 
obtained by subtracting the initial reading from the final reading. The determination of 
the LDH activity (U/L) is according to the following equation: 
AA per min x total reaction volume x 1000 
LDH Activity (U/L) 
6.22 X sample volume x light path 
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where “AA per min，，represent the change in absorbance per minute at 340nm; total 
reaction volume is equal to 315)^ 1; sample volume is 15|il; coefficient of extinction of 
NADH is 6.22; light path is 1cm; and 1000 is the factor to convert units per ml to units 
per liter. 
AAperminx0.315x 1000 
LDH Activity (U/L) 
6.22x0.015 
= AA per min x 3376 
One unit of LDH activity is defined as the amount of enzyme that wil l catalyze the 
formation of 1 jamol of NADH per minute under the conditions of the assay procedure. 
LDH released into the culture medium was assayed as an index for astrocytic 
viability during the different pretreatment and during MPP+ treatment. For each time 
point studied, media from 3 dishes were obtained. Four independent experiments were 
performed for the entire study. 
2.1.4 3,(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) Assay 
MTT assay is an index to show mitochondrial activity in intact cells after different 
drug treatments. Since only live cells can reduce the tetrazolium salt to coloured 
formazan, so MTT levels directly reflect cell viability. 
The measurement of the mitochondria activity by MTT assay was according to 
the method of Hansen et al., (1989). The assay is based on the conversion of tetrazolium 
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salt to coloured formazan. Tetrazolium salts are a large group of heterocyclic organic 
compounds that form highly coloured and often insoluble formazans after reduction, and 
this has been shown to occur at the sites along the mitochondrial electron transport chain. 
(Slater 1963; Mosmann 1983). The formation of the coloured formazan results in an 
increase in absorbance at 750nm that are directly proportional to mitochondria activity. 
MTT assay was performed in 96-well microtiter plates (Nunclon™, Nunc, USA) 
at a seeding density of 1 x lO"^  per well containing 100)il medium. At 0，4，8, 12, 24, 48 h 
after MPP+ treatment, the culture media were collected and MTT reduction in the intact 
cells was performed. MTT was purchased from Sigma (M-2128, USA) and it was first 
dissolved in a concentration of 5mg/ml in sterile PBS at RT, sterilized by 0.22 ^ M filter 
(Schleicher & Schuell，FP03013, Germany) and stored at in a dark bottle equipped 
with a tight cap. It was freshly prepared each time. Lauryl sulfate, sodium salt (SDS), 
and N, N-dimethyl formamide (DMF) were purchased from Sigma (L-3771, D-8654, 
USA) for extraction buffer preparation. Extraction buffer was prepared as follows! 
20%w/v of SDS (RBI D-048, USA) was dissolved at 37°C in a solution of 50% of each 
DMF and double distilled water. The solution was stirred with a magnetic stirrer; pH was 
adjusted to 4.7 by adding 2.5% of and 80% acetic acid and 2.5% 1 N HCl. 
After cells were harvested, 25|LI1 of 5mg/ml stock MTT solution was added to 
each well and incubated for 2 h at 3TC, then lOOjiil of extraction buffer was added. After 
overnight incubation at 3TC, the optical densities were measured at 570nm by using a 
microplate reader (Molecular Device, Vmax, Kinetic Microplate Reader, USA) and 
reading was expressed as relative optical density per well. Culture wells with extraction 
buffer only were read as blanks. For the MTT assay of each time course and each 
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treatment, four independent experiments were performed. 
2.1.5 Reactive Oxygen Species (ROS) Assay 
ROS was measured according to LeBel and Bondy, (1990) using the non-
fluorescent probe 2,7'-dichlorofluorescin diacetate (DCFH-DA) (Molecular Probes D-
399, Netherlands). DCFH-DA has been shown to be more superior for detecting 
intracellular oxidants when compared with 5 (and 6)-carboxy-2\T-dichlorofluorescein 
diacetate and dihydrorhodamine 123 because it is more reactive towards specific 
oxidizing species like H2O2 (Hempel et al., 1999). 
The non-fluorescent probe, DCFH-DA, readily crosses the cell membrane and is 
hydrolyzed by intracellular esterase to form non-fluorescent 2\T-dichlorofluorescin 
(DCFH). In the presence of ROS, DCFH wil l be oxidized to the highly fluorescent 2，，7’-
dichlorofluorescein (DCF). Therefore, the intracellular DCF fluorescence can be used as 
an index to quantify the overall ROS production in cells. 
To perform this assay, astrocytes were subcultured onto poly-L-lysine-coated 96-
well plates (NimclonTM, Nunc, USA) at a seeding density of 1 x 10^ cells per well 
according to Wang and Joseph (1999). 96-well plates were chosen because a large 
amount of samples can be measured at once with low variability. After treatment, the 
culture media were removed and cells gently washed three times with sterilized PBS (pH 
7.4). 
The cells were then incubated in sterilized 480 ^il 40 mM Tris buffer (Sigma, pH 
7.4, USA) with the addition of 20|LI1 of DCFH-DA (2.5 mg/ml; final concentration = 
10|ag/ml) in methanol and incubated for 15 min in 5% C02/95% air at 37°C. The same 
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volume of methanol (without DCFH-DA) was added to another cell sample to correct for 
autofluorescence generated by the cells. The correction for autofluorescence was less 
than 10% of the total. Fluorescence was then measured with a fluorescent 
spectrophotometer (excitation at 488nm, emission at 525nm, 37°C, Cytofluor 2350, 
Millipore, USA). The reading was expressed as DCF fluorescence units per well. Four 
independent experiments were performed for each time point, each treatment and control 
groups. 
2.1.6 Protein Assay 
Whenever a biochemical assay required the units to be expressed as per mg 
protein, astrocytes from which supernatant were removed wi l l be used for protein assay. 
Protein levels of cultured astrocytes were measured according to Lowry et al., (1951). 
When astrocytes were confluent, they were washed three times with cold PBS, then 
scraped with a rubber policeman and homogenized in lysis buffer containing 0.05% 
leupeptin, 0.05% apotitin, 0.05% pepstatin A, 2|LIM PMSF, 1% SDS and LONM Tris HCl. 
lO^il of the cell lysate was diluted 20 fold (10^1 sample + 190|al distilled water) before 
spectrophotometric detection at 750nm. 80|il of each diluted sample was further mixed 
with 320|al water, which gave a final volume of 0.4ml per sample. This was followed by 
an addition of 1.2ml of freshly prepared sodium tartrate and copper sulfate solution 
(100:1 dilution; 50ml sodium tartrate + 0.5ml copper sulfate). The samples were mixed 
well and left to stand for 10 min. 
120|al freshly prepared folin (Sigma F9252, USA) in equal volume of water (1:1) 
was added to each sample. The samples were mixed again and left to stand for a further 
56 
30 min before being measured spectrophotometrically at 750nm (Molecular Device, 
Vmax, Kinetic Microplate Reader, USA). The protein concentration was determined by 
a standard curve prepared from different concentrations of BSA (Sigma A-2153, USA). 
A l l samples and standards were measured in duplicate. 
2.1.7 Statistics 
Al l data were expressed as the mean 士 standard error (SEM). Two-way ANOVA 
was used for LDH, MTT, ROS and GSH measurements, then followed by post-hoc 
Tukey's test. P values < 0.05 were considered as significant. 
2.2 In Vivo Study 
2.2.1 Administration of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) 
Three months old adult male C57 BL/6 mice were provided by the animal house 
of the Chinese University of Hong Kong. 10-12 weeks old MT-I, - I I knock-out (MT-
null) mice and their breeding control, Svl29, were both purchased from Jackson 
Laboratory (Bar Harbor, ME, USA). Al l mice were housed under standard conditions 
(12 h light:dark cycle, 21-22°C) with three per cage and they were allowed free access to 
food and water. 
Al l three strains of mice were divided into two groups and injected 
subcutaneously (s.c), with 1 dose of 40mg/kg MPTP (RBI D-045, USA); control animals 
received normal saline only. Animals were sacrificed 3 days after MPTP treatment. For 
high performance liquid chromatography (HPLC) and DAT analyses, the striatum and 
SN of 3 independent mice from each group were dissected on ice according to Robertson 
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et al” (1989). Three mice from each group were perfused with 4% PFA, embedded in 
paraffin and prepared for immunocytochemistry. 
2.2.2 Tyrosine Hydroxylase (TH) Immunocytochemical Staining 
For the examination of TH positive cells, mice were first anaesthetized by i.p. 
injection with 7% chloralhydrate and then perfused with 25ml 4% PFA. Brains were 
immediately dissected out on ice and post-fixed overnight in the same fixative. 
Whole brains were processed (Shandon Oathcentre, UK), paraffin embedded 
(Thermolyne, Histo-Center II-N, USA) and serial sections (S^im thickness) were obtained 
using a microtome (Leica, Germany). Free-floating sagittal sections were mounted onto 
poly-L-lysine coated slides and dried for immunocytochemical staining. Three 
independent mice from each group were used. 
The dried serial sections were first deparaffinized three times in xylene for 15 
min, then followed by hydration with absolute, 95%, 80% to 70% alcohol, for 5 min each 
to remove excessive xylene. The sections were flushed with running water for 1 min and 
incubated with 0.3-0.5% H2O2 in absolute methanol for 30 min at RT to remove 
endogenous peroxidase. The sections were further flushed with tap water for 1 min and 
rinsed three times in PBS. Then the sections were incubated with primary rabbit anti-TH 
antibody (1:1000) (Calbiochem, 657012, USA) in PBT (PBS with 0.1% BSA，0.01% 
Triton X-100) overnight at RT. Sections without the incubation of primary antibody 
served as negative controls. The sections were then rinsed three times with PBS and 
incubated with biotinylated conjugated goat anti-rabbit IgG secondary antibody (1:500) 
(Jackson 111-065-144, USA), in PBT for 1 h at RT. Sections were rinsed three times 
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with PBS and incubated with HRP-streptavidin (1:1000) (Zymed 43-4323, USA) in PBT 
for 2 hat RT. 
Sections were then washed in PBS and preincubated with ammonium nickel 
sulfate-DAB solution for 10 min followed by glucose oxidase. The reaction sites were 
then visualized by the glucose oxidase-DAB-nickel procedure (Shu et al.，1988) and 
signals were shown in a dark blue colour. The cell nuclei were also counter-stained with 
hematoxylin (Sigma, H-3136, USA). Sections were dehydrated in an alcohol series, from 
70% to absolute alcohol, cleared of xylene and mounted with mountant (Permount SP15-
500, Fisher Scientific, USA). 
Sections were observed under a photomicroscope (Zeiss, Germany) and every one 
out of ten serial sections were stained and TH positive cells were counted. The whole 
half brain of three mice from each group were stained and counted. 
2.2.3 DAT Receptor Binding Assay 
The method of DAT receptor binding assay was modified from Stadlin et al. 
(1994). 
The striata from three mice from each group were dissected on ice and prepared 
for DAT receptor binding assay. Striata were homogenized with 40 volume of ice-cold 
50mM Tris-HCl buffer with 120mM NaCl and 5mM KCl (pH 7.4) in a glass-Telfon 
homogenizer (setting 6, 15s). The homogenates were centrifuged at 50,000 x g 
(Beckman, J2-21 centrifuge, USA) for 10 min and the resulting pellets were washed 
twice and resuspened in 10 volume of SOmM Tris-HCl buffer (as above). 50|LI1 aliquots 
of tissue sample were incubated in triplicate in a total volume of 500|LIL After the 
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mixtures were incubated at RT for 1 h with either 2.5nM ^H-Win 35,428 (84.5 Ci/mmol, 
NEN™ Life Sciences Products, Inc. USA) or 2.5nM ^H-Win 35,428 together with 50|LIM 
Win 35,248 (RBI, USA). The samples were filtered rapidly through Whatman GF/B 
filters with a Brandel Cell Harvester followed by washing of the filters (3 x 5ml Tris-HCl 
buffer at 4°C). The filters were immersed into 3 ml scintillant and extracted overnight 
and radioactivity was quantitated in a Beckman LS 6000 liquid scintillation counter 
(USA). Aliquots of membrane preparations were used for the determination of protein 
content by the Lowry method (Lowry et a l , 1951) with bovine serum albumin as the 
standard. The specific binding was calculated by subtracting the non-specific binding 
from the total binding and then divided by the protein concentration. Results were 
expressed as fmol/mg protein. The specific binding assay for DAT for each group was 
repeated three times. 
2.2.4 Dopamine (DA) and DA metabolites - High Performance Liquid 
Chromatography (HPLC) 
DA and metabolites were measured using the method of Finnegan et al., (1988) 
and Di Monte et al., (1991). Animals were sacrificed by decapitation and the striata from 
three mice from each group were dissected on ice and prepared for HPLC. Striata were 
weighed and homogenized with 1ml of ice-cold 0.4N perchloric acid and sonicated 
(Soniprep 150，MSE Scientific Instruments, UK). The homogenates were centrifuged at 
15,000 rpm (Beckman, J2-21 centrifuge, USA) for 12 min at 4°C and the resulting 
supematants were collected for analysis of DA, DOPAC and HVA by HPLC with 
electrochemical detection (Kilpatrick et al., 1986). The amount of DA, DOPAC and 
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HVA were determined by standard curves, which were prepared from different 
concentrations of DA and its metabolites. The remaining pellets were used for the 
determination of protein content by the Lowry method (Lowry et al., 1951) with bovine 
serum albumin as the standard. Results were expressed as ng/mg protein. The HPLC 
analysis for DA, DOPAC and HVA for each group was repeated three times. 
2.2.5 Statistics 
Al l data were expressed as the mean 土 standard error (SEM). Independent t-test 
was used to analysis the TH cell counts, the specific binding assays and all HPLC 
measurements. P values < 0.05 were considered as significant. 
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CHAPTER THREE: RESULTS 
3.1 In Vitro Study 
3.1.1 Induction of Metallothioneins (MTs) with Zinc Sulfate (ZnS04) 
3.1.1.1 Immunocytochemical changes 
Figure 2 shows the immunocytochemical staining of MTs in mesencephalic, 
striatal and cortical astrocytes after 24 h ZnS04 treatment. The control group consists of 
cells that were incubated in serum-free medium for 24 h. A l l the positive 
immunocytochemical signals were shown in the micrographs as dark blue colour. 
After 24 h ZnSO. treatment (Figs. 2b, d, f), astrocytes showed no obvious 
morphological changes when compared to the control (Figs. 2a, c, e) groups. Astrocytes 
that were positively stained for MTs showed densely stained nuclei and cytoplasmic 
processes. Mesencephalic (Fig. 2b) and striatal (Fig. 2d) astrocytes seemed to show more 
prominent MT staining than cortical astrocytes (Fig. 2f). 
3.1.1.2 Northern Blot Analysis 
Figure 3 shows the mRNA levels of MT-I, -II in the different treatment groups, 
namely i) control, ii) 24 h 50|iM ZnS04 treatment alone, iii) MPP+ treatment alone and 
iv) ZnS04 pretreatment prior to MPP+ treatment. 
After 24 h of 50|iM ZnS04 treatment, MT-I, -II mRNA levels increased by 
98.3%, 28.9%, and 33.4% in mesencephalic, striatal and cortical astrocytes respectively. 
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Fig. 2: Mesencephalic (ME), striatal (ST) and cortical (CO) astrocytes after 24 h 
50|LIM ZnS04 treatment, (b), (d), (f), cells positively stained for MT-I, - I I 
(400 X magnification), (a), (c), (e), cells without ZnS04 treatment (400 x 
magnification). 
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Fig. 3: a) A representative northern blot showing MT-I, - I I mRNA contents in 
mesencephalic (ME), striatal (ST) and cortical (CO) astrocytes. Lanes 1 
represent the control, Lanes 2 represent cells treated with 50jaM ZnSCU for 
24 h, Lanes 3 represent cells treated with 10|aM MPP+ for 48 h and Lanes 4 
represent cells pretreated with 24 h 50|aM ZnS04 prior to 48 h 10|aM MPP+ 
treatment. GADPH contents served as an internal control. 
b) Change in relative levels of MT-I, - I I mRNA expression in 
mesencephalic (ME), striatal (ST) and cortical (CO) astrocytes. Density 
ratios were calculated as MT/GAPDH. 
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(a) Mesencephalic astrocytes (Fig. 3 a) 
48 h MPP+ treatment resulted in the MT-I, - I I mRNA levels which is 96.8% of 
control level. When cells were pretreated with ZnS04 prior to MPP+ treatment, MT-I, - I I 
mRNA level showed a minimal difference (2%) when compared to the control. 
(b) Striatal astrocytes (Fig. 3b) 
Similarly, 48h MPP+ or ZnSCU + MPP+ treatment resulted in minimal changes in 
MT-I, - I I levels when compared to the control. 
(c) Cortical astrocytes (Fig. 3c) 
MPP+ treatment resulted in a minimal increase (12.4%) increase in MT-I, - I I 
mRNA level when compared to the control. ZnS04 + MPP+ treatment showed a 31.4% 
increase in MT-I, - I I mRNA level when compared to the control. 
3.1.1.3 The Effects of ZnS04 Pretreatment on l-methyl-4-phenyl-pyridinium 
(MPP^-treated Astrocytes 
3.1.1.3.1Lactate Dehydrogenase (LDH) Activities 
Figure 4 shows the results of LDH activities of mesencephalic, striatal and 
cortical astrocytes from 0 to 48 h incubation. The treatment groups consisted of i) the 
control group where cells were incubated with serum free medium only, ii) cells that 
were only pretreated with 50)aM ZnSCU for 24 h, iii) cells treated with 10)aM MPP+ 
treatment only and iv) cells pretreated with SO i^M ZnSCU 24 h prior to lO^iM MPP+ 
treatment. LDH activities from cultured media were measured at 0, 4，8, 24 and 48 h 
after treatment. 
63 
Fig. 4: Amount of LDH release into the media from (a) mesencephalic (ME), (b) 
striatal (ST) and (c) cortical (CO) astrocytes in control (•)，50|iM ZnS04 
( • ) , lO^iM MPP+ ( • ) and 50[iM ZuSOa + lOjiM MPP+ ( 0 ) treatment 
groups from 0 - 48 h. Values are expressed as mean 士 SEM. * p < 0.05, as 
compared with corresponding control. # p < 0.05，as compared with the 









































































































































































(a) Mesencephalic astrocytes (Fig. 4a) 
Mesencephalic astrocytes showed that there was no significant increase in LDH 
levels in the control group during 48 h (5.20 士 0.14 U/L at 0 h to 8.72 土 0.49 U/L at 48 h) 
of incubation in serum-free media. Astrocytes that were pretreated with ZnS04 only also 
did not show any significant increase in LDH levels during the 48 h (5.06 ±0.19 U/L at 0 
h to 7.74 土 0.42 U/L at 48 h) incubation. 
After MPP+ treatment, mesencephalic astrocytes showed a rapid increase in LDH 
levels from 4 h (16.25 士 0.80 U/L) onwards. This represented a 1.9 fold significant 
increase (p < 0.05) when compared to the control (5.63 士 0.39 U/L) group. By 48 h 
treatment, LDH increased to 41.99 士 1.63 U/L, a 3.8 fold increase (p < 0.05) when 
compared to the control. 
When mesencephalic astrocytes were pretreated with ZnS04 prior to MPP+ 
treatment, there was a significant decrease (p < 0.05) in LDH levels along all the time 
points studied when compared with MPP+ treatment. At 4 and 48 h of ZnSCU + MPP+ 
treatment, a 1.1 fold (7.60 ± 0.11 U/L in ZnSCU + MPP+ treatment vs 16.25 土 0.80 U/L in 
MPP+ treatment) and 1.2 fold (19.13 土 0.20 U/L in ZnS04 + MPP+ treatment vs 41.99 士 
1.63 U/L in MPP+ treatment) significant decrease (p < 0.05) respectively was observed 
when compared with the MPP+4reated groups. However, when the ZnS04 + MPP+ group 
was compared to their corresponding control (ZnSCU treatment only) group, there was 
still a significant increase (p < 0.05) in LDH levels at 8，24，48h treatment suggesting that 
the ability of ZnSCU to protect against LDH increase is not complete. 
When the ZnSCU + MPP+ group was compared to the ZnS04 group, the LDH level 
showed only a 38.4% increase at 4 h (7.60 土 0.11 U/L in ZnSO* + MPP+ vs 5.49 土 0.42 
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U/L in ZnSCU). When compared to the amount of LDH release resulting from MPP+ 
treatment alone, this represented a 79.6% efficacy of ZnS04 in reducing LDH increase. 
However, at 48 h of ZnS04 + MPP+treatment，the LDH level was 19.13 土 0.20 U/L (p < 
0.05)，this represented a 1.5 fold increase when compared to the ZnS04 group (7.74 士 
0.42 U/L; p <0.05). When compared to the amount of LDH released resulting from MPP+ 
treatment alone, this showed that ZnS04 could effectively decrease MPP+-induced LDH 
production by 61.4%. 
(b) Striatal astrocytes (Fig. 4b) 
Striatal astrocytes showed that there was no significant increase in LDH levels in 
the control group during 48 h (5.48 士 0.42 U/L at 0 h to 9.14 士 0.58 U/L at 48 h) of 
incubation in serum-free media. Astrocytes that were pretreated with ZnSCU only also 
did not show any significant increase in LDH levels during the 48 h (5.21 ± 0.19 U/L at 0 
h to 8.58 士 0.58 U/L at 48 h) incubation. 
After MPP+ treatment, striatal astrocytes showed a rapid increase in LDH levels 
from 4 h (14.28 士 0.35 U/L) onwards. This represented a 1.4 fold increase (p < 0.05) 
when compared to the control (6.05 土 0.42 /L) group. By 48 h treatment, LDH increased 
to 40.09 土 0.81 U/L, a 3.4 fold increase (p < 0.05) when compared to the control. 
When striatal astrocytes were pretreated with ZnS04 prior to MPP+ treatment, 
there was a significant decrease (p < 0.05) in LDH levels along all the time points studied 
when compared with MPP+ treatment. At 4 and 48 h of ZnS04 and MPP+ treatment, a 
78% (8.02 士 0.27 U/L in ZnS04 + MPP+ treatment vs 14.28 士 0.35 U/L in MPP+ 
treatment) and 82% (22.01 土 1.94 U/L in ZnS04 + MPP+ treatment vs 40.09 士 0.81 U/L 
in MPP+ treatment) significant decrease (p < 0.05) respectively was observed when 
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compared with the MPP.-treated groups. However, when the ZnS04 + MPP+ group was 
compared to their corresponding control (ZnS04 treatment only) group, there was still 
significant increases (p < 0.05) in LDH levels at 8，24 and 48h treatment suggesting that 
the ability of ZnS04 to protect against LDH increase is not complete. 
When the ZnS04 + MPP+ group was compared to the ZnSCU group, the LDH 
level showed a 35.7% increase at 4 h (8.02 士 0.27 U/L in ZnS04 + MPP+ vs 5.91 士 0.49 
U/L in control). When compared to the amount of LDH release resulting from MPP+ 
treatment alone, it showed that ZnS04 could effectively decrease MPP^-induced LDH 
production by 73.8%. However, at 48 h of ZnS04 + MPP+treatment, the LDH level was 
22.01 土 1.94 U/L (p < 0.05), this represented a 1.6 fold increase when compared to the 
ZnS04 group (8.58 士 0.58 U/L; p < 0.05). When compared to the amount of LDH release 
resulting from MPP+ treatment alone, it showed that ZnSCU could effectively decrease 
MPP+-induced LDH production by 53.8%. 
(c) Cortical astrocytes (Fig. 4c) 
Similar to the mesencephalic and striatal astrocytes, cortical astrocytes also 
showed no significant increase in LDH levels in the control group during 48 h (5.49 土 
0.42 U/L at 0 h to 8.30 士 0.14 U/L at 48 h) of incubation in serum-free media. Astrocytes 
that were pretreated with ZnS04 only also did not show any significant increase in LDH 
levels during the 48 h (5.20 士 0.14 U/L at 0 h to 8.86 土 0.42 U/L at 48 h) incubation. 
After MPP+ treatment, cortical astrocytes showed a rapid increase in LDH levels 
from 4 h (9.35 土 0.07 U/L) onwards. This represented a 76% significant increase (p < 
0.05) when compared to the control (5.30 ±0.15 U/L) group. By 48 h treatment, LDH 
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increased to 23.00 士 0.87 U/L, a 1.8 fold increase (p < 0.05) when compared to the 
control. 
When the cortical astrocytes were treated with ZnSCU prior to MPP+ treatment, 
there was a 12%, 17% and 59% decrease in LDH levels at 8 (11.32士 0.57 U/L), 24 (12.87 
士 0.63 U/L) and 48 (14.49 士 0.78 U/L; p < 0.05) h treatment respectively when compared 
with the MPP+-treated groups. 
When the ZnSCU + MPP+ group was compared to the ZnS04 group, there was no 
significant reduction in LDH level at 4 h. At 48 h ZnSCU + MPP+ treatment, the LDH 
level was 14.49 士 0.78 U/L (p < 0.05), this represented a 63.5% increase when compared 
to the ZnS04 group (8.86 士 0.42 U/L; p < 0.05). When compared to the amount of LDH 
release resulting from MPP+ treatment alone, it showed that ZnSCU could effectively 
reduced the MPP+-induced LDH production by 64.1%. 
3.1.1.3.2 3,(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) 
Activities 
Figure 5 shows the results of MTT reductions in mesencephalic, striatal and 
cortical astrocytes after different drug treatments. The treatment groups consisted of i) 
the control groups where cells were incubated with serum free medium only, ii) cells that 
were only pretreated with 50jLiM ZnS04 for 24 h, iii) cells treated with lO^iM MPP+ 
treatment only and iv) cells pretreated with 50|LIM ZnS04 24 h prior to lOjuM MPP+ 
treatment. At 0，4，8, 24, 48 h after treatment, MTT activities were measured from intact 
cells. 
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Fig. 5: MTT levels in (a) mesencephalic (ME), (b) striatal (ST) and (c) cortical 
(CO) astrocytes in control (•)，50|aM ZnSCU ( • ), 10|aM MPP+ ( • ) and 
50|aM ZnS04 + lOjaM MPP+ ( _ treatment groups from 0 - 4 8 h . Values 
are expressed as mean 士 SEM. * p < 0.05, as compared with corresponding 
control. # p < 0.05, as compared with the corresponding MPP^-treated 
group. n=4 
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(a) Mesencephalic astrocytes (Fig. 5a) 
Mesencephalic astrocytes showed that there was no significant decrease in MTT 
reduction in the control group (0.235 土 0.036 MTT level/well at 0 h to 0.215 士 0.033 
MTT level/well at 48 h) during 48 h of incubation. After MPP+ treatment, mesencephalic 
astrocytes showed a rapid decrease in MTT reduction from 4 h (0.152 士 0.026 MTT 
level/well) onwards. This represented a 34.5% decrease (p < 0.05) when compared to the 
control (0.232 士 0.037 MTT level/well) group. By 48 h MPP+ treatment, MTT reduction 
was decreased to 0.121 士 0.026 MTT level/well, representing a 43.7% (p < 0.05) 
decrease when compared with the control. 
When mesencephalic astrocytes were treated with ZnSCU alone, there was no 
significant decrease in MTT reductions for all the time points studied (0.258 土 0.040 
MTT level/well at 0 h to 0.221 土 0.031 MTT level/well at 48 h). There was also no 
significant difference when compared with the control groups. When mesencephalic 
astrocytes were pretreated with ZnS04 and followed by 4 - 48 h MPP+ treatment, the 
MTT levels were partially restored along all the time points studied. A 13.8% (0.173 士 
0.028 MTT level/well for ZnS04 + MPP+ vs 0.152士 0.026 MTT level/well for MPP+) and 
62% (p < 0.05; 0.196 士 0.03 MTT level/well for ZnSO* + MPP+ vs 0.121 土 0.026 MTT 
level/well for MPP+) increase in MTT levels at 4 and 48 h respectively were observed 
when compared with the corresponding MPP+ treatment groups. 
When the ZnS04 + MPP+ group was compared to the ZnS04 group, the MTT 
level was only decreased by 25.4% at 4 h (0.173 士 0.028 MTT level/well in ZnS04 + 
MPP+ vs 0.232 士 0.039 in ZnS04). When compared to the amount of MTT reduction 
resulting from MPP+ treatment alone, this represented a 26.4% efficacy of ZnS04 in 
68 
attenuating MTT reduction. However, at 48 h of ZnS04 + MPP+ treatment, MTT 
reduction was decreased by only 11.3% when compared to the ZnS04 group (0.196土 
0.033 MTT level/well in ZnS04 + MPP+ vs 0.221 士 0.031 in ZnSOJ When compared to 
the amount of MTT reduction resulting from MPP+ treatment alone, this showed that 
ZnS04 could effectively decrease MPP+-induced MTT reduction by 74.1%. 
(b) Striatal astrocytes (Fig. 5b) 
Striatal astrocytes showed that there was no significant decrease in MTT 
reduction in the control group (0.242 土 0.026 MTT level/well at 0 h to 0.222 士 0.024 
MTT level/well at 48 h) during 48 h of incubation. After MPP+ treatment, striatal 
astrocytes showed a rapid decrease in MTT reduction from 4 h (0.152 土 0.016 MTT 
level/well) onwards. This represented a 35.9% decrease (p < 0.05) when compared to the 
control (0.237 士 0.027 MTT level/well) group. By 48 h MPP+ treatment, MTT reduction 
was decreased to 0.123 土 0.016 MTT level/well, representing a 44.6% (p < 0.05) 
decrease when compared with the control. 
When striatal astrocytes were treated with ZnS04 alone, there was no significant 
decrease in MTT reductions for all the time points studied (0.254 士 0.031 MTT level 
/well at 0 h to 0.226 士 0.023 MTT level/well at 48 h). There was also no significant 
difference when compared with the control groups. When striatal astrocytes were 
pretreated with ZnS04 and followed by 4 - 48 h MPP+ treatment, the MTT levels were 
partially restored along all the time points studied. A 12.5% (0.171 士 0.015 MTT 
level/well for ZnSO* + MPP+ vs 0.152士 0.016 MTT level/well for MPP+) and 63.4% (p < 
0.05; 0.201 士 0.019 MTT level/well for ZnS04 + MPP+ vs 0.123 土 0.016 MTT level/well 
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for MPP+) increase in MTT levels at 4 and 48 h respectively were observed when 
compared with the corresponding MPP+ treatment groups. 
When the ZnS04 + MPP+ group was compared to the ZnS04 group, the MTT 
level was only decreased by 27.4% at 4 h (0.171 ±0.015 MTT level/well in ZnS04 + 
MPP+ vs 0.236 士 0.027 in ZnSCU). When compared to the amount of MTT reduction 
resulting from MPP+ treatment alone, this represented a 23.4% efficacy of ZnS04 in 
attenuating MTT reduction. However, at 48 h of ZnSCU + MPP+ treatment, MTT 
reduction was decreased by only 1 1 . 1 % when compared to the ZnS04 group ( 0 . 2 0 1土 
0.019 MTT level/well in ZnSO* + MPP+ vs 0.226 士 0.023 in ZnSCU). When compared to 
the amount of MTT reduction resulting from MPP+ treatment alone, this showed that 
ZnS04 could effectively decrease MPP+-induced MTT reduction by 75.1%. 
(c) Cortical astrocytes (Fig. 5c) 
Similar to the mesencephalic and striatal astrocytes, cortical astrocytes showed 
that there was no significant decrease in MTT reduction in the control group (0.215 士 
0.007 MTT level/well at 0 h to 0.194 士 0.01 MTT level/well at 48 h) during 48 h of 
incubation. After MPP+ treatment, cortical astrocytes showed a rapid decrease in MTT 
reduction from 4 h (0.132 土 0.007 MTT level/well) onwards. This represented a 36.8% 
decrease (p < 0.05) when compared to the control (0.209 士 0.008 MTT level/well) group. 
By the end of 48 h MPP+ treatment, MTT reduction was decreased to 0.117 士 0.007 MTT 
level/well, representing a 39.7% (p < 0.05) decrease when compared with the control. 
Cortical astrocytes also showed no significant changes in MTT reductions when 
treated with ZnS04 alone. MTT levels ranged from 0.221 土 0.004 MTT level/well to 
0.196 士 0.013 MTT level/well at 0 and 48 h respectively. When the cortical astrocytes 
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were treated with ZnSCU prior to MPP+ treatment, no significant recovery of MTT levels 
was observed along all the time points studied. At 48 h, MTT levels were increased by 
35% (not significant; 0.158 士 0.009 MTT level/well in ZnS04 + MPP+ vs 0.117土 0.007 
MTT level/well in MPP+) when compared with MPP^-treated only. When ZnSCU + MPP+ 
group was compared to the ZnS04 group, MTT reduction was decreased only by 19.4% 
(0.158 士 0.009 MTT level/well in ZnS04 + MPP+ vs 0.196土 0.014 MTT level/well in 
ZnS04). When compared to the amount of MTT reduction resulting from MPP+ treatment 
alone, this represented a 51.1% efficacy of ZnS04 in attenuating MTT reduction. 
3.1.1.3.3 Reactive Oxygen Species (ROS) Production 
Figure 6 shows ROS production in mesencephalic, striatal and cortical astrocytes 
in the treatment groups consisted of i) the control groups where cells were incubated with 
serum free medium only, ii) cells that were only pretreated with 50|LIM ZnS04 for 24 h, 
ii i) cells treated with lOfiM MPP+ treatment only and iv) cells pretreated with SOjiiM 
ZnS04 24 h prior to 10|liM MPP+ treatment. At 0，4，8, 24, 48 h after treatment, ROS 
productions were measured from intact cells. 
(a) Mesencephalic astrocytes (Fig. 6a) 
Mesencephalic astrocytes showed that there was no significant increase in ROS 
production in cells cultured in medium only during 48 h (3226 土 192 DCF fluorescent 
units/well at 0 h to 3650 土 179 DCF fluorescent units/well at 48 h) of incubation. After 
MPP+ treatment, mesencephalic astrocytes showed a significant increase in ROS 
production from 4 h (4146 ± 167 DCF fluorescent units/well) onwards. This represents a 
23.7% significant increase (p < 0.05) when compared to the control (3351 士 166 DCF 
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Fig. 6: ROS production in (a) mesencephalic (ME), (b) striatal (ST) and (c) cortical 
(CO) astrocytes in control ( • ) , 50|^M ZnSCU , )，10|aM MPP+ ( • ) and 
50jaM ZnS04 + lOjaM MPP+ (0) treatment groups from 0 - 48 h. Values 
are expressed as mean 土 SEM. * p < 0.05, as compared with corresponding 









































































































































































































fluorescent units/well) group at 4 h. By 48 h of MPP+ treatment, ROS production 
increased to 6108 士 164 DCF fluorescent units/well, this represented a maximum of 
67.3% increase (p < 0.05) in ROS production when compared with the control. 
When mesencephalic astrocytes were treated with ZnSCU alone, there was no 
significant increase in ROS levels for all the time points studied (3214 土 190 DCF 
fluorescent units/well at 0 h to 3625 士 156 DCF fluorescent units/well at 48 h). 
Pretreatment of mesencephalic astrocytes with ZnSCU prior to MPP+treatment resulted in 
a significant decrease (p < 0.05) in the ROS production along all time points studied. A 
12.9% (3613 土 161 DCF fluorescent units/well) and 22.5% (4731 士 155 DCF fluorescent 
units/well) decrease at 4 and 48 h respectively were observed when compared with the 
corresponding MPP^-treated groups. 
When the ZnS04 + MPP+ group was compared to the ZnS04-treated control 
group, there was still a significant increase (p < 0.05) in ROS levels at 8, 24，48h 
treatment suggesting that the ability of ZnS04 to protect against ROS increase is not 
complete. 
When the ZnS04 + MPP+ group was compared to the ZnS04 group there was a 
9% increase in ROS level at 4 h (3613 士 161 DCF fluorescent units/well in ZnS04 + 
MPP+ vs 3315 ± 179 DCF fluorescent units/well in ZnS04). When compared to the 
amount of ROS release resulting from MPP+ treatment alone, it showed that ZnS04 could 
effectively decrease MPP+-induced ROS production by 62.2%. At 48 h ZnS04 + MPP+ 
treatment, there was a 30.5% increase (p < 0.05) in ROS levels when compared to the 
ZnS04 treatment only (4731 土 155 DCF fluorescent units/well in ZnSO* + MPP^-treated 
group vs 3625 土 156 DCF fluorescent units/well in ZnS04). When compared to the 
72 
amount of ROS released from MPP+ treatment alone, it represented that ZnS04 could 
effectively reduce MPP+-induced ROS production by 54.7%. 
(b) Striatal astrocytes (Fig. 6b) 
Striatal astrocytes showed that there was no significant increase in ROS 
production in cells cultured in medium only during 48 h (3094 士 166 DCF fluorescent 
units/well at 0 h to 3454 士 109 DCF fluorescent units/well at 48 h) of incubation. After 
MPP+ treatment, striatal astrocytes showed a significant increase in ROS production from 
4 h (3925 土 144 DCF fluorescent units/well) onwards. This represents a 21.8% 
significant increase (p < 0.05) when compared to the control (3223 土 138 DCF 
fluorescent units /well) group at 4 h. By 48 h of MPP+ treatment, ROS production 
increased to 5766 士 83 DCF fluorescent units/well, this represented a maximum of 66.9% 
increase (p < 0.05) in ROS production when compared with the control. 
When striatal astrocytes were treated with ZnS04 alone, there was no significant 
increase in ROS levels for all the time points studied (3080 土 175 DCF fluorescent 
units/well at 0 h to 3443 士 109 DCF fluorescent units/well at 48 h). Pretreatment of 
striatal astrocytes with ZnS04 prior to MPP+ treatment resulted in a significant decrease 
(p < 0.05) in the ROS production along all time points studied. A 9.7% (3546 士 157 DCF 
fluorescent units/well) and 17.1% (4777 土 158 DCF fluorescent units/well) decrease at 4 
and 48 h respectively were observed when compared with the corresponding MPP+-
treated groups. 
When the ZnSCU + MPP+ group was compared to the ZnS04-treated control 
group, there was still a significant increase (p < 0.05) in ROS levels at 8, 24, 48 h 
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treatment suggesting that the ability of ZnSCU to protect against ROS increase is not 
complete. 
When the ZnS04 + MPP+ group was compared to the ZnS04 group there was a 
10.6% increase in ROS level at 4 h (3546 士 157 DCF fluorescent units/well in ZnS04 + 
MPP+ vs 3205 士 141 DCF fluorescent units/well in ZnS04). When compared to the 
amount of ROS release resulting from MPP+ treatment alone, it showed that ZnS04 could 
effectively decrease MPP+-induced ROS production by 51.4%. At 48 h ZnSCU + MPP+ 
treatment, there was a 38.7% increase (p < 0.05) in ROS levels when compared to the 
ZnS04 treatment only (4777 ±158 DCF fluorescent units/well in ZnSCU + MPP^-treated 
group vs 3443 土 109 DCF fluorescent units/well in ZnSCU). When compared to the 
amount of ROS released after MPP+ treatment alone, it represented that ZnS04 could 
effectively reduce the MPP+-induced ROS production by 42.2%. 
(c) Cortical astrocytes (Fig. 6c) 
Cortical astrocytes showed that there was no significant increase in ROS 
production in cells cultured in medium only during 48 h (3216 土 207 DCF fluorescent 
units/well at 0 h to 3549 士 175 DCF fluorescent units/well at 48 h) of incubation. After 
MPP+ treatment, cortical astrocytes showed a significant increase (p < 0.05) in ROS 
production from 4 h (3654 土 150 DCF fluorescent units/well) onwards. This represents a 
11.3% significant increase (p < 0.05) when compared to the control (3284 土 211 DCF 
fluorescent units/well) group at 4 h. By 48 h of MPP+ treatment, ROS production 
increased to 4629 土 100 DCF fluorescent units/well, this represented a maximum of 
30.4% increase (p < 0.05) in ROS production when compared with the control. 
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When cortical astrocytes were treated with ZnSCU alone, there was no significant 
increase in ROS levels for all the time points studied (3182 士 184 DCF fluorescent 
units/well at 0 h to 3462 土 168 DCF fluorescent units/well at 48 h). 
When the cortical astrocytes were treated with ZnSCU + MPP+，the ROS levels 
were reduced 4.2% and 9% at 4 h (3500 土 168 DCF fluorescent units/well) and 48 h 
(4213 土 99 DCF fluorescent units/well) respectively. However these decreases were not 
significant (p < 0.05) when compared with the MPP^-treated groups. 
At 48 h treatment, there was a 21.7% increase (p < 0.05) in ROS level when 
compared to ZnSCU treatment only (4213 土 99 DCF fluorescent units/well for ZnS04 + 
MPP+ vs 3462 士 168 DCF fluorescent units/well for ZnS04). When compared to ROS 
released from MPP+ treatment alone, this showed that ZnS04 could effectively reduce the 
MPP+-indiiced ROS production by 28.6%. 
3.1.2. The Effects of N-Acetyl-cysteine (NAc) Pretreatment on MPP+-treated 
Astrocytes 
3.1.2.1 Glutathione (GSH) levels 
Figure 7 shows the levels of GSH in the different treatment groups, namely i) 
control, ii) 24 h 20mM NAc treatment alone, iii) MPP+ treatment alone and iv) NAc 
pretreatment prior to 48 h MPP+ treatment. The basal levels of GSH for mesencephalic, 
striatal and cortical astrocytes are 19.67 士 0.27, 24.95 土 0.50 and 27.15 士 0.70 nM/mg 
protein respectively. Statistical analysis (independent T-test) showed that the basal level 
of GSH in striatal and cortical astrocytes were statistically greater (p < 0.05) than that of 
mesencephalic astrocytes. 
75 
Fig. 7: GSH levels in (a) mesencephalic (ME), (b) striatal (ST) and (c) cortical 
(CO) in control (p) , 24 h 20mM NAc (_)，48 h 10|aM MPP+ ( • ) and 24 h 
20mM NAc + 48 h lO^iM MPP+ ( 0 ) treatment groups. Values are 
expressed as mean 土 SEM. Ap < 0.05, as compared between the controls of 
all three regions. * p < 0.05 as compared with the control of the same 












































































































































After 24 h of 20mM NAc treatment, GSH levels increased significantly (p < 0.05) 
by 61.5% (31.76 土 0.73 nM/mg protein) and 53.5% (38.29 土 0.64 nM/mg protein) in 
mesencephalic and striatal astrocytes respectively. An 8.8% (29.54 土 0.52 nM/mg 
protein) increase (not significant) in the cortical astrocytes was observed. 
(a) Mesencephalic astrocytes (Fig. 7a) 
48 h MPP+ treatment resulted in a 44.3%, (10.95 士 0.66 nM/mg protein) decrease 
(p < 0.05) in GSH level when compared to the control. Cells pretreated with NAc prior 
to MPP+ treatment showed a reverse in GSH level (p < 0.05) to 24.5% above (24.48 士 
0.43 nM/mg) the control level. This suggested that NAc could ameliorate MPP+-induced 
GSH depletion. 
(b) Striatal astrocytes (Fig. 7b) 
48h MPP+ treatment resulted in the 23.8% (19.01 士 1.62 nM/mg protein) decrease 
(p < 0.05) in GSH level when compared to the control. Cells were pretreated with NAc 
prior to MPP+ treatment showed a reverse in GSH level (p < 0.05) to 21.1% above (30.22 
士 1.53 nM/mg) the control level. Similar to that observed for mesencephalic astrocytes, 
NAc also protected striatal astrocytes from MPP+-induced GSH depletion. 
(c) Cortical astrocytes (Fig. 7c) 
MPP+ treatment resulted in the 20.6% (21.56 士 0.42 nM/mg protein) (p < 0.05) 
reduction in the GSH level when compared to the control value. The pretreatment of NAc 
prior to MPP+ treatment restored GSH (23.54 士 0.55 nM/mg protein) to only 86.7% of 
control values. 
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3.1.2.2 LDH Activities 
Figure 8 shows the results of LDH activities of mesencephalic, striatal and 
cortical astrocytes treated with i) serum free medium only, i i) NAc only, i i i) lOjiM MPP+， 
and iv) NAc + MPP+ from 0 to 48 h. 
(a) Mesencephalic astrocytes (Fig. 8a) 
Mesencephalic astrocytes showed no significant increase in LDH activities in the 
control group from 0 to 48 h (5.06 士 0.69 U/L at 0 h to 9.28 士 0.49 U/L at 48 h) 
incubation. The treatment with NAc alone also did not show any significant increase in 
LDH activities from 0 to 48 h (4.22 土 0.49 U/L at 0 h to 10.55 士 0.42 U/L at 48 h) of 
treatment. However, after MPP+ treatment, mesencephalic astrocytes showed significant 
(p < 0.05) increases in LDH levels from 4 h onwards when compared to the control 
groups. There was a 2 fold increase (p < 0.05) in LDH levels at 4 h (16.67 士 1.06 U/L for 
MPP+ vs 5.49 士 0.42 U/L for control) reaching a maximum of 3.5 fold increase (p < 
0.05) at 48 h (41.78 土 2.45 U/L) when compared with the corresponding controls. 
When mesencephalic astrocytes were pretreated with NAc prior to MPP+ 
treatment, there was a significant decrease (p < 0.05) in LDH levels along all the time 
points studied when compared with MPP+ treatment. At 4 and 48 h of NAc + MPP+ 
treatment, a 24.2% (12.66 土 1.19 U/L) and 33.8% (27.64 士 2.16 U/L) significant decrease 
(p < 0.05) respectively was observed when compared with the MPP+-treated groups. 
However, when the NAc + MPP+ group was compared to their corresponding 
control (NAc treatment only) group, there was still a significant increase (p < 0.05) in 
LDH levels at 8，24, 48h treatment suggesting that the ability of NAc to protect against 
LDH increase is not complete. 
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Fig. 8: Amount of LDH release into the media from (a) mesencephalic (ME), (b) 
striatal (ST) and (c) cortical (CO) astrocytes in control ( • ) , 20mM NAc (圓）， 
10)aM MPP+ ( • ) and 20mM NAc + lO^iM MPP+ (0) treatment groups from 0 
- 4 8 h. Values are expressed as mean 土 SEM. * p < 0.05，as compared with 
corresponding control. # p < 0.05, as compared with the corresponding 






























































































































































































When the NAc + MPP+ group was compared to the NAc group, the LDH level 
showed a 1.3 increase (p < 0.05) at 4 h (12.66 土 1.19 U/L in NAc + MPP+vs 5.48 士 0.40 
U/L in NAc). When compared to the amount of LDH release resulting from MPP+ 
treatment alone, this represented a 35.9% efficacy of NAc in reducing LDH increase. At 
48 h of NAc + MPP+ treatment, the LDH level was 27.64 士 2.16 U/L (p < 0.05)，this 
represented a 2 fold increase when compared to the NAc group (10.55 土 0.39 U/L; p < 
0.05). When compared to the amount of LDH released resulting from MPP+ treatment 
alone, this showed that NAc could effectively decrease MPP+-induced LDH production 
by 43.5%. 
(b) Striatal astrocytes (Fig. 8b) 
Striatal astrocytes showed no significant increase in LDH activities in the control 
group from 0 to 48 h (4.64 土 0.42 U/L at 0 h to 9.71 土 0.41 U/L at 48 h) incubation. The 
treatment with NAc alone also did not show any significant increase in LDH activities 
from 0 to 48 h (3.80 土 0.42 U/L at 0 h to 10.39 土 0.49 U/L at 48 h) of treatment. 
However, after MPP+ treatment, striatal astrocytes showed significant (p < 0.05) 
increases in LDH levels from 4 h onwards when compared to the control groups. There 
was a 2 fold increase (p < 0.05) in LDH levels at 4 h (14.98 ± 1.31 U/L for MPP+ vs 5.06 
士 0.69 U/L for control) reaching a maximum of 3 fold increase (p < 0.05) at 48 h (38.82 士 
0.69 U/L) when compared with the corresponding controls. 
When striatal astrocytes were pretreated with NAc prior to MPP+ treatment, there 
was a significant decrease (p < 0.05) in LDH levels along all the time points studied 
when compared with MPP+treatment. At 4 and 48 h of NAc + MPP+ treatment, a 22.5% 
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(11.61 士 1.16 U/L) and 31.5% (26.59 士 1.74 U/L) significant decrease (p < 0.05) 
respectively was observed when compared with the MPP+-treated groups. 
However, when the NAc + MPP+ group was compared to their corresponding 
control (NAc treatment only) group, there was still a significant increase (p < 0.05) in 
LDH levels at all time points studied suggesting that the ability of NAc to protect against 
LDH increase is not complete. 
When the NAc + MPP+ group was compared to the NAc group, the LDH level 
showed only a 1.5 increase (p < 0.05) at 4 h (11.61 土 1.16 U/L in NAc + MPP+vs 4.64 士 
0.81 U/L in NAc). When compared to the amount of LDH release resulting from MPP+ 
treatment alone, this represented a 23.4% efficacy of NAc in reducing LDH increase. At 
48 h of NAc + MPP+ treatment, the LDH level was 26.59 土 1.74 U/L (p < 0.05), this 
represented a 1.6 fold increase when compared to the NAc group (11.39 士 0.38 U/L; p < 
0.05). When compared to the amount of LDH released resulting from MPP+ treatment 
alone, this showed that NAc could effectively decrease MPP^-induced LDH production 
by 48%. 
(c) Cortical astrocytes (Fig. 8c) 
Cortical astrocytes showed no significant increase in LDH activities in the control 
group from 0 to 48 h (3.80 士 0.42 U/L at 0 h to 8.02 士 0.49 U/L at 48 h) incubation. The 
treatment with NAc alone also did not show any significant increase in LDH activities 
from 0 to 48 h (4.22 土 0.49 U/L at 0 h to 10.55 士 0.42 U/L at 48 h) of treatment. After 
MPP+ treatment, cortical astrocytes showed significant (p < 0.05) increases in LDH levels 
from 4 h onwards when compared to the control groups. There was a 1.1 fold increase (p 
< 0.05) in LDH level at 4 h (9.07 土 0.40 U/L for MPP+ vs 4.22 土 0.49 U/L for control) 
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and reaching a maximum of 2.3 fold increase (p< 0.05) at 48 h (26.59 士 1.27 U/L) when 
compared with the corresponding controls. 
When cortical astrocytes were pretreated with NAc prior to MPP+ treatment, there 
was a 19%, 21.5% and 38.1% decrease in LDH activities at 8 (10.76 土 0.53 U/L), 24 
(13.08 土 0.54 U/L) and 48 h (16.46 士 0.73 U/L; p < 0.05) treatment respectively when 
compared with the MPP^-treated groups. 
When the NAc + MPP+ group was compared to the NAc group, there was no 
significant reduction in LDH level at 4 h. At 48 h NAc + MPP+ treatment, the LDH level 
was 16.46 士 0.73 U/L (p < 0.05), this represented a 56% increase when compared to the 
NAc group (10.55 士 0.42 U/L). When compared to the amount of LDH release resulting 
from MPP+ treatment alone, it showed that NAc could effectively reduced the MPP+-
induced LDH production by 75.8%. 
3.1.2.3 MTT Activities 
Figure 9 shows the results of MTT reductions of mesencephalic, striatal and 
cortical astrocytes in i) serum free medium only, ii) NAc only, ii i) lOjiiM MPP+, and iv) 
NAc + MPP+ from 0 to 48 h. At 0, 4，8，24, 48 h after treatment, MTT activities were 
measured from intact cells. 
(a) Mesencephalic astrocytes (Fig. 9a) 
Mesencephalic astrocytes showed no significant change in MTT activities in the 
control (0.174 士 0.026 MTT level/well at 0 h to 0.154 士 0.026 MTT level/well at 48 h) as 
well as in the NAc-treated (0.175 土 0.025 MTT level/well at 0 h to 0.156 土 0.023 MTT 
level/well at 48 h) group during the 48 h incubation. After MPP+ treatment, MTT levels 
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Fig. 9: MTT levels in (a) mesencephalic (ME), (b) striatal (ST) and (c) cortical 
(CO) astrocytes in control (•)，20|am NAc _ )，10|LIM MPP+ ( • ) and 20nm 
NAc + lOjaM MPP^ (0) treatment groups from 0 - 48 h. Values are 
expressed as mean 士 SEM. * p < 0.05, as compared with corresponding 
control. # p < 0.05, as compared with the corresponding MPP+-treated 
group. n=4 
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decrease rapidly from 4 h (0.114 士 0.014 MTT level/well) onwards. This represents a 
34.1% significant decrease (p < 0.05) when compared to the control (0.173 士 0.026 MTT 
level/well) group. By 48 h treatment, MTT reduction reached 0.087 士 0.014 MTT 
level/well, representing a 43.5% (p < 0.05) decrease when compared with the control. 
When mesencephalic astrocytes were treated with NAc + MPP+，the decrease in MTT 
activities were restored slightly (not significant) from 8 h onwards and reached a 
maximum of 21.8% increase at 48 h (0.106 士 0.015 MTT level/well) when compared to 
MPP+ treatment only. 
When the NAc + MPP+ group was compared to the NAc group, the MTT level 
was only decreased by 33.7% at 4 h (0.114 士 0.016 MTT level/well in NAc + MPP+ vs 
0.172 士 0.027 in NAc). When compared to the amount of MTT reduction resulting from 
MPP+ treatment alone, this represented a 1.2% efficacy of NAc in attenuating MTT 
reduction. However, at 48 h of NAc + MPP+treatment, MTT reduction was decreased 
by only 32.1% when compared to the NAc group (0.106 士 0.015 MTT level/well in NAc 
+ MPP+ vs 0.156 士 0.023 in ZnS04). When compared to the amount of MTT reduction 
resulting from MPP+ treatment alone, this showed that NAc could effectively decrease 
MPP+-indiiced MTT reduction by 26.2%. 
(b) Striatal astrocytes (Fig. 9b) 
Striatal astrocytes showed no significant change in MTT activities in the control 
(0.161 士 0.015 MTT level/well at 0 h to 0.143 士 0.016 MTT level/well at 48 h) as well as 
in the NAc-treated (0.164 土 0.016 MTT level/well at 0 h to 0.141 土 0.014 MTT level/well 
at 48 h) groups during the 48 h incubation. After MPP+ treatment, MTT levels decreased 
rapidly from 4 h (0.109 土 0.010 MTT level/well) onwards. This represents a 31.4% 
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significant decrease (p < 0.05) when compared to the control (0.159 土 0.015 MTT 
level/well) group. By 48 h treatment, MTT reduction reached 0.086 士 0.008 MTT 
level/well, representing a 39.9% (p < 0.05) decrease when compared with the control. 
When striatal astrocytes were treated with NAc + MPP+，the decrease in MTT activities 
were restored slightly (not significant) from 4 h onwards and reached a maximum of 
16.3% increase at 48 h (0.100 土 0.013 MTT level/well) when compared with MPP+ 
treatment. 
When the NAc + MPP+ group was compared to the NAc group, the MTT level 
was only decreased by 26.4% at 4 h (0.114 士 0.013 MTT level/well in NAc + MPP+ vs 
0.159 土 0.016 in NAc). When compared to the amount of MTT reduction resulting from 
MPP+ treatment alone, this represented a 15.9% efficacy of NAc in attenuating MTT 
reduction. However, at 48 h of NAc + MPP+treatment，MTT reduction was decreased 
by only 29.1% when compared to the NAc group (0.100 土 0.013 MTT level/well in NAc 
+ MPP+ vs 0.141 士 0.014 in ZnSCU). When compared to the amount of MTT reduction 
resulting from MPP+ treatment alone, this showed that NAc could effectively decrease 
MPP+-induced MTT reduction by 27.1%. 
(c) Cortical astrocytes (Fig. 9c) 
The MTT content of the control cortical astrocytes decreased gradually from 
0.118 土 0.022 MTT level/well at 0 h to 0.110 土 0.021 MTT level/well at 48 h. There was 
no significant decrease in MTT levels when cells were treated with NAc alone (0.122 土 
0.023 MTT level/well at 0 h to 0.107 士 0.022 MTT level/well at 48 h). MPP+ treatment 
showed a 17.9% to 26.4 % decrease in MTT level at 4 (0.096 ±0.018 MTT level/well) 
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and 48 h (0.081 ±0.016 MTT level/well) respectively. However, this decrease was not 
significant when compared with the control group. 
When the cortical astrocytes were treated with NAc + MPP+，the MTT levels were 
not significantly restored to control values along all the time points studied. There was 
minimal attenuation even at 48 h, where MTT levels were increased by 15.9% (not 
significant; 0.090 士 0.017 MTT level/well in NAc + MPP+ vs 0.107土 0.022 MTT 
level/well in NAc) when compared with the NAc group. When compared to the amount 
of MTT reduction resulting from MPP+ treatment alone, this represented a 39.8% 
efficacy of NAc in attenuating MTT reduction. 
3.1.2.4 ROS Production 
Figure 10 shows the results of ROS production of mesencephalic, striatal and 
cortical astrocytes with i) serum free medium only, ii) NAc only, iii) 10)iM MPP+，and 
iv) NAc + MPP+ from 0 to 48 h. 
(a) Mesencephalic astrocytes (Fig. 10a) 
Mesencephalic astrocytes showed no significant change in ROS production in the 
control (3499 土 68 DCF fluorescent units/well at 0 h to 3827 土 67 DCF fluorescent 
units/well at 48 h) as well as in the NAc-treated (3472 土 77 DCF fluorescent units/well at 
0 h to 3845 土 70 DCF fluorescent units/well at 48 h) groups during the 48 h incubation. 
After MPP+ treatment, ROS production increased rapidly from 4 h (4367 土 81 DCF 
fluorescent units/well) onwards. This represents a 23.1% significant (p < 0.05) increase 
when compared to the control (3547 土 67 DCF fluorescent units/well) group. By 48 h, 
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Fig. 10: ROS production in (a) mesencephalic (ME) (b) striatal (ST) and (c) cortical 
(CO) astrocytes in control ( • ), 20mM NAc (圓），10|liM MPP+ ( • ) and 
20mM NAc + lOfiM MPP+ ( 0 ) treatment groups from 0 - 48 h. Values are 
expressed as mean 土 SEM. * p < 0.05, as compared with corresponding 




























































































































































































































































































































ROS production increased to 6283 士 80 DCF fluorescent units/well, representing a 64.2% 
(p < 0.05) increase when compared with the control. 
Pretreatment of mesencephalic astrocytes with NAc prior to MPP+ treatment 
resulted in a significant decrease (p < 0.05) in the ROS production along all time points 
studied. A 7.1% (4056 土 72 DCF fluorescent units/well) and 13.1% (5457 土 120 DCF 
fluorescent units/well) decrease at 4 and 48 h respectively were observed when compared 
with the corresponding MPP^-treated groups. 
When the NAc + MPP+ group was compared to the NAc-treated control group, 
there was still a significant increase (p < 0.05) in ROS levels at all time points studied 
suggesting that the ability of NAc to protect against ROS increase is not complete. 
When the NAc + MPP+ group was compared to the NAc group there was a 14.5% 
increase (p < 0.05) in ROS level at 4 h (4056 士 11 DCF fluorescent units/well in NAc + 
MPP+ vs 3542 士 65 DCF fluorescent units/well in NAc). When compared to the amount 
of ROS release resulting from MPP+ treatment alone, it showed that NAc could 
effectively decrease MPP+-induced ROS production by 37.2%. At 48 h NAc + MPP+ 
treatment, there was a 41.9% increase (p < 0.05) in ROS levels when compared to the 
NAc treatment only (5457 士 120 DCF fluorescent units/well in NAc + MPP+-treated 
group vs 3845 士 70 DCF fluorescent units/well in NAc)。When compared to the amount 
of ROS released from MPP+ treatment alone, it represented that NAc could effectively 
reduce MPP+-induced ROS production by 34.7%. 
(b) Striatal astrocytes (Fig. 10b) 
Striatal astrocytes showed no significant change in ROS production in the control 
(3520 土 50 DCF fluorescent units/well at 0 h to 3843 土 47 DCF fluorescent units/well at 
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48 h) as well as in the NAc-treated (3480 士 55 DCF fluorescent units/well at 0 h to 3869 
±39 DCF fluorescent units/well at 48 h) groups during the 48 h incubation. After MPP+ 
treatment, ROS production increased rapidly from 4 h (4328 土 57 DCF fluorescent 
units/well) onwards. This represents a 21% significant (p < 0.05) increase when 
compared to the control (3577 士 46 DCF fluorescent units/well) group. By 48 h, ROS 
production increased to 6070 士 64 DCF fluorescent units/well, representing a 57.9% (p < 
0.05) increase when compared with the control. 
Pretreatment of striatal astrocytes with NAc prior to MPP+ treatment resulted in a 
significant decrease (p < 0.05) in the ROS production along all time points studied. A 
6.3% (4054 土 53 DCF fluorescent units/well) and 10.4% (5437 士 70 DCF fluorescent 
units/well) decrease at 4 and 48 h respectively were observed when compared with the 
corresponding MPP.-treated groups. 
When the NAc + MPP+ group was compared to the NAc-treated control group, 
there was still a significant increase (p < 0.05) in ROS levels at all time points studied 
suggesting that the ability of NAc to protect against ROS increase is not complete. 
When the NAc + MPP+ group was compared to the NAc group there was a 13.2% 
increase (p < 0.05) in ROS level at 4 h (4054 土 53 DCF fluorescent units/well in NAc + 
MPP+ vs 3580 ± 52 DCF fluorescent units/well in NAc). When compared to the amount 
of ROS release resulting from MPP+ treatment alone, it showed that NAc could 
effectively decrease MPP+-induced ROS production by 37.1%. At 48 h NAc + MPP+ 
treatment, there was a 40.5% increase (p < 0.05) in ROS levels when compared to the 
NAc treatment only (5437 土 70 DCF fluorescent units/well in NAc + MPP+-treated group 
vs 3869 土 39 DCF fluorescent units/well in NAc). When compared to the amount of 
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ROS released from MPP+ treatment alone, it represented that NAc could effectively 
reduce the MPP+-induced ROS production by 30.1%. 
(c) Cortical astrocytes (Fig. 10c) 
Cortical astrocytes showed no significant change in ROS production in the control 
(3382 士 92 DCF fluorescent units/well at 0 h to 3737 土 80 DCF fluorescent units/well at 
48 h) as well as in the NAc-treated (3375 土 91 DCF fluorescent units/well at 0 h to 3718 
士 74 DCF fluorescent units/well at 48 h) groups during the 48 h incubation. After MPP+ 
treatment, ROS production increased rapidly from 4 h (3845 士 78 DCF fluorescent 
units/well) onwards. This represents a 11.4% significant (p < 0.05) increase when 
compared to the control (3452 土 76 DCF fluorescent units/well) group. By 48 h, ROS 
production increased to 4996 士 84 DCF fluorescent units/well, representing a maximum 
of 33.7% (p < 0.05) increase when compared with the control. 
When the cortical astrocytes were treated with NAc + MPP+，the ROS levels were 
reduced 2.4% from 4 (3751土 77 DCF fluorescent units/well) h onwards reaching a 5.9% 
decrease at 48 (4703 土 85 DCF fluorescent units/well) h. However the decreases were 
not significant (p < 0.05) when compared with the MPP+ treated group. 
At 48 h treatment, there was a 26.5% increase in ROS level when compared to 
NAc treatment only (4703 士 85 DCF fluorescent units/well for NAc + MPP+ vs 3718 士 
74 DCF fluorescent units/well for NAc). When compared to ROS released from MPP+ 
treatment alone, this showed that NAc could effectively reduce the MPP+-induced ROS 
production by 21.4%. 
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3.1.3 The Effects of Deferoxamine on MPP+-treated Astrocytes 
3.1.3.1 LDH Activities 
Figure 11 shows the results of LDH activities of mesencephalic, striatal and 
cortical astrocytes after MPP+ or 200 | iM deferoxamine (Def) and MPP+ co-treatment 
from 0 to 48 h. Astrocytes in the control group were incubated with serum free medium 
only. 
(a) Mesencephalic astrocytes (Fig. 1 la) 
Astrocytes from the control group did not show a significant increase in LDH 
level from 0 (4.22 士 0.49 U/L) to 48 (8.02 土 0.42 U/L) h incubation. MPP+ treatment 
caused a rapid increase in LDH levels from 4 h (19.83 士 0.42 U/L) onwards, represented 
a 3.3 fold significant increase (p < 0.05) when compared to the control (4.64 士 0.42 U/L) 
group. By 48 h, LDH production increased to 51.91 士 111 U/L, representing a 5.5 fold 
increase (p < 0.05) in LDH activities when compared to the control. 
When mesencephalic astrocytes were treated with Def + MPP+, there was partial 
attenuation of MPP+-induced LDH increase, the LDH levels were decreased along all the 
time points studied. These decreases were significant (p < 0.05) along all the time points 
studied when compared with MPP+treatment alone. Def and MPP+ co-treatment resulted 
in a 10.6% (17.72 土 0.84 U/L) and 29.3% (36.71 士 1.74 U/L) significant decrease (p < 
0.05) in LDH levels at 4 h and 48 h respectively when compared to the MPP+-treated 
groups. When compared with the control, this represented a 2.8 and 3.6 fold increase (p 
< 0.05) in LDH levels at 4 and 48 h respectively. This indicated that Def could effectively 
reduce the MPP^-induced LDH production by 13.9% and 34.6% at 4 and 48 h 
respectively. 
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Fig. 11 ： Amount of LDH release into medium from (a) mesencephalic (ME), (b) 
striatal (ST) and (c) cortical (CO) astrocytes in control ( • ) , lO[iM MPP+(_) 
and 200|aM Def + lOjaM MPP+ (0) treatment groups from 0 - 48 h. Values 
are expressed as mean 土 SEM. * p < 0.05, as compared with corresponding 



















































































































































































































































(b) Striatal astrocytes (Fig. 1 lb) 
Similar to the mesencephalic astrocytes, striatal astrocytes from the control group 
did not show a significant increase in LDH level from 0 (4.02 ±0.19 U/L) to 48 (9.28 土 
0.42 U/L) h incubation. MPP+ treatment caused a rapid increase in LDH levels from 4 h 
(19.84 士 1.06 U/L) onwards, represented a 2.5 fold significant increase (p < 0.05) when 
compared to the control (5.75 士 0.42 U/L) group. By 48 h, LDH production increased to 
52.33 士 1.19U/L, representing a 4.6 fold increase (p < 0.05) in LDH activities when 
compared to the control. 
When striatal astrocytes were treated with Def + MPP+，there was partial 
attenuation of MPP -induced LDH increase, the LDH levels were decreased along all the 
time points studied. These decreases were significant (p < 0.05) along all the time points 
studied when compared with MPP+treatment alone. Def and MPP+ co-treatment resulted 
in a 15% (16.88 士 1.19 U/L) and 27.4% (37.98 土 1.46 U/L) significant decrease (p < 
0.05) in LDH levels at 4 h and 48 h respectively when compared to the MPP^-treated 
groups. When compared with the control, this represented a 1.9 and 3.1 fold increase (p 
< 0.05) in LDH levels at 4 and 48 h respectively. This indicated that Def could effectively 
reduce the MPP+-induced LDH production by 21% and 33.3% at 4 and 48 h respectively. 
(c) Cortical astrocytes (Fig. 1 Ic) 
Cortical astrocytes from the control group did not show a significant increase in 
LDH level from 0 (3.80 士 0.42 U/L) to 48 (8.02 土 0.42 U/L) h incubation. After MPP+ 
treatment, there was a rapid increase in LDH level from 4 h (10.55 土 0.42 U/L) onwards, 
represented a 1.5 fold significant increase (p < 0.05) when compared to the control (4.22 
土 0.49 U/L) group. By 48 h, LDH production increased to 25.32 土 1.19 U/L, 
88 
representing a 2.2 fold increase (p < 0.05) in LDH activities when compared to the 
control. 
Astrocytes co-treated with Def + MPP+ showed minimal attenuation (not 
significant) in MPP+-induced increase in LDH levels along all the time points studied. At 
48 h Def and MPP+ co-treatment, there was only a 10% decrease (22.79 士 1.46 U/L) in 
LDH level when compared with MPP+ treatment alone. This represented a 1.8 fold 
increase (p < 0.05) in LDH level when compared with the control, this showed that Def 
can effectively reduce the MPP+-induced LDH production by only 14.6%. 
3.1.3.2 ROS Production 
Figure 12 shows the results of ROS production of mesencephalic, striatal and 
cortical astrocytes after MPP+ or Def and MPP+ co-treatment from 0 to 48 h. Astrocytes 
in the control group were incubated with serum free medium only 
(a) Mesencephalic astrocytes (Fig. 12a) 
ROS level of control group did not show any significant increase from 0 (3822 士 
20 DCF fluorescent units/well) to 48 (4065 士 25 DCF fluorescent units/well) h of 
incubation. After MPP+ treatment, mesencephalic astrocytes showed a rapid increase in 
ROS production from 4 h (4760 土 8 DCF fluorescent units/well) onwards, represented 
23.8% significant increase (p < 0.05) when compared to the control (3845土 23 DCF 
fluorescent units/well) group. By 48 h, ROS production increased to 6746 士 41 DCF 
fluorescent units/well, representing a 66% significant increase (p < 0.05) in ROS when 
compared with the control. 
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Fig. 12: ROS production in (a) mesencephalic (ME), (b) striatal (ST) and (c) cortical 
(CO) astrocytes in control ( • )，lOjaM MPP+ ( • ) and 200|^M Def + lO^iM 
MPP+ (El) treatment groups from 0 - 4 8 h. Values are expressed as mean 士 
SEM. * p < 0.05, as compared with corresponding control. # p < 0.05, as 



































































































































































































































When mesencephalic astrocytes were co-treated with Def + MPP+，there was a 
partial decline (p < 0.05) in ROS levels along all the time points studied when compared 
with MPP+ treatment alone. Def and MPP+ co-treatment resulted in a 7% (4429 ± 3 0 
DCF fluorescent units/well) and 14% (5803 土 88 DCF fluorescent units/well) significant 
decrease (p < 0.05) in ROS levels at 4 h and 48 h respectively when compared to the 
MPP+-treated groups. When compared with the control, this represented a 15.2% and 
42.8% increase (p < .05) in ROS levels at 4 and 48 h respectively. This indicated that Def 
could effectively reduce the MPP+-induced ROS production by 36.1% and 35.2% at 4 
and 48 h respectively. 
(b) Striatal astrocytes (Fig. 12b) 
Similar to the mesencephalic astrocytes, striatal ROS level of control group did 
not show any significant increase from 0 (3768 土 41 DCF fluorescent units/well) to 48 
(4011 士 60 DCF fluorescent units/well) h of incubation. After MPP+ treatment, striatal 
astrocytes showed a rapid increase in ROS production from 4 h (4596 士 79 DCF 
fluorescent units/well) onwards, represented 20.7% significant increase (p < 0.05) when 
compared to the control (3809土 59 DCF fluorescent units/well) group. By 48 h, ROS 
production increased to 6697 土 52 DCF fluorescent units/well, representing a 67% 
significant increase (p < 0.05) in ROS when compared with the control. 
When striatal astrocytes were co-treated with Def + MPP+，there was a partial 
decline (p < 0.05) in ROS levels along all the time points studied when compared with 
MPP+treatment alone. Def and MPP+ co-treatment resulted in a 4.5% (4338 士 47 DCF 
fluorescent units/well) and 13.5% (5796 士 62 DCF fluorescent units/well) significant 
decrease (p < 0.05) in ROS levels at 4 and 48 h respectively when compared to the 
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corresponding MPP+ -treated groups. When compared with the control, this represented 
a 13.9% and 44.5% increase (p < 0.05) in ROS levels at 4 and 48 h respectively. This 
indicated that Def could effectively reduce the MPP^-induced ROS production by 32.9% 
and 33.6% at 4 and 48 h respectively. 
(c) Cortical astrocytes (Fig. 12c) 
ROS level of control group did not show any significant increase from 0 (3630 土 
43 DCF fluorescent units/well) to 48 (3854 士 74 DCF fluorescent units/well) h of 
incubation. After MPP+ treatment, cortical astrocytes showed a rapid increase in ROS 
production from 4 h (4479 土 59 DCF fluorescent units /well) onwards, represented 23% 
significant increase (p < 0.05) when compared to the control (3640土 44 DCF fluorescent 
units /well) group. By 48 h, ROS production increased to 5567 土 68 DCF fluorescent 
units /well, representing a 44.4% significant increase (p < 0.05) in ROS when compared 
with the control. 
Astrocytes co-treated with Def + MPP+ showed minimal attenuation (not 
significant) in MPP+-induced increase in ROS levels along all the time points studied. At 
48 h Def and MPP+ co-treatment, there was only a 6.4% decrease (5208 土 80 DCF 
fluorescent units /well) in ROS level when compared with MPP+ treatment alone. This 
represented a 35.1% increase in ROS level when compared with the control, this showed 
that Defeat! effectively reduce the MPP^-induced ROS production by only 20.9%. 
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3.1.4 The Effects of ZnSO* and NAc Combined Treatment on MPP+-treated 
Astrocytes 
3.1.4.1 LDH Activities 
Figure 13 shows the protective effects of the combined treatment of i) 24 h 50|iM 
ZNS04 + 20mM NAc prior to 0 - 48 h LOJUM MPP+ or ii) the addition of 200|liM Def + 
10|aM MPP+ after ZnS04 + NAc pretreatment. The control group was treated with 50jiM 
ZnS04 + NAc only for 0 - 48 h. 
(a) Mesencephalic astrocytes (Fig. 13a) 
Mesencephalic astrocytes treated with ZnSCU + NAc alone showed no significant 
increase in LDH levels from 0 (3.80 土 0.42 U/L) to 48 (8.02 土 0.42 U/L) h. The level of 
change in LDH activities after MPP+ treatment are the values reported in Section 3.1.3.1 
(Fig. 10a) because the combined treatment study was performed at the same time as that 
of the Def treatment alone. When mesencephalic astrocytes were pretreated with ZnS04 
+ NAc prior to MPP+ treatment, the LDH levels were significantly decreased (p < 0.05) 
when compared to the MPP+treatment only. A 51% (9.71 士 0.42 U/L) and 56.1% (22.79 
士 1.09 U/L) significant decrease (p < 0.05) were observed at 4 and 48 h respectively 
when compared with the corresponding MPP+- treated groups. At 48 h，when LDH 
activity of ZnS04 + NAc + MPP+ was compared with the control, a 1.8 fold increase (p < 
0.05) in LDH content was observed, this represented that ZnS04 + NAc can effectively 
reduce MPP+-induced LDH production by 66.3%. 
When mesencephalic astrocytes pretreated with ZnS04 + NAc and was further 
treated with Def + MPP+, the LDH levels were further decreased (p < 0.05) along all the 
time points studied when compared to MPP^-treated groups. This combined treatment 
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Fig. 13: Amount of LDH release into medium from (a) mesencephalic (ME), (b) 
striatal (ST) and (c) cortical (CO) astrocytes in 50|aM ZnSCU + 20mM NAc 
( • ) , lOjuM MPP+ _ ), 50|aM ZnS04 + 20mM NAc + lOjiM MPP+ (S) and 
50)aM ZnS04 + 20mM NAc + 200|liM Def + lO^iM MPP+ (日）treatment 
groups from 0 - 4 8 h. Values are expressed as mean 士 SEM. * p < 0.05, as 
compared with corresponding control. # p < 0.05, as compared with the 





























































































































































































resulted in a 59.6% (8.02 土 0.42 U/L) and 70% (15.61 士 0.81 U/L) significant decrease (p 
< 0.05) at 4 and 48 h respectively when compared with the corresponding MPP^-treated 
groups. When compared to the cells pretreated with ZnS04 + NAc only, the combined 
treatment showed only a 72.8% and 94.6% increase (p < 0.05) in LDH levels at 4 and 48 
h respectively when compared with ZnSCU + NAc control values. This represented a 
maximum effectiveness in reduce MPP+-induced LDH production by 72.5% and 82.7% 
respectively. 
(b) Striatal astrocytes (Fig. 13b) 
Striatal astrocytes treated with ZnS04 + NAc alone showed no significant 
increase in LDH levels from 0 (4.64 土 0.42 U/L) to 48 (8.86 土 0.40 U/L) h. The levels of 
change in LDH activities after MPP+ treatment are the values reported in Section 3.1.3.1 
(Fig. 10b) because the combined treatment study was performed at the same time as that 
of the Def treatment alone. When striatal astrocytes were pretreated with ZnS04 + NAc 
prior to MPP+ treatment, the LDH levels were significantly decreased (p < 0.05) when 
compared to the MPP+treatment only. A 44.7% (10.97 士 0.48 U/L) and 49.2% (26.59 士 
2.7 U/L) significant decrease (p < 0.05) were observed at 4 and 48 h respectively when 
compared with the corresponding MPP+- treated groups. At 48 h, when LDH activity of 
ZnS04 + NAc + MPP+ was compared with the control, a 2 fold increase (p < 0.05) in 
LDH content was observed, this represented that ZnS04 + NAc can effectively reduce 
MPP+-induced LDH production by 56.9%. 
When striatal astrocytes pretreated with ZnS04 + NAc and was further treated 
with Def + MPP+, the LDH levels were further decreased (p < 0.05) along all the time 
points studied when compared to MPP+-treated groups. This combined treatment 
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resulted in a 59.2% (8.10 士 0.42 U/L) and 64.5% (18.57 土 1.19 U/L) significant decrease 
(p < 0.05) at 4 and 48 h respectively when compared with the corresponding MPP+-
treated groups. When compared to the cells pretreated with ZnS04 + NAc only, the 
combined treatment showed only a 90% and 1.1 fold increase (p < 0.05) in LDH levels at 
4 and 48 h respectively when compared with ZnS04 + NAc control values. This 
represented a maximum effectiveness in reduce MPP+-induced LDH production by 
62.5% and 76.4% respectively. 
(c) Cortical astrocytes (Fig. 13c) 
Similar to that of the mesencephalic and striatal astrocytes, cortical astrocytes 
treated with ZnS04 + NAc alone showed no significant increase in LDH levels from 0 
(4.22 土 0.49 U/L) to 48 (8.02 土 0.41 U/L) h. The levels of change in LDH activities after 
MPP+ treatment are the values reported in Section 3.1.3.1 (Fig. 10c) because the 
combined treatment study was performed at the same time as that of the Def treatment 
alone. When cortical astrocytes were pretreated with ZnSCU + NAc prior to MPP+ 
treatment, the LDH levels were significantly decreased (p < 0.05) when compared to the 
MPP+treatment only. A 24.1% (8.01 士 0.42 U/L) and 20% (20.26 土 1.19 U/L) decrease 
were observed at 4 and 48 h respectively when compared with the corresponding MPP+-
treated groups. At 48 h, when LDH activity of ZnSO* + NAc + MPP+ was compared 
with the control, a 1.5 fold increase (p < 0.05) in LDH content was observed, this 
represented that ZnSCU + NAc can effectively reduce MPP+-induced LDH production by 
29.3%. 
When cortical astrocytes pretreated with ZnS04 + NAc and was further treated 
with Def + MPP+, the LDH levels were further decreased (p < 0.05) along all the time 
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points studied when compared to MPP^-treated groups. This combined treatment 
resulted in a 32% (7.17 士 0.42 U/L) and 25% (18.99 土 1.27 U/L) significant decrease (p < 
0.05) at 4 and 48 h respectively when compared with the corresponding MPP+-treated 
groups. When compared to the cells pretreated with ZnSCU + NAc only, the combined 
treatment showed only a 54.5% and 1.4 fold increase (p < 0.05) in LDH levels at 4 and 
48 h respectively when compared with ZnS04 + NAc control values. This represented a 
maximum effectiveness in reduce MPP+-induced LDH production by 63.7% and 36.6% 
respectively. 
3.1.4.2 ROS Production 
Figure 14 shows the protective effects of the combined treatment of i) 24 h 50)aM 
ZnS04 + 20mM NAc prior to 0 - 48 h 10|aM MPP+ or ii) the addition of 200|iM Def + 
lOjLiM MPP+ after ZnS04 + NAc pretreatment. Control group was treated with SOjuM 
ZnS04 + NAc only for 0 - 48 h. 
(a) Mesencephalic astrocytes (Fig. 14a) 
Mesencephalic astrocytes treated with ZnSCU + NAc alone showed no significant 
increased ROS levels for all time points studied, from 3824 士 25 DCF fluorescent 
units/well at 0 h to 4034 土 30 DCF fluorescent units/well at 48 h. The results for ROS 
production after MPP+ treatment are the values reported in Section 3.1.3.2 (Fig. 11a) 
because the combined treatment study was done at the same time as that of the Def 
treatment alone. When mesencephalic astrocytes were pretreated with ZnS04 + NAc 
prior to MPP+treatment, the ROS levels were decreased along all the time points studied 
and showed significant decreases (p < 0.05) when compared to the corresponding MPP+ 
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Fig. 14: ROS production in (a) mesencephalic (ME), (b) striatal (ST) and (c) cortical 
(CO) astrocytes in 50jaM ZnS04 + 20mM NAc (圍），lO i^M MPP+ ( • ) , 
50|aM ZnS04 + 20mM NAc + 10|aM MPP+ (Q) and 50|aM ZnSCU + 20mM 
NAc + 200|liM Def + 10|AM MPP+ (曰)treatment groups from 0 - 48 h. 
Values are expressed as mean 土 SEM. * p < 0.05，as compared with 
corresponding control. # p < 0.05，as compared with the corresponding 
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treatment. A 13.8% (4101 士 38 DCF fluorescent units/well) and 29.5% (4755 土 110 DCF 
fluorescent units/well) decrease were observed at 4 and 48 h respectively when compared 
with the corresponding MPP+- treated groups. At 48 h, when ROS level ofZnS04 + NAc 
+ MPP+ was compared with the control, a 17.9% increase (p < 0.05) in ROS production 
was observed, this represented that ZnS04 + NAc can effectively reduce MPP+-induced 
ROS production by 72.9%. 
When mesencephalic astrocytes pretreated with ZnS04 + NAc and was further 
treated with Def + MPP+，the ROS levels were further decreased (p < 0.05) along all the 
time points studied when compared to MPP+-treated groups. This combined treatment 
resulted in a 16.3% (3983 士 39 DCF fluorescent units/well) and 33.4% (4496 土 112 DCF 
fluorescent units/well) significant decrease (p < 0.05) at 4 and 48 h respectively when 
compared with the corresponding MPP+-treated groups. When compared to the cells 
pretreated with ZnSCU + NAc only, the combined treatment showed only a 3.7% and 
11.5% increase (p < 0.05) in ROS levels at 4 and 48 h respectively when compared with 
ZnS04 + NAc control values. This represented a maximum effectiveness in reduce 
MPP+-induced ROS production by 84.5% and 82.6% respectively. 
(b) Striatal astrocytes (Fig. 14b) 
Striatal astrocytes treated with ZnSCU + NAc alone showed no significant 
increased ROS levels for all time points studied, from 3760 士 31 DCF fluorescent 
units/well at 0 h to 4011 ± 55 DCF fluorescent units/well at 48 h. The results for ROS 
production after MPP+ treatment are the values reported in Section 3.1.3.2 (Fig. l i b ) 
because the combined treatment study was done at the same time as that of the Def 
treatment alone. When striatal astrocytes were pretreated with ZnSCU + NAc prior to 
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MPP+ treatment, the ROS levels were decreased along all the time points studied and 
showed significant decreases (p < 0.05) when compared to the corresponding MPP+ 
treatment. A 11.6% (4064 士 65 DCF fluorescent units/well) and 30.8% (4637 士 161 DCF 
fluorescent units/well) decrease were observed at 4 and 48 h respectively when compared 
with the corresponding MPP+- treated groups. When compared with the control 48 h, 
there was 15.6% increase (p < 0.05) in ROS and this represented that ZnSCU + NAc can 
effectively reduce the MPP+-induced ROS production by 76.7%. 
When striatal astrocytes pretreated with ZnS04 + NAc and was further treated 
with Def + MPP+，the ROS levels were further decreased (p < 0.05) along all the time 
points studied when compared to MPP^-treated groups. This combined treatment 
resulted in a 12.8% (4008 土 50 DCF fluorescent units/well) and 32.3% (4534 土 71 DCF 
fluorescent units/well) significant decrease (p < 0.05) at 4 and 48 h respectively when 
compared with the corresponding MPP+-treated groups. When compared to the cells 
pretreated with ZnSCU + NAc only, the combined treatment showed only 5.2% and 13% 
increase (p < 0.05) in ROS levels at 4 and 48 h respectively when compared with ZnS04 
+ NAc control values. This represented a maximum effectiveness of ZnS04 + NAc + 
Def in reduce MPP+-induced ROS production by 74.9% and 80.6%. 
(c) Cortical astrocytes (Fig. 14c) 
Similar to the mesencephalic and striatal astrocytes, cortical astrocytes treated 
with ZnS04 + NAc alone showed no significant increased ROS levels for all time points 
studied, from 3638 士 43 DCF fluorescent units/well at 0 h to 3862 士 89 DCF fluorescent 
units/well at 48 h. The results for ROS production after MPP+ treatment are the values 
reported in Section 3.1.3.2 (Fig. 11c) because the combined treatment study was done at 
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the same time as that of the Def treatment alone. When cortical astrocytes were 
pretreated with ZnS04 + NAc prior to MPP+ treatment, the ROS levels were decreased 
along all the time points studied and showed significant decreases (p < 0.05) when 
compared to the corresponding MPP+treatment. A 11.7% (3957 土 81 DCF fluorescent 
units/well) and 17.6% (4587 土 89 士 110 DCF fluorescent units/well) decrease were 
observed at 4 and 48 h respectively when compared with the corresponding MPP+-
treated groups. When compared with the control 48 h, there was 18.8% increase (p < 
0.05) in ROS and this represented that ZnS04 + NAc can effectively reduce the MPP+-
induced ROS production by 57.7%. 
When cortical astrocytes pretreated with ZnS04 + NAc and was ftirther treated by 
Def + MPP+，the ROS levels were further decreased (p < 0.05) along all the time points 
studied when compared to MPP+-treated groups. This combined treatment resulted in a 
10.4% (4012 士 70 DCF fluorescent units/well) and 22% (4343 士 95 DCF fluorescent 
units/well) significant decrease (p < 0.05) at 4 and 48 h respectively when compared with 
the corresponding MPP+-treated groups. When compared to the cells pretreated with 
ZnS04 + NAc only, the combined treatment showed only 9.6% and 12.5% increase (p < 
0.05) in ROS levels at 4 and 48 h respectively when compared with ZnS04 + NAc control 
values. This represented a maximum effectiveness of ZnS04 + NAc + Def in reduce 
MPP+-induced ROS production by 58.3% and 71.9%. 
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3.2 Effects of l-inethyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) on MT-I, -11 
Knock-out Mice 
3.2.1 The Effects of MPTP on Cell Loss in the Substantia Nigral (SN) 
TH-positive cells in the SN were counted in C57 BL/6, Svl29 and MT-null mice 
3 days after MPTP treatment. Results showed that there was a significant decrease (p < 
0.05) in TH cell no. after MPTP treatment in C57 BL/6 mice and MT-null mice but not in 
Svl29 mice (Fig. 15a). When expressed as percentage cell loss (Fig. 15b), C57 BL/6 and 
MT-null mice showed a 36% (from 2627 土 236 to 1685 士 136) and 48% (from 2491 士 
341 to 1296 土 189) decrease in the no. of TH-positive cells respectively, while Svl29 
mice showed a 32% (from 2527 士 350 to 1710 土 348) decrease. There was no species 
difference in the no. of TH-positive cells in the saline treated animals (Fig, 15a). The 
decrease in TH cell numbers of both C57 BL/6 and MT-null mice were significant (p < 
0.05) when compared to their saline-treated groups. The decrease in the Svl29 group is 
however not significant. 
3.2.2 The Effects of MPTP on Striatal (ST) and SN Dopamine Transporter (DAT) 
Binding 
Figure 16 shows the results of specific binding of DAT in the ST and SN 3 days 
after MPTP treatment. It was shown that there was a species difference in the specific 
binding of both the control and MPTP treatment groups. There is a significant difference 
(P < 0.05) in specific binding between C57 BL/6 (221.12 土 36.7 fmol/mg protein) and 
Svl29 (346.2 土 20.4 fmol/mg protein) to MT-null mice (612.8 士 33.2 fmol/mg protein). 
MPTP treatment resulted in a significant decrease (p < 0.05) in DAT binding in the ST of 
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Fig. 15: (a) The number of TH-positive cells in the SN of C57/BL ( • )，Svl29 (B) 
and MT-null ( • ) mice after 1 dose 40mg/kg (s.c.) of MPTP treatment. 
Values are expressed as mean 士 SEM (n=3). * p < 0.05, as compared with 
the corresponding saline-treated control group. 
(b) Results expressed as percentage cell loss when compared to the 
corresponding control groups. 
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Fig. 16: Change in (a) striatal and (b) SN DAT levels of C57/BL (•), Svl29 (圓）and 
MT-null ( • ) mice after 1 dose of 40mg/kg (s.c.) MPTP treatment. Values 
are expressed as mean 土 SEM (n=3). * p < 0.05, as compared with the 
corresponding saline-treated control groups. # p < 0.05, when MT-null 
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all three groups studied. There was a 47.6% decrease (p < 0.05; 221.1 土 36.7 to 115.9 士 
18.4 fmol/mg protein) in DAT binding in C57 BL/6 mice whilst MT-null mice showed a 
48.1% decrease (p < 0.05; 612.8 土 33.2 to 318.1 土 65.1 fmol/mg protein). Svl29 mice 
showed a 50.5% reduction (p < 0.05; 346.2 士 20.4 to 171.3 士 47 fmol/mg protein) in 
DAT binding when compared to the MPTP-treated group (Fig. 16a). 
DAT binding in the SN did not show any significant difference between the 
control and MPTP treatment groups although a slight decrease in DAT binding was 
observed in the C57 BL/6 and Svl29 mice after MPTP treatment (Fig. 16b). 
3.2.3 The Effects of MPTP on ST DA Metabolites 
Figure 17 shows the result striatal DA and its metabolites DOPAC and HVA 
contents. 
(a) DA content (Fig. 17a) 
The basal DA content of MT-null mice was higher than that of the Svl29 and the 
C57 BL/6 mice. After MPTP treatment, the DA content of MT-null mice showed a 44% 
decrease (p < 0.05) from 206.8 土 9.7 to 115.9 士 19.9 ng/mg protein, while Svl29 mice 
showed a 20.9% decrease (p < 0.05) from 173.3 士 12.5 to 137.0 土 7.2 ng/mg protein. C57 
BL/6 mice showed a 41.5% decrease (p < 0.05) from 124.2 土 6.4 to 72.7 士 4.5 ng/mg 
protein. 
(b) DOPAC content (Fig. 17b) 
MT-null mice showed a 31.3% decrease in DOAPC content from 14.7 士 1.2 to 
10.1 土 1.6 ng/mg protein, while Svl29 mice showed a 28.6% decrease (p< 0.05) 
decrease from 13.3 土 0.8 to 9.5 士 1.0 ng/mg protein. C57 BL/6 mice showed a 39.1% 
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Fig. 17: Change in (a) DA (b) DOPAC and (c) HVA contents in the striata of 
C57/BL ( • ) , Svl29 (S ) and MT-null , ) mice after 1 dose of 40mg/kg 
(s.c.) MPTP treatment. Values are expressed as mean 土 SEM (n=3). * p < 

























































































































decrease (p < 0.05) from 9.5 土 0.2 to 5.8 土 0.7 ng/mg protein after MPTP treatment, 
(c) HVA content (Fig. 17c) 
C57 BL/6, Svl29 and MT-null mice all showed a significant (p < 0.05) reduction 
in HVA content after MPTP treatment. MT-null mice showed a 28.4% decrease (p < 
0.05) from 23.2 士 0.4 ng/mg protein to 16.6 土 1.4 ng/mg protein while Svl29 mice 
showed a 24.8% decrease (p < 0.05) from 23.0 土 1.5 to 17.3 士 0.8 ng/mg protein. C57 
BL/6 mice showed a 26.5% decrease (p < 0.05) from 15.2 士 0.6 to 11.2 士 0.8 ng/mg 
protein after MPTP treatment. 
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CHAPTER FOUR: DISCUSSION AND CONCLUSION 
MPP+-induced neurotoxicity 
The present study shows that MPP+ induced ROS production in astrocytes during 
48 h of MPP+ treatment and that astrocytes from different brain regions seemed to 
respond differently to the MPP+ treatment (Figs. 6，10，12). By 48 h MPP+treatment, the 
amount of ROS production is in the order of mesencephalic > striatal > cortical 
astrocytes. The percentage of ROS increase at 4 and 48h treatment ranged from 23.1 -
23.8%, 20.7 - 21.8% and 11.3 - 23% at 4 h to 64.2 -67.3%, 57.9 - 67% and 30.4 - 44.4% 
at 48 h for mesencephalic, striatal and cortical astrocytes respectively. 
MPP+-induced increase in LDH activities was also observed (Figs. 4, 8，11) with 
a regional difference in the order of mesencephalic > striatal > cortical astrocytes when 
cultured under the same standard conditions. The amount of increase at 4 and 48h 
treatment ranged from 1.9 - 3.3 fold, 1.4 - 2.5 fold and 0.76 - 1.5 fold at 4 h to 3.5 - 5.5 
fold, 3.0 - 4.6 fold and 1.8 - 2.3 fold at 48 h for mesencephalic, striatal and cortical 
astrocytes respectively. 
The increase in LDH activities also showed a concomitant decrease in 
mitochondrial activities as measured by MTT activities (Figs. 5, 8). MTT decrease 
ranged from 34.1 - 34.5%, 31.4 - 35.9% and 18.6 - 36.8% at 4 h to 43.5 - 43.7%, 39.9 -
44.6% and 26.4 - 39.7% at 48 h in mesencephalic, striatal and cortical astrocytes 
respectively. These results are consistent with the ROS data and confirmed that 
mesencephalic and striatal astrocytes are more vulnerable to MPP+-induced toxicity when 
compared to cortical astrocytes. 
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The cardinal neurochemical characteristic of PD is a loss of DA neurons in the SN 
and the depletion of DA in the striatum. It was shown that not all DA neurons degenerate 
to the same extent in PD brains and the greatest cell loss (76%) is in the SN pars 
compacta, followed by SN pars lateralis (34%), ventral tegmental area (55%) and 
minimal in the central gray substances (7%) (Hirsch et al” 1988; Damier et al., 1997; 
Hirsch et al., 1999). This suggested that DA neurons in the SN are more susceptible to 
the disease than those in the other regions. Interestingly, the most susceptible neurons in 
SN have been shown to be particularly sensitive to oxidative stress (for review, see 
Damier et al., 1993). Such SN neurons produce more oxygen free radicals than those 
which are less susceptible to the disease, judging from the fact that they contain 
neuromelanin (Hirsch et al., 1988) and the synthesis of which is known to be associated 
with the production of oxygen free radicals (Graham, 1979). Furthermore, it was 
suggested that they are less well protected against oxygen free radicals, as they are 
located in an environment containing few glial cells expressing GSH-Px (Damier et al., 
1993), an enzyme that catabolizes H2O2, thus preventing the formation of highly toxic 
OH. 
Further evidence was shown in the increased accumulation of iron within the DA 
neurons in PD (Dexter et al., 1989a; Hirsch et al., 1991; Jellinger et al., 1992). Laser 
microprobe studies indicated that iron accumulated primarily within the neuromelanin 
granules of dopaminergic neurons (Good et al., 1992). Moreover, increased Mn-SOD 
activity was reported in the SN of patients with PD (Saggu et al., 1989), probably leading 
to an accumulation of H2O2. Alternations in mitochondrial function that lead to the 
accumulation of ROS have been reported in the SN of PD brains (Schapira et al., 1990a). 
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Therefore, it seems that the neurons in the SN that are most sensitive to PD are poorly 
protected against an increase in the level of ROS. The density of GFAP-positive cells was 
also increased correlating with the severity of the DA neuronal loss in parkinsonian 
midbrains. Therefore, this suggested the involvement of astrocytes in the pathogenesis of 
PD (Damier et al., 1993). More recently, Damier et al., (1996) found that the density of 
astroglial cells was also the lowest in the most severely affected group of SN neurons 
(Damier et al., 1996). These data suggest that neurons may be less susceptible to PD 
when they are located in an astroglia-rich rather than an astroglia-poor environment (for 
review, see Hirsch et al., 1998). 
Astrocytes have received little attention in the pathogenesis of PD; earlier interest 
in astrocytes in PD was focused on glial scarring in the SN. The identification of the 
neurotoxin MPTP and the development of the MPTP animal model for PD (Bums et al., 
1983) have generated new interests in examination of the part played by astrocytes in the 
degenerative process. 
Astrocytes has been implicated in the pathogenesis of PD because astrocytes 
contain large amounts of MAO-B (Levitt et al., 1982) in the CNS. MPTP that is 
accumulated in astrocytes are converted to its toxic metabolites MPP+ (Brooks et al., 
1989) by MAO-B which is located predominately in astrocytes (Levitt et al., 1982). 
Therefore, astrocytes are the primary site for the bioactivation of MPTP where MPTP is 
converted to its toxic metabolite MPP+ (Yang et al., 1988; Di Monte et al., 1991). It is 
however unknown whether the ROS that was produced during this conversion process are 
derived from astrocytes and thus generate ROS like O2 and OH which wil l finally cause 
neuronal death (Chiueh et al., 1992; Zang and Misra 1993). It has been shown, however, 
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that astrocytes have a high capacity for MPP+ retention and efflux (Tsai and Lee 1994; 
Schinelli et a l , 1988; Di Monte et al., 1992b; Wu et al., 1992). Results from the present 
study and that of previous studies (Wong et al., 1999) in our laboratory showed that the 
presence of MPP+ is able to induce ROS production, thus further establishing an 
important role for astrocytes in the degenerative process. 
Apart from the primary conversion site of MPTP, astrocytes also contain large 
amount of antioxidants such as GSH, CuZn and Mn-SOD，catalase (Hirsch 1992; 
Thiffault et al., 1995) and GSH-Px (Damier et al., 1993). This indicates that astrocytes 
may also play an important role in the defense against oxidative stress in the CNS. The 
high concentration of astrocytic SOD (Saint-Jacques et al., 1998) and GSH when 
compared to neurons (Raps et al., 1989; Sagara et al., 1993; Lowndes et al., 1994)，and 
oligodendrocytes (Thorbume and Juurlink, 1996) further suggest that astrocytes are 
important for the detoxification of ROS. The difference in antioxidant content among the 
astrocytes from the three different regions in this study may account for this different 
extent of ROS production. Although the SOD content did not differ in astrocytes from 
these three regions (Wong et al., 1999)，the present study showed that GSH content was 
however different. It is in the order of cortical > striatal > mesencephalic astrocytes (Fig. 
7), thus may be one of the reasons why mesencephalic astrocytes are the most vulnerable 
to MPP^-induced ROS production. 
In addition to the antioxidant content among astrocytes, it had been shown that the 
high resistant to oxidative stress of astrocytes is due to the low level of iron which is 20 
fold less than oligodendrocytes (Thorbume and Juurlink, 1996). Therefore, another 
possible mechanism for the regional difference in the amount of ROS production may be 
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dependent on variations in the concentration of iron or the iron-redox equilibrium present 
• 
in the astrocytes. MPTP has been shown to complex ferrous iron (Fe ) to form O2 and 
ferric iron (Fe^^). O2 that was formed, through an iron dependent Haber-Weiss reaction 
with H2O2, can generate OH (Poirier and Barbeau, 1985). Apart from this, MPTP had 
been shown to also react with iron resulting in the rapid production of MPDP+ (Poirier 
and Barbeau, 1985) and also in rapid oxidation of MPDP+ to MPP+ in astrocytes (Di 
Monte et al., 1995). Therefore, areas in the brain that contain high iron content like the 
DA neurons in the SN (Gerlach et al., 1994) may, in the presence of H2O2, generate 
highly reactive OH , resulting in lipid peroxidation of cell membrane and subsequent 
neuronal cell death (Floyd and Carney, 1992). Preliminary results from our laboratory 
showed there is no difference in Fe content in mesencephalic, striatal and cortical 
astrocytes. However a decrease in ratio in the order of mesencephalic > striatal 
> cortical astrocytes was observed during 0 - 24 h MPTP treatment (unpublished data). 
These studies also indicated that iron is involved in MPTP-induced toxicity with 
mesencephalic, followed by striatal astrocytes being more susceptible to oxidative stress 
when compared to cortical astrocytes. Although the present study only examined the 
direct effects of MPP+- and not MPTP-induced toxicity, the iron chelator Def can 
partially attenuate ROS production suggesting that MPP+ could also induce the release of 
iron. By 48 h, Def treatment can only reduce ROS levels by 35.2, 33.6 and 21% in 
mesencephalic, striatal and cortical astrocytes respectively (Fig. 11; Section 3.1.3.2; 
Table la), suggesting that the contribution of iron in ROS formation cannot be ruled out. 
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The effects of ZnS04 pretreatment on MPP+-induced neurotoxicity 
24 h ZnS04 pretreatment resulted in an increase in MT-I, - I I mRNA similar to 
that reported by Ebadi et al. (1996). The induction of MT-I, - I I transcripts is primarily 
within astrocytes because they are reported to be absent from selected neurons and other 
glial cells such as microglia and oligodendrocytes (Nishimura et al., 1992; Choudhuri et 
al., 1995). In the present study, ZnSCU pretreatment enhanced MTs mRNA in all three 
regions with mesencephalic astrocytes showing the most prominent increase (98.3%), this 
was followed by cortical (33.4%) and striatal (28.9%) astrocytes showing moderate 
increase (Fig. 3). 
The mechanism whereby ZnS04 induced an increase in MT-I, - I I level is not fully 
understood. The induction of MTs gene expression by metals is initiated by metal 
interactions with trans-acting regulatory element binding factors (MRBF) that in turn 
bind to cis-acting DNA sequences [termed metal regulatory elements (MREs)] upstream 
from the TATA box (Andrews 1990，2000). Four functional MREs (Andrews, 1990) and 
MTF-1 (a MRBF containing six zinc finger motifs) have been identified (Heuchel et al., 
1994). MTF-1 has been postulated to act as a ‘metal sensing mechanism' in the 
regulation of metal homeostasis. Palmiter (1994), proposed that MTF-1 respond to an 
increase in the concentration of ‘free’ metals primarily zinc. This in turn stimulates the 
interaction of MTF-1 with the MREs, thereby activating transcription of MTs genes. 
There were no obvious changes in MT-I, - I I mRNA levels after MPP+ treatment in 
astrocytes from all three regions (Fig. 3). Apart from zinc, MTs levels can also be 
induced indirectly either by increasing the free concentration of other metals; by 
increasing the levels of brain glucocorticoids (Hidalgo et al., 1994); or by the generation 
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of ROS (Shiraga et al., 1993). In addition, it has been reported that chemicals that 
produce oxidative stress can also induce the synthesis of MTs (Bauman et al., 1991). 
However, in the present study, MPP+ alone did not induce MTs mRNA expression. 
MPP+-induced ROS production also did not induce MTs level. 
However, when astrocytes pretreated with SOjiiM ZnS04 followed by 48 h MPP+ 
treatment, MTs mRNA contents were reduced to control levels in mesencephalic and 
striatal astrocytes, while in cortical astrocytes, there was still a 31.4% increase when 
compared with the control (Fig. 3). It seemed that MPP+ was able to cause a reduction of 
MTs only i f MTs were induced, as in this study, by the presence of ZnSCU. It had been 
reported that MPTP treatment in mice resulted in a decrease in MTs level when MTs 
were induced with cadmium or dexamethasone prior to MPTP treatment (Rojas and Rios, 
1997). This further confirms that MPTP or MPP+ is able to reduce MTs levels after its 
induction. 
The present study showed that ZnS04 pretreatment can reduce MPP+-induced ROS 
production by 54.7, 42.2 and 28.6% in mesencephalic, striatal and cortical astrocytes 
respectively at 48 h post treatment (Fig. 6, Section 3.1.1.3.3, Table la). In mesencephalic 
and striatal astrocytes, its effectiveness in reducing ROS production is time dependent 
because at 4 h，the effectiveness was 62.2 and 51.4% respectively (Fig. 6, Section 
3.1.1.3.3). Similarly, ZnSCU pretreatment can also reduce the effects of MPP+ treatment 
on cell viability. At 48 h, LDH release was reduced by 61.4, 53.8 and 64.1% (Fig. 4， 
Section 3.1.1.3.1，Table la) and MTT reduction by 74.1, 75.1 and 51.1% (Fig. 5, Section 
3.1.1.3.2) in mesencephalic, striatal and cortical astrocytes respectively. In 
mesencephalic and striatal astrocytes, the effectiveness of ZnS04 to reduce LDH release 
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Table 1: a) Summary table of the maximum effectiveness of different treatment 
paradigms in reducing ROS production at 48 h MPP+. Results were 
extracted from Sections 3.1.1.3.3, 3.1.2.4，3.1.3.2 and 3.1.4.2. 
b) Summary table of the maximum effectiveness of different treatment 
paradigms in reducing LDH production at 48 h MPP+. Results were 
extracted from Sections 3.1.1.3.1，3.1.2.2, 3.1.3.1 and 3.1.4.1. 
(a) % Decrease in ROS 
48 h ZnS04 NAc Def Zn+NAc Zn+NAc+Def 
ME 54.7 34.7 35.2 72.9 82.6 
ST 42.2 30.1 33.6 76.7 80.6 
CO 28.6 21.4 21.0 57.7 71.9 
(b) % Decrease in LDH 
48 h ZnS04 NAc Def Zn+NAc Zn+NAc+Def 
ME 61.4 43.5 34.6 66.3 82.7 
ST 53.8 48.0 33.3 56.9 76.4 
CO 64.1 75.8 14.6 29.3 36.6 
is also time dependent where at 4 h, it was shown to be 79.6 and 73.8% respectively (Fig. 
4，Section 3.1.1.3.1). However ZnS04，s effectiveness in reducing MTT reduction is a 
delayed process, since at 4 h, it is only effective in reducing MTT reduction by 26.4 and 
23.4% respectively. 
The action of MTs as a OH scavenger had been suggested (Thomalley and Vasak, 
1985). Enhanced synthesis of MTs to prevent damage caused by paraquat-induced 
oxygen radicals had been reported (Nakagawa et a l , 1998) further suggesting the role of 
MTs in free radical scavenging. MTs itself may function as a thiol donor and free radical 
scavenger, thus providing a line of protection against oxidative damage (Lazo et al., 
1995). As thiols are known targets for both peroxynitrite anion and peroxynitrous acid 
(Radi et al., 1991)，it is plausible that MTs may intercept both these oxidizers to further 
produce OH , thus decrease the ROS production and the cytotoxicity of MPP+ towards 
astrocytes that was observed in the present study. 
Moreover, it has been suggested that MTs’ antioxidant properties may depend on its 
metal speciation since MTs have high affinity for both essential (zinc and copper) and 
non-essential (cadmium and mercury) metals (Wan et al., 1993). MTs may sequester iron 
in such a fashion that it is no longer capable of contributing to the Fenton reaction 
(Muller et al., 1991). Therefore, another possible antioxidant properties of MTs may be 
due to the formation of iron-thiol-nitrosyl complexes, secondary to the sequestration of 
the transition metals, iron, by MTs (Schwarz et al., 1995). Since the free iron level was 
decreased, the potent OH which was generated by the Fenton reaction in the presence of 
iron wi l l be decreased, thus reducing the ROS level and MPP^-induced toxicity. 
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Besides, the protective effect of MTs may also depend on the ability of oxygen 
free radicals to release zinc from MTs thiolate clusters, and the antioxidant activity of 
zinc on plasma membranes and on other nuclear and cytoplasmic proteins (Hainaut and 
Milner, 1993). Zinc released from MTs in turn can protect against lipid peroxidation and 
stabilizes the membrane. Zinc suppresses lipid peroxidation by decreasing the uptake of 
iron, by inhibiting the activity of NADPH-cytochrome c reductase, or by increasing the 
activity of GSH-Px (Coppen et al., 1988). Enzymes that form GSSG or other enzymes 
that generate disulfides are thought to be coupled to events that signals the release of zinc 
from MTs (Maret, 1994). In toxic conditions involving oxidative stress, zinc-sulfur 
bonds are also important in the mobilization and release of zinc from MTs (Schwarz et 
al., 1995). Moreover, the release of zinc from MTs might suppress the radical-mediated 
damage (Thomas et al” 1986). 
From this study, it seems that the functional significance of MTs induction within 
astrocytes represents an attempt by these cells to maintain and control cerebral 
homeostasis by mitigating the toxicity of MPP+. A number of mechanisms may be 
associated with the ability of MTs to protect against MPP+ toxicity. First, MTs，high -SH 
content (Hughes, 1957). Secondly, MTs’ ability to scavenge ROS as formation of ROS 
is a known outcome of MPTP or MPP+ exposure. Thirdly, increased MTs could 
potentially provide sulfhydryl nucleophiles to "neutralize" ROS (Aschner, 1996). Others 
have suggested that the cysteine residues of MTs might serve as an expandable target for 
ROS (Lazo et a l , 1995). Numerous studies attest to the protective role of MTs (Aschner. 
1996). Thus, increased MTs expression may represent a generalized response to 
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oxidative stress and heavy metal exposure, protecting astrocytes, and perhaps also 
indirectly, the juxtaposed neurons. 
The effects of NAc pretreatment on MPP+-mduced neurotoxicity 
Oxidative stress is not only the result of ROS overproduction, it may also be the 
consequence of a decreased level of antioxidant which normally renders protection 
against ROS (Halliwell and Gutteridge, 1985). It is a constant finding in the literature 
that MPTP administration to mice results in a decrease in brain concentrations of reduced 
GSH (Ferraro et a l , 1986; Yong et al , 1986; Adams, et al., 1989)，a well-known thiol-
dependent cellular mechanism of defense against ROS (Halliwell and Gutteridge 1985). 
In this regard, it is interesting to show that there is also a partial protective effect of GSH 
in MPP+-induced toxicity by pretreating the astrocytes with the GSH inducer, NAc. 
The present study showed that mesencephalic astrocytes have the lowest basal 
GSH (19.67 士 0.27 nM/mg protein) level when compared with striatal (24.95 士 0.50 
nM/mg protein) and cortical astrocytes (27.15 士 0.70 nM/mg protein) (Fig. 7). This is 
consistent to that reported previously where GSH content in cortical astrocytes was 
shown to be approximately 23% greater than striatal and mesencephalic astrocytes 
(Langeveld et al., 1996). Because of the low basal level of GSH-Px (Damier et al., 1993) 
and GSH in mesencephalic astrocytes observed in the present study, these cells may be 
more susceptible to MPP+-indiiced toxicity when compared to the astrocytes from the 
other two regions. This was confirmed by the present study that MPP+ treatment caused 
significant decreases in GSH levels in the order of mesencephalic (44.3%) > striatal 
(23.8%) > cortical (20.6%) astrocytes (Fig. 7). Previous studies in our laboratory also 
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showed that because of the 30% lower level of endogenous GSH content in 
mesencephalic astrocytes when compared to striatal and cortical astrocytes, there was an 
early depletion of GSH levels in mesencephalic astrocytes after MPTP treatment 
(unpublished data). Therefore, the lower endogenous GSH level of mesencephalic 
astrocytes may render the cells less capable to counteract MPTP- or MPP+-induced 
oxidative stress. Since astrocytes are the main location of cellular GSH (Raps et al., 
1989; Rice and Russo-Menna 1998)，a higher endogenous level of GSH may provide 
better protection for neurons against oxidative stress. It was shown that striatal astrocytes, 
when cocultured with DA neurons, exert a protective effect against H202-induced 
neuronal damage (Langeveld et al., 1995). 
After cultured astrocytes were pretreated with NAc, there was an increase in GSH 
levels with mesencephalic (61.5%) > striatal (53.5%) > cortical (8.8%) astrocytes (Fig. 
7). Despite the lower endogenous level of GSH in mesencephalic astrocytes, the presence 
of NAc could raise the level of GSH to that of striatal and cortical astrocyte levels. NAc 
pretreatment prior to MPP+ treatment ameliorated MPP+-induced decrease in GSH levels 
in both mesencephalic and striatal astrocytes. This suggested that by increasing 
endogenous astrocytic GSH level, cells may be protected against MPP+-induced toxicity. 
The present study showed that pretreatment with NAc prior to MPP+ treatment 
could partially attenuate MPP+-induced ROS production. ROS production was shown to 
be reduced by 34.7, 30.1 and 21.4% in mesencephalic, striatal and cortical astrocytes 
respectively at 48 h post treatment (Fig. 10，Section 3.1.2.4, Table la). In mesencephalic 
and striatal astrocytes, its effectiveness in reducing ROS production is also time 
dependent because at 4 h the effectiveness was 37.2 and 37.1 % (Fig. 10，Section 3.1.2.4) 
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respectively. Similarly, NAc can also reduce the effects of MPP+ treatment on cell 
viability. At 48h, LDH release was reduced by 43.5, 48 and 75.8% (Fig. 8, Section 
3.1.2.2, Table la) and MTT reduction by 26.2, 27.1 and 39.8% (Fig. 9，Section 3.1.2.3) in 
mesencephalic, striatal and cortical astrocytes respectively. Unlike that observed for 
ROS, the effectiveness of NAc to reduce LDH release (Fig. 8, Section 3.1.2.2) and MTT 
reduction (Fig. 9，Section 3.1.2.3) increased with time with maximal effect reached at 48 
h post treatment. 
Therefore, it seemed that mesencephalic astrocytes are more susceptible to MPP+-
induced oxidative stress as observed by its low endogenous level of GSH and by the 
highest percentage of ROS formation observed. Previous studies in our laboratory 
showed by MPTP depletes GSH (unpublished data), SOD and ATP (Wong et al., 1999) 
more rapidly in mesencephalic astrocytes than in striatal and cortical astrocytes. A l l these 
evidences further support the present tenet that mesencephalic astrocytes may be the most 
vulnerable to oxidative stress. 
GSH functions as a major antioxidant in the cellular defense against oxidative 
stress derived from H2O2 (Cohen and Spina 1989; Meister, 1991) and acts directly as a 
free radical scavenger (Ward et al., 1990). Since most of GSH in the brain has been 
shown to be situated in the astrocytes (Raps et al., 1989; Rice and Russo-Menna, 1998), 
the oxidative mechanism involved in the degenerative process of DA neurons in PD may 
be partly related to the GSH content in astrocytes. Di Monte et al. (1992) showed that 
mitochondrial deficits caused a decrease in ATP content of astrocytes, which in turn 
impairs GSH synthesis and reduces total GSH levels. Conversely, GSH depletion results 
in H2O2 accumulation and promotes mitochondrial damage. Therefore, impairment of the 
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GSH defense system would compromise the ability of the brain to eliminate H2O2, 
resulting in secondary mitochondrial dysfunction and critically impair cellular energy 
production (Pearce et al., 1997). In addition, loss of intracellular ATP is associated with 
increased efflux of GSH from the cell, as was shown in cultured hepatocytes exposed to 
MPP+ (Di Monte et al., 1986). As a result, the increase of GSH by NAc may restore ATP 
loss indirectly and hence increase cell viability. This was shown by the reduction of LDH 
(Fig. 8) and increase of MTT reduction (Fig. 9) observed in the present study. Peuchen et 
al., (1997) concluded that due to the higher GSH content in astrocytes than neurons in the 
CNS, one of the roles of astrocytes is to counteract oxidative stress (Sengstock et al., 
1994; Bolanos et al., 1995). The present study further supports the tenet that an increase 
in astrocytic GSH wil l provide antioxidant support against MPTP- or MPP+-induced 
toxicity. 
The effects of combined treatments on MPP+-induced neurotoxicity 
Table 1 summarized the amount of reduction in ROS and LDH afforded by the 
different treatment regimen. When astrocytes were treated with ZnS04 + MPP+，the 
intracellular ROS showed a significant decrease (Fig. 6) with the amount of reduction of 
ROS in the order with mesencephalic (54.7%) > striatal (42.2%) > cortical (28.6 %) 
(Table la). The protective ability of in terms of decreasing LDH (Fig. 4) was similar to 
that of ROS reduction, where the amount of reduction is in the order of mesencephalic 
(61.4%) > striatal (53.8%) > cortical (64.1 %) (Table lb). 
For NAc + MPP+ treatment group, the amount of reduction of ROS (Fig. 10) in 
the order with mesencephalic (34.7%) > striatal (30.1%) > cortical (21.4 %) (Table la) 
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and LDH (Fig. 8) was similar to that of ROS reduction, where the amount of reduction is 
in the order of mesencephalic (43.5%) > striatal (48%) > cortical (75.8 %) (Table lb). 
It is noteworthy that in the astrocytes exposed to the highly toxic compound 
MPP+, the neurotoxicity appears at concentrations higher than those at which MTs 
induction is saturated. This might reflect the toxicity exerted by ROS in excess of the 
metal binding and ROS scavenging capacity of induced MTs. This interpretation is 
consistent with the observation that increase in MT-I, - I I prior to MPP+ treatment did not 
totally protect astrocytes from the MPP+-induced toxicity by investigating the LDH (Fig. 
4)，MTT (Fig. 5) and ROS (Fig. 6) production. 
NAc-induced GSH also showed partial protection against the MPP+-induced 
neurotoxicity (Fig. 7, 8, 9. 10). However, in the present study, the protective effect of 
increased GSH by NAc is less than that of ZnSCVinduced MT-I, -II. This maybe due to 
the high rate constant of MTs for its reaction with OH (Sato and Bremner, 1993) since it 
was shown that the scavenging activity of MTs was approximately 50 times greater then 
reduced GSH on a molar basis (Toshiki et al., 1997). Moreover, an in vitro study 
(xanthine and xanthine oxidase system) showed that MTs are superior in scavenging 
superoxide radicals when compared to NAc as evidenced by the inhibition of nitrite 
formation (Hussain et al” 1996). These results further suggested that MTs have a higher 
capacity to scavenge ROS as compared to other sulfhydryl containing molecules and 
hence can act as a better neuroprotective agent. 
Apart from ROS being a critical factor for the pathogenesis of PD, iron also play a 
role in pathogenesis in PD. Iron is a key element for the generation of OH from H2O2 
through Fenton reaction or in combination with O2 by the Haber-Weiss reaction. 
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Therefore iron-associated oxidative stress is an important element of the degenerative 
process in the SN. An increase in iron content (Riederer et al., 1989; Clow et al., 1991; 
Good et al” 1992) and a decrease in the ratio ofFe^VFe^^ (Sofic et al., 1991; Good et al” 
1992), in the SN, followed by in the ST were observed in PD brains whilst low levels of 
change in iron content were observed in other brain regions. It has been observed that 
2+ 3+ 
Fe reacts with MPTP to produce Fe in a cell free in vitro system (Poirier and Barbeau, 
1985), putting forward that physiological iron, other than catalyzing free radical 
formation, may also play a role in causing cellular damage. Furthermore, there is a 
marked decrease in transferrin receptors in the ST of MPTP-treated mice (Mash et al., 
1991) and MPTP has been shown to induce an accumulation of both Fe and Fe in the 
SN of dying neurons (Temlett et al., 1994). The direct infusion of iron into the SN results 
in an increase in oxidative stress (Lan and Jiang, 1997) and neuronal death (Sengstock et 
al., 1992) further confirms the important role of iron in the generating of ROS and as a 
result, neuronal damage. Di Monte et al. (1995) reported the presence of the iron-
mediated bioactivation of MPTP in glial cultures. Al l these evidences suggest that iron 
may play a role in MPTP/MPP^-induced toxicity. Therefore, in the present study, the role 
of iron in MPP+-induced ROS production was further examined. Although the present 
study only examined the direct effects of MPP+- and not MPTP-induced toxicity, the 
contribution of iron in ROS formation cannot be ruled out. 
When astrocytes were treated with iron chelator, Def, together with MPP+，ROS 
level (Fig. 12) showed a significant decrease with the amount of reduction of ROS 
production was in the order of mesencephalic (35.2%) > striatum (33.6%) > cortical 
(21%) astrocytes (Table la). This further confirmed a recent study in our laboratory 
« 
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which showed that the intracellular Fe /Fe ratio was significantly augmented after Def 
+ MPTP treatment (unpublished data), suggesting that iron can maintained in the Fe^^ 
state with minimal conversion to the Fe^^ state when treated with Def. Def may therefore 
offer some protective mechanism by lowering intracellular free iron level, this in turn wil l 
reduce the availability of Fe to undergo the Fenton reaction and thus produce OH . The 
protective ability of Def in terms of decreasing LDH (Fig. 11) was similar to that of ROS 
reduction, where the amount of reduction is in the order of mesencephalic (34.6%) > 
striatal (33.3%) > cortical (14.6%) astrocytes (Table lb). The effectiveness of Def to 
remove ROS and reduce LDH activities is the least when compared with ZnS04-induced 
MTs and NAc-induced GSH pretreatments. 
The present study showed that the increase of antioxidant MTs and GSH, and the 
chelation of free iron individually could partially protect against MPP+-induced 
neurotoxicity. Therefore, the protective effects of combined treatments were also 
examined to ascertain whether a multiple treatment paradigm may be the most effective 
means in ameliorating MPP+-induced ROS production. 
When astrocytes were pretreated with ZnS04 + NAc prior to MPP+ treatment, 
there was a significant reduction in LDH (Fig. 13) and ROS (Fig. 14) production when 
compared with the MPP+ treatment group. The amount of reduction of ROS production 
was in the order of striatum (76.7%) > mesencephalic (72.9%) > cortical (57.7%) 
astrocytes (Table la). The protective ability of ZnSCU + NAc in terms of decreasing 
LDH (Fig. 13) in the order of mesencephalic (66.3%) > striatal (56.9%) > cortical 
(29.3%) astrocytes (Table lb). It can be seen that ZnS04 + NAc pretreatment was more 
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effective when compared with ZnS04 or NAc pretreatment alone. This may be due to the 
increased ability of ZnS04 and NAc to scavenge both OH and H2O2 respectively. 
When astrocytes were treated with ZnSCU + NAc + Def, a maximum protective 
ability in ROS reduction was shown. The amount of reduction in ROS production was in 
the order of mesencephalic (82.6%) > striatal (80.6%) > cortical (71.9%) astrocytes 
(Table la). The protective ability of ZnS04 + NAc + Def in terms of decreasing LDH 
(Fig. 13) was similar to that of ROS production, where the amount of reduction is in the 
order of mesencephalic (82.7%) > striatal (76.4%) > cortical (36.6%) astrocytes (Table 
lb). However, when compared with the ZnS04 + NAc pretreatment, the further addition 
of Def to ZnS04 + NAc was shown to be more effective in protecting astrocytes against 
the MPP+-induced toxicity. These results suggested that the efficacy in protecting 
astrocytes against ROS production and reduction in cell viability is in the order of MTs > 
GSH > Def, and that a combination of all three treatments together offered the best 
protection. 
MT-null mice and MPTP treatment 
To further evaluate the protective effects of MTs in an in vivo model of MPTP-
induced toxicity, an in vivo study using MT-I, - I I knockout (MT-null) mice was used. 
MPTP treatment resulted in a significantly higher SN cell loss (48%) in MT-null mice 
when compared with C57 BL/6 (36%) and Svl29 (32%) mice (Fig. 15). The loss of TH-
positive cells in the SN had been widely reported in the MPTP model (Chan et a l , 1997). 
The total number of TH-positively stained neurons in control animals was around 10,188 
(Liberatore et a l , 1999) - 11,800 bilaterally (Chan et al.，1997), which is similar to that 
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reported in normal mice (Chadi et al., 1993) and it is twice the value observed from the 
present study which is around 5254 in C57 BL/6, 4981 in MT-null and 5054 in Svl29 
mice bilaterally (Fig. 15). In the present study, the TH-positively stained cells are 
counted manually every 50|Lim instead of stereologically. Therefore, to obtain a more 
accurate estimate of total TH-positively stained neurons, the use of stereology means may 
be the best. 
This increase in cell loss may also be partly due to the low GSH level and high 
iron content in the SN, and exacerbated by the absence of the protective effect of MTs. 
MPTP toxicity is related to oxidative stress since its toxic metabolite, MPP+, is able to 
increase lipid peroxidation (Rojas and Rios, 1993)，and to decrease copper and 
manganese after MPTP administration (Rios et al., 1995). Indeed, the formation of an 
iron-MTs complex has been shown to occur in an in vitro system (Good and Vasak, 
1986). It is possible that the ability of MTs to bind metals such as zinc (Ebadi et a l , 
1995), copper and iron, may play an important role in protecting DA neurons from free 
radicals induced by MPTP or MPP+. 
Therefore, i f the mice lack MT-I, -II, the scavenging ability of ROS and metal ion 
chelation may be reduced, thus result in higher cell loss in the SN when compared to the 
other two species. 
There was also a significant decrease in DAT level in all three groups of mice 
(48.1% in MT-null, 47.6% in C57 BL/6 and 50.5% in Svl29) (Fig. 16) after MPTP 
treatment. In addition, a species difference in DAT specific binding was observed. It is 
noteworthy that the basal ST DAT level in MT-null mice (612.8 士 33.2 fmol/mg protein) 
is significantly higher than C57 BL/6 (221.1土 36.7 fmol/mg protein) and Svl29 (346.2 士 
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20.4 fmol/mg protein) mice although the degree of DAT decrease is not different 
amongst the 3 species. DAT at the DA nerve terminal is an absolute requirement for 
MPTP neurotoxicity (Gainetdinov et al., 1997) as it is important for DA reuptake (Horn 
1990) and MPP+ transport into the neurons (Javitch et al., 1985; Pifl et a l , 1993). 
Therefore, the high DAT binding level of MT-null mice suggested that MT-null mice 
may be more sensitive to MPTP/MPP+ toxicity and this may partly explain the increased 
cell loss in the SN of the MT-null mice. Previous study showed that MAO-A knock-out 
mice have an elevated brain levels of serotonin and dopamine (Shih and Chen, 1999) and 
the present study showed an elevated DAT level in MT-null mice, suggesting that this 
may be a compensatory mechanism due certain genes being knocked-out. 
Similar to that observed for DAT binding, the present study showed a significant 
decrease in ST DA (Fig. 17a) in MT-null (44%), C57 BL/6 (41%) and Svl29 (20.9%) 
mice. There was however no species difference in ST DA content although the basal DA 
content of MT-null was higher than that of C57 BL/6 and Svl29 mice. Even the DA 
depletion after MPTP treatment was not significantly different when compared across the 
species, it is interesting to note that without MT-I, -II, DA depletion was more severe 
(Fig 17a). Proportional changes in tissue DOPAC (Fig. 17b) and HVA (Fig. 17c) content 
in the ST of all three groups of mice after MPTP treatment were also observed. One of 
the drawbacks in this study is the small no. of animals used for the binding assay as well 
as measure of DA metabolites, therefore an increase in the number of animals used in this 
study may further delineate any species difference. 
These results indicated that the lack of MTs expression enhanced the toxic effects 
of MPTP on DA neurons in the SN. The amount of DA terminal damage as seen by a 
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decrease in DAT and an increase in DA efflux in the ST were similar for all three species 
studied although the effects seemed slightly more prominent in the MT-null mice. 
In conclusion, MPP+ induced an increase in ROS formation. The induction of 
MTs by ZnS04, GSH by NAc and Def were each shown to partially protect the astrocytes 
against the MPP^-induced toxicity with effectiveness in the order ZnSCU > GSH > Def 
and that the combined treatment of ZnSCU + NAc + Def is the most effective in reducing 
ROS formation and increasing cell viability. This treatment is also most effective in the 
order of mesencephalic > striatal > cortical astrocytes. This suggested that although 
mesencephalic astrocytes are the most vulnerable to MPP+-induced oxidative stress, they 
are also the most responsive to antioxidant treatment. 
O2 can react with nitric oxide (NO) to form peroxynitrite，which can diffuse into 
mitochondria and cause lipid oxidation, protein oxidation DNA strand break, PARS 
activation, NAD and ATP depletion and cell death (Przedborski et al” 1996). Thus, apart 
from the hypothesis that free radicals may cause the degeneration of dopaminergic 
neurons, NO has been proposed to play a role in mediating cell death in the SN. 
Moreover, inhibition of NO synthesis by 7-nitroindazole prevents the loss of 
dopaminergic neurons after MPTP treatment (Hantraye et al., 1996). Furthermore, knock-
out mice lacking neuronal nitric oxide synthase (NOS) was shown to be partially 
protective against MPTP-induced neurotoxicity (Przedborski et al., 1996). Most recent 
study showed that inducible NOS-derived nitric oxide produced in microglia plays an 
important role in the death of dopaminergic neurons, conclude that inhibition of iNOS 
may be a promising target for the treatment of PD (Dehmer et al., 2000). Schwarz et al. 
(1995) showed that over-expression of MTs also protects against NO formation, thus 
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further studies using NO inhibitors in combination of ZnS04 + NAc + Def should be 
conducted in the future to ascertain the maximum protective effect of MPP+-induced 
toxicity in astrocytes. 
In vivo study of MT-null mice showed a significantly more severe loss of SN 
neurons when compared to Svl29 and C57 BL/6 mice. The percentage of DAT, DA, 
DOPAC and HVA loss after MPTP treatment did not differ significantly amongst the 3 
types of mice studied suggested that MTs，role in protecting SN neurons is more critical. 
This suggested that a decrease in thiol-related defenses against free radicals associated to 
MPTP action may exacerbate the injury process in the SN. This could explain why some 
thiol-containing molecules like MTs and GSH can protect against MPTP neurotoxicity 
(Oishi et al., 1993). It seems from the present study that a deficiency in MT-I, -I I 
enhances the sensitivity of SN neurons to oxidative stress. It was shown that over-
expression of MTs genes confer cells resistance against potent oxidant molecules, like 
nitric oxide (Schwarz et al., 1995). It wil l be pertinent, therefore, to conduct future 
studies to examine the protective role of MTs in using MT-I, - I I overexpressing mice. 
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